
<html lang="en"     class="pb-page"  data-request-id="02194fee-1a78-47c4-9fcf-c6d47b11a3f5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00350"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme" /></meta><meta name="dc.Creator" content="Bruce A.  Hay" /></meta><meta name="dc.Creator" content="Kavitha  Godugu" /></meta><meta name="dc.Creator" content="Noureldien H. E.  Darwish" /></meta><meta name="dc.Creator" content="Kazutoshi  Fujioka" /></meta><meta name="dc.Creator" content="Thangirala  Sudha" /></meta><meta name="dc.Creator" content="Ozlem Ozen  Karakus" /></meta><meta name="dc.Creator" content="Shaker A.  Mousa" /></meta><meta name="dc.Description" content="We have previously reported that the αvβ3 inhibitor P-bi-TAT, a bifunctional version of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) conjugated to polyethylene glycol (PEG) MW ..." /></meta><meta name="Description" content="We have previously reported that the αvβ3 inhibitor P-bi-TAT, a bifunctional version of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) conjugated to polyethylene glycol (PEG) MW ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 22, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00350" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00350" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00350" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00350" /></link>
        
    
    

<title>New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00350" /></meta><meta property="og:title" content="New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0012.jpeg" /></meta><meta property="og:description" content="We have previously reported that the αvβ3 inhibitor P-bi-TAT, a bifunctional version of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) conjugated to polyethylene glycol (PEG) MW 4000, has excellent efficacy in a glioblastoma multiforme (GBM) mouse model. However, bioanalysis problems due to PEG polydispersity and large-scale synthesis issues led to a search for new molecules, culminating in the discovery of fb-PMT, a conjugate of tetrac and monodisperse PEG36, with a lipophilic 4-fluorobenzyl group at the opposite end of the PEG chain. fb-PMT reduces GBM tumor growth and viability by up to 98%, is suitable for large-scale synthesis, and is amenable to bioanalysis using mass spectrometry-based detection. We also showed that changes in lipophilicity at the opposite end of the PEG chain from the active tetrac component affected the proton NMR chemical shift of the tetrac moiety in D20 and brain levels of the compound after subcutaneous dosing." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00350"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00350">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00350&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00350&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00350&amp;href=/doi/10.1021/acs.jmedchem.1c00350" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 6300-6309</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00339" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00369" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">New Thyrointegrin α<sub>v</sub>β<sub>3</sub> Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bruce A. Hay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bruce A. Hay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+A.++Hay">Bruce A. Hay</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4318-1951" title="Orcid link">http://orcid.org/0000-0002-4318-1951</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kavitha Godugu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kavitha Godugu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kavitha++Godugu">Kavitha Godugu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Noureldien H. E. Darwish</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Noureldien H. E. Darwish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Noureldien+H.+E.++Darwish">Noureldien H. E. Darwish</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kazutoshi Fujioka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kazutoshi Fujioka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kazutoshi++Fujioka">Kazutoshi Fujioka</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thangirala Sudha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thangirala Sudha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thangirala++Sudha">Thangirala Sudha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ozlem Ozen Karakus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ozlem Ozen Karakus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ozlem+Ozen++Karakus">Ozlem Ozen Karakus</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shaker A. Mousa</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaker A. Mousa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4d3e252c26283f632022383e2c0d2c2e3d253e63282938"><span class="__cf_email__" data-cfemail="4e3d262f252b3c6023213b3d2f0e2f2d3e263d602b2a3b">[email protected]</span></a>. Phone: +01 518 694 7397. Fax: +01 518 694 7560.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaker+A.++Mousa">Shaker A. Mousa</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9294-015X" title="Orcid link">http://orcid.org/0000-0002-9294-015X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00350&amp;href=/doi/10.1021%2Facs.jmedchem.1c00350" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 6300–6309</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 February 2021</li><li><span class="item_label"><b>Published</b> online</span>22 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00350" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00350</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6300%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBruce%2BA.%2BHay%252C%2BKavitha%2BGodugu%252C%2BNoureldien%2BH.%2BE.%2BDarwish%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.1c00350%26title%3DNew%2BThyrointegrin%2B%25CE%25B1v%25CE%25B23%2BAntagonist%2Bwith%2Ba%2BScalable%2BSynthesis%252C%2BBrain%2BPenetration%252C%2Band%2BPotent%2BActivity%2Bagainst%2BGlioblastoma%2BMultiforme%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6309%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00350"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">324</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00350" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;A. Hay&quot;},{&quot;first_name&quot;:&quot;Kavitha&quot;,&quot;last_name&quot;:&quot;Godugu&quot;},{&quot;first_name&quot;:&quot;Noureldien&quot;,&quot;last_name&quot;:&quot;H. E. Darwish&quot;},{&quot;first_name&quot;:&quot;Kazutoshi&quot;,&quot;last_name&quot;:&quot;Fujioka&quot;},{&quot;first_name&quot;:&quot;Thangirala&quot;,&quot;last_name&quot;:&quot;Sudha&quot;},{&quot;first_name&quot;:&quot;Ozlem&quot;,&quot;last_name&quot;:&quot;Ozen Karakus&quot;},{&quot;first_name&quot;:&quot;Shaker&quot;,&quot;last_name&quot;:&quot;A. Mousa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6300-6309&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00350&quot;},&quot;abstract&quot;:&quot;We have previously reported that the αvβ3 inhibitor P-bi-TAT, a bifunctional version of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) conjugated to polyethylene glycol (PEG) MW 4000, has excellent efficacy in a glioblastoma multiforme (GBM) mouse model. However, bioanalysis problems due to PEG polydispersity and large-scale synthesis issues led to a search for new molecules, culminating in the discovery of fb-PMT, a conjugate of tetrac and monodisperse PEG36, with a lipophilic 4-fluorobenzyl group at the opposite end of the PEG chain. fb-PMT reduces GBM tumor growth and viability by up to 98%, is suitable for large-scale synthesis, and is amenable to bioanalysis using mass spectrometry-based detection. We also showed that changes in lipophilicity at the opposite end of the PEG chain from the active tetrac component affected the proton NMR chemical shift of the tetrac moiety in D20 and brain levels of the compound after subcutaneous dosing.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00350&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00350" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00350&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00350" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00350&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00350" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00350&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00350&amp;href=/doi/10.1021/acs.jmedchem.1c00350" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00350" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00350" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00350%26sid%3Dliteratum%253Aachs%26pmid%3D33886292%26genre%3Darticle%26aulast%3DHay%26date%3D2021%26atitle%3DNew%2BThyrointegrin%2B%25CE%25B1v%25CE%25B23%2BAntagonist%2Bwith%2Ba%2BScalable%2BSynthesis%252C%2BBrain%2BPenetration%252C%2Band%2BPotent%2BActivity%2Bagainst%2BGlioblastoma%2BMultiforme%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D6300%26epage%3D6309%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We have previously reported that the α<sub>v</sub>β<sub>3</sub> inhibitor P-bi-TAT, a bifunctional version of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) conjugated to polyethylene glycol (PEG) MW 4000, has excellent efficacy in a glioblastoma multiforme (GBM) mouse model. However, bioanalysis problems due to PEG polydispersity and large-scale synthesis issues led to a search for new molecules, culminating in the discovery of fb-PMT, a conjugate of tetrac and monodisperse PEG36, with a lipophilic 4-fluorobenzyl group at the opposite end of the PEG chain. fb-PMT reduces GBM tumor growth and viability by up to 98%, is suitable for large-scale synthesis, and is amenable to bioanalysis using mass spectrometry-based detection. We also showed that changes in lipophilicity at the opposite end of the PEG chain from the active tetrac component affected the proton NMR chemical shift of the tetrac moiety in D<sub>2</sub>0 and brain levels of the compound after subcutaneous dosing.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Integrins are a family of heterodimeric transmembrane proteins, expressed at the surface of all mammalian cells.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> They are overexpressed by cancer cells and in tumor-associated blood vessels,<a onclick="showRef(event, 'ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref6">(3,6)</a> which make them attractive targets for cancer therapeutics.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7−10)</a> Angiogenesis is modulated by the α<sub>v</sub> integrins including α<sub>v</sub>β<sub>3</sub>, α<sub>v</sub>β<sub>5</sub>, and α<sub>v</sub>β<sub>1</sub>, which have high affinities for the arginine–glycine–aspartic acid (RGD) peptide sequence that is found in several angiogenesis modulators present in the extracellular matrix (ECM). Because integrins play a critical role in tumor angiogenesis<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and are present in the neovasculature of many different cancer cells, they have been frequent targets for cancer therapeutics. One example is the cyclic peptide cilengitide,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a selective inhibitor of the integrins α<sub>v</sub>β<sub>3</sub> and α<sub>v</sub>β<sub>5</sub>, which ultimately failed in phase III clinical trials for glioblastoma multiforme (GBM),<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> most likely due to pharmacokinetic (PK) and biodistribution problems associated with the peptide nature of the compound.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Generally, treatment of GBM continues to be challenging.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Our laboratory has recently described P-bi-TAT<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a version of the “thyrointegrin” antagonist tetraiodothyroacetic acid (tetrac, <b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) conjugated to polydisperse MW 4000 polyethylene glycol (PEG). Compound <b>1</b> is a potent inhibitor of integrin α<sub>v</sub>β<sub>3</sub> (0.14 nM)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and is a potential therapeutic for the treatment of GBM. It has excellent aqueous solubility and readily crosses the blood–brain barrier (BBB) <i>via</i> thyroid hormone-related transporter transthyretin (pre albumin or TTR),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and PEGylation results in the removal of any potential off-target adverse events associated with nuclear translocation facilitated by tetrac-modulated thyroid hormone activity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> There were, however, a few issues with <b>1</b> that we wanted to improve on. The large, polydisperse PEG portion of the molecule led to analysis issues, both in quality control and in bioanalytical assays. Detection with mass spectrometry (MS), the standard in bioanalytical analysis, was difficult because there is no specific mass available for the compound. Scale-up of the material was also challenging. The scale-up issues became clearer when we looked at the high-pressure liquid chromatography (HPLC) analysis of <b>1</b> using a charged aerosol detector (CAD)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and found that the purity was less than 95% after process optimization. We thus set out to design a new molecule that would solve the analysis problems and ease the scale-up issues while retaining the excellent aqueous solubility, potency, pharmacokinetics, and biological efficacy of <b>1</b>. This culminated in the identification of our lead candidate, fb-PMT (<b>13</b>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Thyroid hormone derivatives with integrin α<sub>v</sub>β<sub>3</sub> activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and Synthesis</h3><div class="NLM_p">Monodisperse PEG derivatives with different terminal substitutions and as many as 36 ethylene glycol monomer units have recently become available on a commercial scale.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Using the same method that we used for the synthesis of <b>1</b>, we synthesized the smaller, monodisperse PEG36 derivative <b>2</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Monodisperse <b>2</b> had high integrin α<sub>v</sub>β<sub>3</sub> binding potency similar to <b>1</b> (0.23 nM <i>vs</i> 0.14 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and solved the analysis issues associated with polydisperse <b>1</b>, allowing for high-resolution MS detection in bioanalytical studies. However, a much higher ratio of lipophilic tetrac relative to PEG led to much lower aqueous solubility in the pH 7.4 TRIS buffer: 1.4 mg/mL for <b>2</b><i>versus</i> 120 mg/mL for <b>1</b>. Scale-up of the synthesis of <b>2</b> was problematic as well. Scalable syntheses of compounds with large, appended PEGs are often more difficult than that of traditional small molecules because they are typically noncrystalline amorphous solids or oils that are frequently not amenable to normal phase chromatography, thus limiting purification options. Both <b>1</b> and <b>2</b> require two Cu(I)-catalyzed azide–alkyne cyclization (CuAAC)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> reactions in the final step (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), and the second CuAAC reaction always proceeded much slower than the first. The incomplete CuAAC reaction resulted in some of the monoazide intermediate <b>8b</b> in the final product, and this potentially toxic byproduct could not be removed by any means other than a difficult, inefficient reverse phase preparative chromatography step. Pushing the reaction harder to convert the remaining monoazide intermediate <b>8b</b> to product <b>2</b> using excess catalysts, excess intermediate <b>7</b>, longer reaction times, higher temperatures, and other process permutations led to an increase in low-level impurities, with HPLC/CAD purity significantly less than 95% without preparative reverse phase chromatography. These issues limited the options for a large-scale synthesis of <b>2</b>. Another problem with <b>2</b> was that it was an oil at room temperature, where <b>1</b> was a solid. This made it more difficult to purify the product by precipitation,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> particularly for removing excess <b>7</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) from the product.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding affinity of compounds <b>1</b>, <b>2</b>, <b>10</b>, and <b>13</b> to purified integrin α<sub>v</sub>β<sub>3</sub>. Ninety-six-well plates were coated with purified α<sub>v</sub>β<sub>3</sub> receptors and incubated with different concentrations of compounds in the presence and absence of fibrinogen. The dose–response curve (mean IC<sub>50</sub> ± SD) represents three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of P-bi-TAT <b>1</b> and <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsCl, Et<sub>3</sub>N, and DCM; (b) NaN<sub>3</sub>, DMF, 60 °C; and (c) Cu<sup>+</sup>, TBTA, and <i>t</i>BuOH/H<sub>2</sub>O.</p></p></figure><div class="NLM_p">Low aqueous solubility and problems with scale-up of the synthesis of <b>2</b> led us to look at compound <b>10</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). This compound has only one lipophilic tetrac moiety and thus requires only a single CuAAC reaction in the synthesis. The syntheses of <b>10</b>, 1 step from commercially available <b>9</b>, turned out to be very clean, with HPLC–CAD purities > 98% and HPLC–UV purities > 99%, with no reverse-phase chromatography. Compound <b>10</b> had an inhibitory concentration 50 (IC<sub>50</sub>) of 0.36 nM for integrin α<sub>v</sub>β<sub>3</sub>, comparable to 0.23 nM observed for <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). (Note that molar concentrations of dimeric <b>1</b> and <b>2</b> are calculated assuming 2 equiv of tetrac per molecule, where <b>10</b> and other monomeric compounds are calculated using only 1 equiv of tetrac.) Aqueous solubility for <b>10</b>, >120 mg/mL in the pH 7.4 TRIS buffer, was even better than <b>1</b> and a huge improvement <i>versus</i> 1.4 mg/mL for <b>2</b>. However, much to our initial surprise, there were problems with brain levels in mice after dosing with <b>10</b> that were not seen with <b>1</b> and <b>2</b>. After a 21-day efficacy experiment dosing mice subcutaneously (SC) with <b>1</b>, <b>2</b>, and <b>10</b> daily at 1, 3, and 10 mg/kg body weight, we harvested the brains 24 h after the last dose and found that compound <b>10</b> was undetectable, while <b>1</b> and <b>2</b> were present in reasonable concentrations, 72.5 and 313.4 ng/g, respectively, for the 10 mg/kg dose (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While this was not a typical PK experiment, which would have been a single dose of compound, followed by checking compound levels at one or more shorter time points, we recognized that this was still a potential red flag for compound <b>10</b>. Brain levels for GBM treatments are important parameters, as the BBB is believed to be intact in many if not most GBM patients.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>7</b>, Cu<sup>+</sup>, TBTA, and THF/H<sub>2</sub>O.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Brain Levels (ng/g) of <b>1</b>, <b>2</b>, and <b>10</b> at 24 h after Dosing for 21 days in Mice<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="3" align="center" char=".">Compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char=".">1</th><th class="rowsep1 colsep0" align="center" char=".">2</th><th class="rowsep1 colsep0" align="center">10</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg body weight)</th><th class="colsep0 rowsep0" colspan="3" align="center" char=".">brain Level (ng/g)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">13.6</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">27.7</td><td class="colsep0 rowsep0" align="char" char=".">67.9</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char=".">72.5</td><td class="colsep0 rowsep0" align="char" char=".">313.4</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">n.d. = not detectable, compounds 1, 2, and 10 were administered SC once a day for 21 days, and brain levels were determined 24 h after the last dose.</p></div></div></div><div class="NLM_p">Although there are many factors than can affect brain levels of different compounds, this was still a surprising result for us. We believed that brain penetration of these large molecules was most likely mediated through thyroid hormone transporters,<a onclick="showRef(event, 'ref18 ref24'); return false;" href="javascript:void(0);" class="ref ref18 ref24">(18,24)</a> particularly TTR, that recognize thyroid hormones and close derivatives. At first glance, it did not seem likely that the thyroid hormone transporter affinity for compound <b>10</b> would be different than that for <b>1</b> and <b>2</b>, as compounds <b>1</b>, <b>2</b>, and <b>10</b> all contain the same thyroid hormone-binding element, tetrac, albeit two in <b>1</b> and <b>2</b> and one in <b>10</b>. If there is any passive transport across the BBB, we might expect that the smaller <b>10</b> would cross more readily than <b>1</b> or <b>2</b>, although the higher polarity of <b>10</b> might have the opposite effect. We also thought that differences in ATP-binding cassette transporter-mediated clearance from the brain would be unlikely to favor clearance of <b>10</b><i>versus</i><b>1</b> and <b>2</b> because of the smaller size and higher polarity of <b>10</b>. However, one possible explanation for differences in transporter recognition and brain penetration might be different levels of PEG shielding of the thyromimetic (bi-aryl ether) portion of the molecules. Proton NMR spectra in D<sub>2</sub>O offered some support for this theory, as the resonances of both the inner ring and outer ring protons are shifted downfield in <b>10</b><i>versus</i><b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Aryl region 600 MHz <sup>1</sup>H NMR spectra (298 K, 50 mM tetrac equivalents) of compounds <b>2</b>, <b>10</b>, and <b>13</b> in D<sub>2</sub>O, showing the resonances for the inner (a) and outer (b) ring protons in the thyromimetic portion of the molecule. The outer ring protons in compound <b>13</b> overlap with some of the protons in the fluorobenzyl group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The change in chemical shift can only be explained by a change in the environment of the protons in question, possibly a result of differences in the amount of PEG shielding of the protons in the lipophilic aryl rings from the aqueous solvent. If this is the case, then lowering the ratio of PEG to lipophilic components might be expected to increase transporter binding and brain levels. We did not feel that we could significantly decrease the length of the PEG chain in compound <b>10</b>, as a smaller PEG would most likely result in an increase in the transport of the thyromimetic portion to the nucleus, resulting in undesirable off-target activity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> We could, however, decrease the degree of PEG shielding of the aryl portion of <b>10</b> by adding additional lipophilicity to the molecule at the opposite end of the PEG chain. Adding additional lipophilicity would change the ratio of PEG: lipophilic components, which should effectively decrease the amount of PEG available for shielding the transporter element. This could potentially increase transporter binding, as it has been well documented that increasing PEG substitution can lower the binding affinities of many therapeutics.<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25−28)</a> To this end, we synthesized compound <b>13</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), with a fluorobenzyl group in place of the methyl group in <b>10</b>. Compound <b>13</b> also had a clean, scalable synthesis, one more step than <b>10</b>, with HPLC–CAD purities >97%, HPLC–UV purities > 99%, comparable aqueous solubility to <b>10</b> (120 mg/mL in the pH 7.4 TRIS buffer), and comparable α<sub>v</sub>β<sub>3</sub> binding affinity (0.23 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We also found that the <sup>1</sup>H NMR resonances for both the inner and outer ring protons of <b>13</b> were shifted upfield relative to <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). More importantly, while plasma levels were comparable, the brain levels of <b>13</b> in mice after 3 h (10 mg/kg dose) were twice the levels observed for <b>10</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The discrepancy in brain levels for compound <b>10</b> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> is most likely due to differences in the experimental design, as the numbers given in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were from brains removed from mice 24 h after the last dose following 21 consecutive days of dosing, compared to 3 h after a single dose in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, and 4-fluorobenzylbromide. (b) <b>7</b>, Cu<sup>+</sup>, TBTA, and THF/H<sub>2</sub>O.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Three-Hour Brain and Plasma Levels after a Single 10 mg/kg Body Weight Subcutaneous Dose of Compounds <b>10</b> and <b>13</b> in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">plasma (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">brain (ng/g)</th><th class="colsep0 rowsep0" align="center" char=".">B/P<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">4060 ± 230</td><td class="colsep0 rowsep0" align="char" char="±">55.1 ± 8.6</td><td class="colsep0 rowsep0" align="char" char=".">0.0136</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char="±">3497 ± 715</td><td class="colsep0 rowsep0" align="char" char="±">108.4 ± 15.7</td><td class="colsep0 rowsep0" align="char" char=".">0.0309</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Brain/plasma ratio, 3 h. Values are ±S.D.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vivo</i> Effect of Compound <b>13</b> on GBM Tumor Growth</h3><div class="NLM_p">Subcutaneous injection with compound <b>13</b> for 21 days in mice at 1, 3, 6, and 10 mg/kg dramatically reduced the GBM tumor size, measured by tumor weight and luminescent signal intensity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In a second experiment, mice were dosed with <b>13</b> for 21 days as in the previous experiment and then no treatment was carried out for an additional 21 days. Tumors were even smaller relative to controls after the additional 21 days off-treatment, with a maximum of 98% loss of tumor <i>versus</i> control at the 10 mg/kg dose. Hematoxylin and eosin (H and E) staining (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) shows that tumor cells have been replaced by normal cells.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor effect of compound <b>13</b> on glioblastoma xenografts implanted in mice using U87-luc cells for 21 days (ON daily treatment SC) and 21 days on treatment daily SC with compound <b>13</b>, followed by discontinuation of treatment for 21 days (ON + OFF treatment). Mice were treated with compound <b>13</b> at four different doses (1, 3, 6, and 10 mg/kg, SC) daily for 21 days (ON treatment). In another group, the mice were treated for 21 days as above, and then, treatment was discontinued for 21 days (ON + OFF treatment). The subcutaneous xenograft tumors were harvested at the conclusion of both experiments. (A) Tumor weights. (B) Bioluminescence signal intensity. (C) Cell viability measured with in vivo imaging system (IVIS) imaging (bioluminescent signal). The vertical luminescent color bar represents viability ranging from nonviable (blue) to fully viable (red). Values are expressed as mean ± SD. ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Histopathological changes in U87 tumor xenografts in nude mice treated with compound <b>13</b> daily for 21 days (ON treatment) and 21 days on daily treatment with compound <b>13</b>, followed by discontinuation of treatment for 21 days (ON + OFF treatment). Black arrows indicate the viable tumor cells. Scale bar 40×. There was ∼100% infiltration of malignant cells in controls and almost complete conversion to adipose tissue in treated mice, with <2% viable malignant cells in treated <i>vs</i> control groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Fluorescence of the Dye-Labeled Derivative in Brain</h3><div class="NLM_p">Bodipy dye-labeled compound <b>13</b> was dosed in mice with and without GBM brain tumors. We saw a strong signal intensity (>250 times) of the labeled compound in brain with GBM tumor compared to animals without tumors (<i>N</i> = 4) 24 h after dosing the labeled compound, indicating that the labeled compound readily crossed the BBB and was differentially localized into GBM brain tumor tissues <i>versus</i> normal brain tissues (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Uptake of bodipy dye-labeled compound <b>13</b> in brain with and without GBM. (A) Brain, no GBM, no dye-labeled compound. (B) Brain, no GBM, 24 h after dosing with the dye-labeled compound. (C) Brain, with GBM (U87-luc orthotopic tumor) 24 h after dosing with dye-labeled compound <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetics of Compound <b>13</b> in Nude Mice with Orthotopic GBM Tumors</h3><div class="NLM_p">Nude mice with orthotopic GBM tumors were dosed SC with compound <b>13</b> at 1, 3, 6, and 10 mg/kg, and plasma and brain levels were determined over a 24 h period (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Compound <b>13</b> had a dose-dependent relationship with plasma area under curve (AUC), with 0–24 h AUCs of 2118, 2816, 7631, and 10677 ng/mL*h at 1, 3, 6, and 10 mg/kg SC dose, respectively. Brain levels were about 10% of plasma levels. There were no significant differences in the AUC between the 1 and 3 mg/kg doses, but there were statistically significant (<i>P</i> < 0.01) increases in AUC between the 3 <i>versus</i> the 6 and 10 mg/kg doses. Plasma levels for <b>13</b> exceeded the 100% displacement concentration of 0.1 × 10<sup>–7</sup> M by 2–3 folds for 3–4 h at the 1 and 3 mg/kg doses and by 4–6 folds for 6–8 h at the 6 and 10 mg/kg doses. A dose-dependent increase in delivery and brain tumor uptake and retention was demonstrated with a maximal profile at the 6 and 10 mg/kg doses. Thus, the optimal biological dose for compound <b>13</b> is determined to be 6 mg/kg, despite the increased plasma levels at 10 mg/kg.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Plasma and brain pharmacokinetics of compound <b>13</b> in nude mice with orthotopic GBM tumors, 0–24 h. (A) Plasma levels for <b>13</b>. (B) Plasma AUCs for different doses of <b>13</b>. (C) Brain levels for <b>13</b>. (D) Brain AUCs for different doses of <b>13</b>. NS = not significant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compound <b>13</b> (fb-PMT) is a potent thyrointegrin α<sub>v</sub>β<sub>3</sub> inhibitor that decreases GBM tumor weight and tumor cell viability in mice. Unlike our earlier polydisperse lead P–Bi-TAT (<b>1</b>), monodisperse <b>13</b> can be readily synthesized on a 30 g scale and is amenable to bioanalysis using MS detection. IP dosing in mice resulted in brain levels greater than 1000 ng/g, and there was a 98% decrease in tumor weight in an orthotopic GBM model after SC dosing for 21 days, followed by an additional 21 days with no treatment, with tumor cells replaced by normal cells. We saw an increase in brain levels after dosing with compound <b>13</b> compared to a similar analogue <b>10</b>, possibly because the increase in lipophilicity at the distant end of the PEG chain in <b>13</b> resulted in a lower amount of PEG shielding of the transporter-binding element, resulting in an increase in transporter affinity. We continue to run studies with compound <b>13</b> in additional cancer model systems.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Materials and Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemicals and Materials</h3><div class="NLM_p last">All commercially available chemical reagents were used without further purification. All new compounds gave satisfactory <sup>1</sup>H NMR and MS analysis. <sup>1</sup>H and <sup>13</sup>C NMR spectra for characterization were run in dimethylsulfoxide (DMSO)-<i>d</i><sub>6</sub> at 600 and 150 MHz, respectively. <sup>1</sup>H NMR spectra in D<sub>2</sub>O were run at 600 MHz with 0.2 mg/mL NaOH added to the NMR solvent. The NMR experiments were performed on a Bruker ADVANCE II 600 MHz spectrometer at the Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute (Troy, NY).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Syntheses of Compounds <b>1</b> and <b>7</b> Were Described in a Previous Report<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Synthesis of <b>5b</b></h4><div class="NLM_p last">Discrete PEG-36-OH <b>4b</b> (4 g, 2.49 mmol, PurePEG, San Diego, CA) was dissolved in anhydrous dichloromethane (DCM) (100 mL) under argon. Triethylamine (5 equiv, 1.72 mL, 12.48 mmol) was added slowly, followed by the addition of <i>p</i>-toluene sulfonyl chloride (5 equiv, 2.38 g, 12.48 mmol) in portions over a period of 15 min. After addition, the reaction mixture was stirred for 30 min, heated to 36 °C, and stirred at the same temperature under argon. After 72 h, the completion of the reaction was confirmed with thin-layer chromatography (TLC) (10% MeOH/DCM, visualized with UV and I2) and liquid chromatography/MS (LC/MS). The reaction mixture was diluted with DCM (70 mL) and washed with USP purified water (2 × 120 mL), followed by brine (120 mL). The organic layer was dried using Na<sub>2</sub>SO<sub>4</sub> and filtered to remove Na<sub>2</sub>SO<sub>4</sub>. The filtrate was concentrated under vacuum at 40 °C to obtain crude <i>bis</i>-tosylate PEG-36. The crude <i>bis</i>-tosylate PEG-36 was purified with chromatography on a 330 g normal phase silica gel column with MeOH/DCM (0–10%), yielding 5.47 g of <b>5b</b>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 7.783 (d, 4H), 7.481 (d, 4H), 4.106 (m, 4H), 3.57 (m, 4H), 3.4–3.6 (m, 140H), and 2.498 (dd, 6H). MS(ESI): 973.9 [M + 2NH<sub>4</sub>]<sup>+2</sup>/2. Purity was >95% measured by HPLC with CAD detection.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Synthesis of <b>6b</b></h4><div class="NLM_p last"><i>Bis</i>-tosylate <b>5b</b> (5.37 g, 2.81 mmol) was dissolved in anhydrous dimethylformamide (DMF) (56 mL) under argon. Sodium azide (6 equiv, 1.10 g, 16.86 mmol) was added, and the reaction mixture was heated to 61 °C and stirred at the same temperature under argon. After 16 h, the completion of the reaction mixture was confirmed with TLC (10% MeOH/DCM, visualized with UV and I<sub>2</sub>) and LC/MS. The reaction mixture was cooled to room temperature and diluted with USP purified water (100 mL). The crude product was extracted using DCM (3 × 150 mL). The combined organic layer was washed with USP purified water (50 mL), followed by brine (100 mL). The organic layer was dried using Na<sub>2</sub>SO<sub>4</sub> and filtered. The filtrate was concentrated under vacuum at 40 °C to obtain 6.0 g of crude <b>6b</b>, which was purified with chromatography on a 330 g normal phase silica column with MeOH/DCM (0–10%) to yield 4.15 g of <b>6b</b>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 3.606 (d, 4H), 3.5–3.6 (m, 136H), and 3.395 (m, 4H). MS(ESI): 1670.9 [M + NH<sub>4</sub>]<sup>+</sup>. Purity was >95% measured by HPLC with CAD detection.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Synthesis of <b>2</b></h4><div class="NLM_p last"><i>Bis</i>-azide <b>6b</b> (2.7 g, 1.63 mmol) and <b>7</b> (2.5 equiv, 3.21 g, 4.08 mmol) were suspended in <i>t</i>-BuOH (81 mL, 30 vol) under argon. A solution of sodium-<span class="smallcaps smallerCapital">l</span>-ascorbate (1.2 equiv, 0.388 g, 1.9 mmol) and copper sulfate.5H<sub>2</sub>O (0.6 equiv, 0.245 g, 0.98 mmol) in USP purified water (81 mL, 30 vol) was added. The reaction mixture was heated to 40 °C and stirred at the same temperature under argon. After 18 h, the completion of the reaction mixture was confirmed with TLC (10% MeOH/DCM, visualized with UV and I<sub>2</sub>) and LC/MS. The reaction mixture was concentrated at 38 °C under vacuum to remove <i>t</i>-BuOH. The concentrated reaction mixture was diluted with USP purified water (250 mL), and the crude compound <b>2</b> was extracted using 400 mL of DCM. The DCM layer was washed with an aqueous saturated solution of ethylenediamine tetra-acetic acid (EDTA) (3 × 300 mL), followed by brine (200 mL). The organic layer was dried using Na<sub>2</sub>SO<sub>4</sub> and filtered. The filtrate was concentrated under vacuum at 40 °C to obtain 5.7 g of crude <b>2</b>. This was dissolved in tetrahydrofuran (THF) (25 mL), and 50 mL of hexane was added while stirring. The mixture was stirred for 2 min and left undisturbed for 15 min, and then, the supernatant was decanted away from the bottom oil layer. This procedure was repeated multiple times until no <b>7</b> was observed in the product oil. Crude <b>2</b> (5.28 g) was purified with chromatography on a 400 g HP C18 reverse phase column, yielding 1.5 g of the product. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 8.247 (s, 1H), 7.878 (s, 4H), 7.194 (s, 4H), 5.753 (s, 3H), 5.010 (s, 4H), 4.575 (s, 4H), 3.845 (s, 4H), 3.641 (s, 6H), 3.4–3.6 (m, 142H), 3.330 (s, 6H), and 2.500 (s, 6H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM) 171.931, 152.796, 152.362, 151.208, 141.966, 141.074, 137.027, 125.705, 125.589, 125.063, 91.838, 91.307, 54.831, 49.411, and 38.229. MS(ESI): 1613.4 [M + 2H]<sup>+2</sup>/2. Purity was 96.7% measured by HPLC with UV detection.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Synthesis of <b>10</b></h4><div class="NLM_p last">MeO–PEG<sub>36</sub>–N<sub>3</sub> (830 mg, 505 mmol, PurePEG), 474 mg of <b>7</b> (1.2 equiv), and 13.7 mg of tris(benzyltriazolylmethyl)amine (TBTA) (5%) were dissolved in 20 mL of THF. Copper sulfate hydrate (12.6 mg, 0.1 equiv) and sodium ascorbate (60 mg, 0.6 equiv) were dissolved in 5 mL of water and added to the THF solution. The reaction mixture was stirred under N<sub>2</sub> for 16 h, and then, the liquid was decanted from the small amount of blue solids on the bottom of the flask. THF was stripped from the solution under reduced pressure, 10 mL of water was added, and the mixture was acidified to pH 3 with dilute HCl and extracted with 3 × 40 mL of DCM. The combined organic layers were washed with 3 × 5 mL of the saturated EDTA solution and then with 5 mL of saturated brine. DCM was stripped under reduced pressure, and the remainder was dissolved in 20 mL of warm THF. Hexane (20 mL) was added, and the mixture was warmed until almost everything is dissolved. The mixture was then cooled to room temperature, and the liquid was decanted from the small amount of solid and oil on the bottom of the vial. The mixture was allowed to precipitate at −20 °C overnight; the solids were filtered off and washed with cold hexane. The white filtrate was dried under reduced pressure, yielding 685 mg of the crude product. This was dissolved in 6.5 mL of H<sub>2</sub>O with 2.5 mL of 1 M NaOH and 1 mL of saturated NaCl and washed with 2 × 25 mL of 3:2 hexane/DCM. Additional saturated NaCl (1 mL) was added, and the mixture was washed with another 2 × 25 mL of 3:2 hexane/DCM. The aqueous layer was acidified to pH 2.0 with dilute HCl and extracted 3 × 25 mL with DCM. The combined organic layers were washed with saturated NaCl, and the solvent was removed under reduced pressure. The residue was then precipitated from 20 mL of THF and 20 mL of hexane, yielding 491 mg of product <b>10</b>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 8.255 (s, 1H), 7.853 (s, 2H), 7.195 (m, 4H), 5.013 (s, 2H), 4.581 (m, 2H), 3.851 (m, 2H), and 3.55–3.4 (m, 144H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 152.93, 152.31, 150.67, 142.01, 140.90, 125.55, 125.11, 91.96, 91.20, 71.26, 69.75, 69.65, 69.58, 69.56, 68.73, 66.25, 58.03, 49.65, 39.85, 39.73, 39.61, 39.50, 39.38, 39.26, and 39.14. MS <i>m</i>/<i>z</i>: 1223.6 (M + 2H) and 821.7 (M + 3H). Purity was 96.3% measured by HPLC with CAD detection.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Synthesis of <b>12</b></h4><div class="NLM_p last">60% NaH (2.2 g, 55.25 mmol) was added portion-wise to 30 g of <b>9</b> (18.42 mmol, purePEG) in 600 mL of anhydrous THF over 20 min under an argon atmosphere. After stirring for 30 min, 4-fluorobenzyl bromide (6.9 mL, 55.25 mmol) was added dropwise, and the reaction mixture was stirred for 18 h at room temperature. The reaction mixture was then quenched with the saturated sodium bicarbonate solution, and THF was removed under reduced pressure. Brine (450 mL) was added, and the mixture was extracted twice with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate was concentrated. The crude material was triturated with hexane (5 × 180 mL) to remove unreacted 4-fluorobenzyl bromide and mineral oil and purified on a 440 g silica gel column with 0–5% methanol in DCM, yielding 30.1 g (94%) of <b>10</b>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 7.371 (m, 2H), 7.172 (m, 2H), 4.475 (s, 2H), and 3.4–3.6 (m, 152H). MS(ESI): 1754.8 [M + NH<sub>4</sub>]<sup>+</sup>. Purity was >95% measured by HPLC with CAD detection.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Synthesis of <b>13</b></h4><div class="NLM_p last">Thirty grams (17.27 mmol) of <b>12</b>, 1.7 g (29.36 mmol) of <b>7</b>, and 458 mg (0.86 mmol) of TBTA were dissolved in 400 mL of anhydrous THF, and the mixture was purged with argon. An argon-sparged solution of sodium ascorbate (3.83 g, 19.34 mmol) and CuSO<sub>4</sub> 5 hydrate in 90 mL of USP purified water was added over a period of 5 min. The reaction mixture was stirred at room temperature under argon for 3.5 h and concentrated under reduced pressure to remove THF. The mixture was diluted with 375 mL of brine and 45 mL of 1 M HCl and extracted with 2 × 600 mL of DCM. The combined organic layers were washed with 3 × 600 mL of a saturated aqueous solution of EDTA, followed by 600 mL of saturated ammonium chloride and 600 mL of brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to obtain 55 g of the crude product. The crude product was dissolved in 750 mL of warm THF with the aid of a 45 °C water bath, and 750 mL of hexane was added, resulting in a cloudy solution. The mixture was slowly cooled to −20 °C with stirring. The supernatant was then decanted off, and the solid was washed twice with a precooled solution of 200 mL of THF and 800 mL of hexane. After HPLC analysis indicated 3.4% residual <b>7</b>, the precipitation procedure was repeated, yielding 41.98 g of crude <b>13</b>. This was purified on a 300 g normal phase silica gel column using 3–7% methanol in DCM as the eluent, yielding two fractions: fraction 1 (11 g) was compound <b>13</b> with some less polar impurities by TLC and fraction 2 (25.8 g) was pure <b>13</b> by TLC. Fraction 1 was repurified on a 100 g silica gel pad with 3–7% methanol with 0.4% water in DCM, yielding 7.7 g of pure material based on TLC. The two fractions were combined (33.5 g) and chromatographed once more on a 300 g silica pad with 3–7% methanol with 0.4% water in DCM, yielding two fractions. The major fraction was triturated to obtain <b>13</b> as a white solid, 27.2 g (62%), 97.14% pure by HPLC–CAD. A minor fraction provided an additional 2.0 g of material, 97.5% pure by HPLC–CAD. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 8.246 (s, 1H), 7.879 (s, 2H), 7.361 (dd, 2H), 7.167 (m, 4H), 5.013 (s, 2H), 4.575 (m, 2H), 4.466 (s, 2H), 3.847 (m, 2H), 3.640 (s, 2H), and 3.55–3.4 (m, 144H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ (PPM), 171.955, 162.089, 160.710, 152.770, 152.294, 151.132, 141.924, 141.037, 137.022, 134.626, 134.609, 129.473, 129.427, 125.493, 125.032, 114.923, 114.803, 91.888, 91.341, 71.132, 69.744, 69.691, 69.581, 69.518, 68.992, 68.662, 66.182, 49.382, 39.788, 39.660, 39.549, 39.430, 39.311, 39.192, and 39.072. MS <i>m</i>/<i>z</i>: 1262.8 (M + 2H), 842.5 (M + 3H), and 632.2 (M + 4H).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Competitive Binding of Compounds to Purified α<sub>v</sub>β<sub>3</sub></h3><div class="NLM_p last">The binding affinity of compounds <b>1</b>, <b>2</b>, <b>10</b>, and <b>13</b> to purified α<sub>v</sub>β<sub>3</sub> was measured using previously described methods<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> with slight modifications. The purified α<sub>v</sub>β<sub>3</sub> (1 μg/mL) was coated to polystyrene microtiter plate wells at 4 °C overnight, and then, the wells were blocked with 3% bovine serum albumin (BSA) for 2 h at room temperature. The wells were washed with buffer A (50 mM Tris, 100 mM NaCl, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 1% BSA). Then, fibrinogen followed by compounds at different concentrations was added for 2 hours at room temperature to the purified α<sub>v</sub>β<sub>3</sub> receptor (to compete on binding to α<sub>v</sub>β<sub>3</sub> receptors), and then, anti-α<sub>v</sub>β<sub>3</sub> conjugated with biotin as the secondary antibody was added. Then, wells were washed 3 times with buffer and incubated with a streptavidin HRP conjugate (1:1000 in buffer) for 1 h at room temperature. Finally, wells were washed 3 times with buffer and 100 μL of peroxidase substrate 3,3′,5,5′-tetramethylbenzidine (TMB) was added, and the reaction was terminated after 30 min with a 50 μL of 450 nm stop solution of TMB. Absorbance was determined at 450 nm with a plate reader. The best fit IC<sub>50</sub> values for the compounds were calculated by fitting the data with nonlinear regression using Graphpad Prism (GraphPad, San Diego CA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Animals</h3><div class="NLM_p last">Immunodeficient female NCr nude homozygous mice aged 5–6 weeks weighing 20–25 g were purchased from Taconic Biosciences, Inc (Germantown, NY). All animal studies were conducted at the animal facility of the Veteran Affairs (VA) Medical Center (Albany, NY) in accordance with institutional guidelines for humane animal treatment and according to the current guidelines, and the protocol was approved by the VA. Mice were maintained under specific pathogen-free conditions and housed under controlled conditions of temperature (20–24 °C) and humidity (60–70%) and 12 h light/dark cycle with <i>ad libitum</i> access to water and food. Mice were allowed to acclimatize for 5 days before the study.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Glioblastoma Subcutaneous Xenografts</h3><div class="NLM_p last">For the subcutaneous glioblastoma tumor model, U87-luc cells (ATCC, Manassas, VA, USA) were harvested, suspended in 100 μL of <b>Dulbecco’s modified eagle medium</b> (DMEM) with 50% Matrigel and 2 × 10<sup>6</sup> cells were implanted SC dorsally in each flank to achieve two independent tumors per animal. Immediately prior to initiation of treatments, animals were randomized into treatment groups (5 animals/group) by the tumor volume measured with Vernier calipers. Treatments were begun after detection of palpable tumor mass (4–5 days postimplantation). The treatments were control [phosphate-buffered saline (PBS)], and compound <b>13</b> was dosed at 1, 3, 6, and 10 mg/kg. The compounds were administered daily, SC for 21 days. Another group of animals was also treated for 21 days, and then, treatment was discontinued for 21 days. Animals were then humanely sacrificed, and tumors were collected and fixed in 10% formalin.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Bioluminescence</h3><div class="NLM_p last">The animals were injected SC with 50 μL of <span class="smallcaps smallerCapital">d</span>-luciferin K<sup>+</sup> salt substrate in PBS (150 mg luciferin/kg body weight). The excised tumors were imaged in an IVIS (PerkinElmer Inc., Waltham, MA). Photographic and luminescence images were taken at a constant exposure time. Xenogen IVIS Living Image software (version 3.2) was used to quantify nonsaturated bioluminescence in regions of interest (ROI). Bioluminescence was quantified as photon/s for each ROI. <i>Ex vivo</i> tumor imaging was performed to confirm the signal intensity in the tumors after termination of the study.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Histopathology</h3><div class="NLM_p last">The fixed samples were placed in cassettes and dehydrated using an automated tissue processor. The processed tissues were embedded in paraffin wax, and the blocks were trimmed and sectioned to about 5 × 5 × 4 μm using a microtome. The tissue sections were mounted on glass slides using a hot plate and subsequently treated in the order of 100, 90, and 70% ethanol for 2 min each. Finally, the tissue sections were rinsed with water, stained with Harris’s H and E stain, and examined under a light microscope.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Orthotopic Glioblastoma Xenografts</h3><div class="NLM_p last">For the orthotopic brain cancer tumor model, U87-luc cells were harvested, suspended in 20 μL of DMEM, and 0.1 × 10<sup>6</sup> cells were implanted in the brain. Thirty-two animals per dose (total mice = 128) were randomized into four groups. Compound <b>13</b> was dosed at 1, 3, 6, and 10 mg/kg body weight. Compound <b>13</b> was administered SC 24 h after implantation of cells on the ventral side of the animal. Blood was collected from four mice in each treatment group at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18, 22, 23, and 24 h. Four mice from each treatment group were terminated, and brains were harvested at time points 0.5, 1, 2, 3, 6, 9, 12, 18, and 24 h.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Uptake of the Dye-Labeled Compound in Brain</h3><div class="NLM_p last">To assess the brain uptake and localization of the compound in brain tumors, compound <b>13</b> was labeled with bodipy dye and dosed in athymic female mice of age 5–6 weeks weighing 20–25 gm with orthotopic tumors. GBM cancer cells expressing luciferase (U87-luc) were orthotopically implanted into immunocompromised mouse brains for the development of orthotopic mouse xenografts. Mice were anesthetized with 5% isoflurane, and U87-luc cells (1 × 10<sup>6</sup>) in 3 μL of PBS were injected with a Hamilton syringe into the mediolateral from the midline of the brain at a syringe depth of 3 mm. The next day, the animals were injected with compound <b>13</b> labeled with the bodipy dye (3 mg/kg body weight), SC on the ventral posterior flank of the animal. Using IVIS, the fluorescence signals of the dye were detected at Ex/Em 630 /650 nm after 24 h.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Sample Preparation of the Plasma and Brain Homogenate with Liquid–Liquid Extraction</h3><div class="NLM_p last">Fifty microliters of mouse plasma with or without compounds <b>1</b>, <b>2</b>, <b>10</b>, and <b>13</b> (150 ng/mL) and internal standard [2-(4-(4-(3-((3-aminopropyl)amino)propoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> 150 ng/mL] were vortex-mixed with 1 mL of acetonitrile/water (80/20 v/v) for 30 min. After centrifugation, the solvent was evaporated under a nitrogen stream at 50 °C. Extracts were reconstituted with 50 μL of acetonitrile/water (80/20 v/v). Brain samples were thawed, weighed, and homogenized with the same volume of ice-cold water with a FastPrep-24 tissue and cell homogenizer (MP Biomedicals, Solon, OH). The mouse brain homogenate (50 μL) with or without compounds <b>1</b>, <b>2</b>, <b>10</b>, and <b>13</b> (150 ng/mL) and IS (DAT, 150 ng/mL) was vortex-mixed with 1 mL of acetonitrile/water (80/20 v/v) for 30 min. After centrifugation, the solvent was evaporated under a nitrogen stream at 50 °C. Extracts were reconstituted with 50 μL of acetonitrile/water (80/20 v/v).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> LC–MS/MS Instrumentation</h3><div class="NLM_p last">An API-4000 mass spectrometer (Sciex, Framingham, MA) equipped with a Shimadzu ultra-high pressure liquid chromatography (UPLC) system (Kyoto, Japan) was used for LC–MS/MS analyses. A Kinetex 2.6 μm Biphenyl 100 LS column (50 × 2.1 mm, Phenomenex, Torrance, CA) was used for reversed-phase separation. Mobile phases were (A) water containing 0.1% formic acid and 5% acetonitrile and (B) acetonitrile with 0.1% formic acid. The flow rate was 0.4 mL/min, and the gradient was linear from 25% B to 95% B for 2–4 min. The oven temperature was 40 °C, and the injection volume was 5 μL. Electrospray ionization (ESI) was used in the positive MRM mode. Mass transitions for analytes were as follows: Q1/Q3: 747.6/494.0 (compounds <b>1</b>, <b>2</b>, and <b>10</b>); 841.991/109.26 (compound <b>13</b>); 862.9/845.7 (IS). The operative parameters of the mass spectrometer were as follows: declustering potentials (DP): 56 V; entrance potentials (EP): 10; collision energies (CE): 90 eV; collision cell exit potential (CXP), 6 V; curtain gas (CUR), 10 psi; gas 1 (GS1, nebulizer gas) 40 psi; gas 2 (GS2, heater gas) 40 psi; ion spray voltage (IS), 5500 V; temperature (TEM), 500 °C; collision activate dissociation gas: 9 psi; and dwell time: 150 ms. Nitrogen was used for the gases. Standard curves were obtained using standard solutions of the analytes with concentrations of 2500, 1250, 625, 313, 156, 78, 39, 19.5, and 9.8 ng/mL. The LC–MS/MS method for standard solutions with the internal standard (IS) was linear (<i>r</i> = 0.99 or more) from a concentration of 9.8 to 2500 ng/mL for each analyte. The limit of quantification was estimated to be 10 ng/mL or less under the current conditions for each analyte. Accuracy ranged from 90 to 100%; and recovery was 75% or more for each analyte.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Statistical Analysis</h3><div class="NLM_p last">Statistical analysis was performed with GraphPad Prism 7 software. Data are presented as mean ± SD. For comparison between groups, ANOVA was used. *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 were considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00350" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00350?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00350</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR spectra, HPLC traces, and molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Smiles strings of compounds <b>2</b>, <b>10</b>, and <b>13</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_001.pdf">jm1c00350_si_001.pdf (942.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_002.csv">jm1c00350_si_002.csv (0.65 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00350" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaker A. Mousa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9294-015X" title="Orcid link">http://orcid.org/0000-0002-9294-015X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ff8c979e949a8dd192908a8c9ebf9e9c8f978cd19a9b8a"><span class="__cf_email__" data-cfemail="07746f666c6275296a68727466476664776f7429626372">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce A. Hay</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4318-1951" title="Orcid link">http://orcid.org/0000-0002-4318-1951</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kavitha Godugu</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noureldien H. E. Darwish</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazutoshi Fujioka</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thangirala Sudha</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ozlem Ozen Karakus</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer 12144, New York, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): S.A.M. is a primary inventor and founder of Nanopharmaceuticals LLC, which is developing anticancer drugs. All other authors declare no conflict of interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34808" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34808" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank M. K., H. K., X. L., and K. D. from Dalton Pharma Services for helping with the scale-up and syntheses. Funding was received from both NanoPharmaceuticals LLC and from the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">List of Abbreviations</td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood brain barrier</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">CAD</td><td class="NLM_def"><p class="first last">charged aerosol detector</p></td></tr><tr><td class="NLM_term">CuAAC</td><td class="NLM_def"><p class="first last">Cu(I)-catalyzed azide–alkyne cyclization</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediamine tetra-acetic acid</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">g</td><td class="NLM_def"><p class="first last">gram</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma multiforme</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">Inhibitory concentration 50</p></td></tr><tr><td class="NLM_term">IS</td><td class="NLM_def"><p class="first last">internal standard</p></td></tr><tr><td class="NLM_term">IVIS</td><td class="NLM_def"><p class="first last"><i>In vivo</i> imaging system</p></td></tr><tr><td class="NLM_term">kg</td><td class="NLM_def"><p class="first last">kilogram</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">LOQ</td><td class="NLM_def"><p class="first last">limit of quantitation</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">μg</td><td class="NLM_def"><p class="first last">microgram</p></td></tr><tr><td class="NLM_term">mg</td><td class="NLM_def"><p class="first last">milligram</p></td></tr><tr><td class="NLM_term">mHz</td><td class="NLM_def"><p class="first last">millihertz</p></td></tr><tr><td class="NLM_term">μL</td><td class="NLM_def"><p class="first last">microliter</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">ng</td><td class="NLM_def"><p class="first last">nanogram</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NS</td><td class="NLM_def"><p class="first last">not significant</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PPM</td><td class="NLM_def"><p class="first last">parts per million</p></td></tr><tr><td class="NLM_term">RGD</td><td class="NLM_def"><p class="first last">argine–glycine–aspartic acid</p></td></tr><tr><td class="NLM_term">ROI</td><td class="NLM_def"><p class="first last">region of interest</p></td></tr><tr><td class="NLM_term">SC</td><td class="NLM_def"><p class="first last">subcutaneously</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">TBTA</td><td class="NLM_def"><p class="first last">Tris(benzyltriazolylmethyl)amine</p></td></tr><tr><td class="NLM_term"><i>t</i>BuOH</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl alcohol</p></td></tr><tr><td class="NLM_term">Tetrac</td><td class="NLM_def"><p class="first last">tetraiodothyroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">TTR</td><td class="NLM_def"><p class="first last">transthyretin</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultra-high pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">V/V</td><td class="NLM_def"><p class="first last">volume/volume</p></td></tr><tr><td class="NLM_term">VA</td><td class="NLM_def"><p class="first last">veterans affairs</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">The role of angiogenesis in cancer treatment</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.3390/biomedicines5020034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.3390%2Fbiomedicines5020034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVGgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=34&author=M.+Rajabiauthor=S.+A.+Mousa&title=The+role+of+angiogenesis+in+cancer+treatment&doi=10.3390%2Fbiomedicines5020034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The role of angiogenesis in cancer treatment</span></div><div class="casAuthors">Rajabi, Mehdi; Mousa, Shaker A.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">34/1-34/12</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A no. of anti-angiogenesis drugs have been FDA-approved and are being used in cancer treatment, and a no. of other agents are in different stages of clin. development or in preclin. evaluation.  However, pharmacol. anti-angiogenesis strategies that arrest tumor progression might not be enough to eradicate tumors.  Decreased anti-angiogenesis activity in single mechanism-based anti-angiogenic strategies is due to the redundancy, multiplicity, and development of compensatory mechanism by which blood vessels are remodeled.  Improving anti-angiogenesis drug efficacy will require identification of broad-spectrum anti-angiogenesis targets.  These strategies may have novel features, such as increased porosity, and are the result of complex interactions among endothelial cells, extracellular matrix proteins, growth factors, pericyte, and smooth muscle cells.  Thus, combinations of anti-angiogenic drugs and other anticancer strategies such as chemotherapy appear essential for optimal outcome in cancer patients.  This review will focus on the role of anti-angiogenesis strategies in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVZbMB7TcqbVg90H21EOLACvtfcHk0lgageFtgQZMQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVGgsLY%253D&md5=1b746595b46851c065d21a9ef49a8b4e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines5020034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines5020034%26sid%3Dliteratum%253Aachs%26aulast%3DRajabi%26aufirst%3DM.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DThe%2520role%2520of%2520angiogenesis%2520in%2520cancer%2520treatment%26jtitle%3DBiomedicines%26date%3D2017%26volume%3D5%26spage%3D34%26doi%3D10.3390%2Fbiomedicines5020034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sökeland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, U.</span></span> <span> </span><span class="NLM_article-title">The functional role of integrins during intra- and extravasation within the metastatic cascade</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0937-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1186%2Fs12943-018-0937-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=30657059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BB3cjivVSjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=12&author=G.+S%C3%B6kelandauthor=U.+Schumacher&title=The+functional+role+of+integrins+during+intra-+and+extravasation+within+the+metastatic+cascade&doi=10.1186%2Fs12943-018-0937-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The functional role of integrins during intra- and extravasation within the metastatic cascade</span></div><div class="casAuthors">Sokeland Greta; Schumacher Udo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Formation of distant metastases is by far the most common cause of cancer-related deaths.  The process of metastasis formation is complex, and within this complex process the formation of migratory cells, the so called epithelial mesenchymal transition (EMT), which enables cancer cells to break loose from the primary tumor mass and to enter the bloodstream, is of particular importance.  To break loose from the primary cancer, cancer cells have to down-regulate the cell-to-cell adhesion molecuIes (CAMs) which keep them attached to neighboring cancer cells.  In contrast to this downregulation of CAMS in the primary tumor, cancer cells up-regulate other types of CAMs, that enable them to attach to the endothelium in the organ of the future metastasis.  During EMT, the expression of cell-to-cell and cell-to-matrix adhesion molecules and their down- and upregulation is therefore critical for metastasis formation.  Tumor cells mimic leukocytes to enable transmigration of the endothelial barrier at the metastatic site.  The attachment of leukocytes/cancer cells to the endothelium are mediated by several CAMs different from those at the site of the primary tumor.  These CAMs and their ligands are organized in a sequential row, the leukocyte adhesion cascade.  In this adhesion process, integrins and their ligands are centrally involved in the molecular interactions governing the transmigration.  This review discusses the integrin expression patterns found on primary tumor cells and studies whether their expression correlates with tumor progression, metastatic capacity and prognosis.  Simultaneously, further possible, but so far unclearly characterized, alternative adhesion molecules and/or ligands, will be considered and emerging therapeutic possibilities reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-MrG1fXAfThBrI9DTGjC0fW6udTcc2eaeozaK2u4Smrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjivVSjsg%253D%253D&md5=8790bdf6a90ce4fcb41776e3ddfb2c7a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0937-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0937-3%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B6keland%26aufirst%3DG.%26aulast%3DSchumacher%26aufirst%3DU.%26atitle%3DThe%2520functional%2520role%2520of%2520integrins%2520during%2520intra-%2520and%2520extravasation%2520within%2520the%2520metastatic%2520cascade%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D12%26doi%3D10.1186%2Fs12943-018-0937-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gogiraju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochenek, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, K.</span></span> <span> </span><span class="NLM_article-title">Angiogenic endothelial cell signaling in cardiac hypertrophy and heart Ffailure</span>. <i>Front. Cardiovasc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.3389/fcvm.2019.00020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.3389%2Ffcvm.2019.00020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=30895179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWmtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=20&author=R.+Gogirajuauthor=M.+L.+Bochenekauthor=K.+Sch%C3%A4fer&title=Angiogenic+endothelial+cell+signaling+in+cardiac+hypertrophy+and+heart+Ffailure&doi=10.3389%2Ffcvm.2019.00020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure</span></div><div class="casAuthors">Gogiraju, Rajinikanth; Bochenek, Magdalena L.; Schaefer, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cardiovascular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20</span>CODEN:
                <span class="NLM_cas:coden">FCMRCE</span>;
        ISSN:<span class="NLM_cas:issn">2297-055X</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Endothelial cells are, by no., one of the most abundant cell types in the heart and active players in cardiac physiol. and pathol.  Coronary angiogenesis plays a vital role in maintaining cardiac vascularization and perfusion during physiol. and pathol. hypertrophy.  On the other hand, a redn. in cardiac capillary d. with subsequent tissue hypoxia, cell death and interstitial fibrosis contributes to the development of contractile dysfunction and heart failure, as suggested by clin. as well as exptl. evidence.  Although the mol. causes underlying the inadequate (with respect to the increased oxygen and energy demands of the hypertrophied cardiomyocyte) cardiac vascularization developing during pathol. hypertrophy are incompletely understood.  Research efforts over the past years have discovered interesting mediators and potential candidates involved in this process.  In this review article, we will focus on the vascular changes occurring during cardiac hypertrophy and the transition toward heart failure both in human disease and preclin. models.  We will summarize recent findings in transgenic mice and exptl. models of cardiac hypertrophy on factors expressed and released from cardiomyocytes, pericytes and inflammatory cells involved in the paracrine (dys)regulation of cardiac angiogenesis.  Moreover, we will discuss major signaling events of crit. angiogenic ligands in endothelial cells and their possible disturbance by hypoxia or oxidative stress.  In this regard, we will particularly highlight findings on neg. regulators of angiogenesis, including protein tyrosine phosphatase-1B and tumor suppressor p53, and how they link signaling involved in cell growth and metabolic control to cardiac angiogenesis.  Besides endothelial cell death, phenotypic conversion and acquisition of myofibroblast-like characteristics may also contribute to the development of cardiac fibrosis, the structural correlate of cardiac dysfunction.  Factors secreted by (dysfunctional) endothelial cells and their effects on cardiomyocytes including hypertrophy, contractility and fibrosis, close the vicious circle of reciprocal cell-cell interactions within the heart during pathol. hypertrophy remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6MdE4j6JAybVg90H21EOLACvtfcHk0lgageFtgQZMQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWmtLfO&md5=16225d5568579d9f374c64c25330274e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffcvm.2019.00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcvm.2019.00020%26sid%3Dliteratum%253Aachs%26aulast%3DGogiraju%26aufirst%3DR.%26aulast%3DBochenek%26aufirst%3DM.%2BL.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DK.%26atitle%3DAngiogenic%2520endothelial%2520cell%2520signaling%2520in%2520cardiac%2520hypertrophy%2520and%2520heart%2520Ffailure%26jtitle%3DFront.%2520Cardiovasc.%2520Med.%26date%3D2019%26volume%3D6%26spage%3D20%26doi%3D10.3389%2Ffcvm.2019.00020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caswell, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadrevu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J. C.</span></span> <span> </span><span class="NLM_article-title">Integrins: masters and slaves of endocytic transport</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">853</span>, <span class="refDoi"> DOI: 10.1038/nrm2799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrm2799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=19904298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2hs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=843-853&author=P.+T.+Caswellauthor=S.+Vadrevuauthor=J.+C.+Norman&title=Integrins%3A+masters+and+slaves+of+endocytic+transport&doi=10.1038%2Fnrm2799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins: masters and slaves of endocytic transport</span></div><div class="casAuthors">Caswell, Patrick T.; Vadrevu, Suryakiran; Norman, Jim C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-853</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since it has become clear that adhesion receptors are trafficked through the endosomal pathway and that this can influence their function, much effort has been invested in obtaining detailed descriptions of the mol. machinery responsible for internalizing and recycling integrins.  New findings indicate that integrin trafficking dictates the nature of Rho GTPase signaling during cytokinesis and cell migration.  Furthermore, integrins can exert control over the trafficking of other receptors in a way that drives cancer cell invasion and tumor angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoonj62hSypLLVg90H21EOLACvtfcHk0lglZmZxvQjlPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2hs7fI&md5=e48a279467d140d584dfc222172bc458</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2799%26sid%3Dliteratum%253Aachs%26aulast%3DCaswell%26aufirst%3DP.%2BT.%26aulast%3DVadrevu%26aufirst%3DS.%26aulast%3DNorman%26aufirst%3DJ.%2BC.%26atitle%3DIntegrins%253A%2520masters%2520and%2520slaves%2520of%2520endocytic%2520transport%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D843%26epage%3D853%26doi%3D10.1038%2Fnrm2799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shattil, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, M. H.</span></span> <span> </span><span class="NLM_article-title">The final steps of integrin activation: the end game</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/nrm2871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrm2871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20308986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1Kju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=288-300&author=S.+J.+Shattilauthor=C.+Kimauthor=M.+H.+Ginsberg&title=The+final+steps+of+integrin+activation%3A+the+end+game&doi=10.1038%2Fnrm2871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The final steps of integrin activation: the end game</span></div><div class="casAuthors">Shattil, Sanford J.; Kim, Chungho; Ginsberg, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">288-300</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cell-directed changes in the ligand-binding affinity ('activation') of integrins regulate cell adhesion and migration, extracellular matrix assembly and mechanotransduction, thereby contributing to embryonic development and diseases such as atherothrombosis and cancer.  Integrin activation comprises triggering events, intermediate signaling events and, finally, the interaction of integrins with cytoplasmic regulators, which changes an integrin's affinity for its ligands.  The 1st 2 events involve diverse interacting signaling pathways, whereas the final steps are immediately proximal to integrins, thus enabling integrin-focused therapeutic strategies.  Recent progress provides insight into the structure of integrin transmembrane domains, and reveals how the final steps of integrin activation are mediated by integrin-binding proteins such as talins and kindlins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJodIAdYgfn7Vg90H21EOLACvtfcHk0lglZmZxvQjlPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1Kju7g%253D&md5=3fd9cbf3b676edbdff66724f40a17a22</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2871%26sid%3Dliteratum%253Aachs%26aulast%3DShattil%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DGinsberg%26aufirst%3DM.%2BH.%26atitle%3DThe%2520final%2520steps%2520of%2520integrin%2520activation%253A%2520the%2520end%2520game%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D288%26epage%3D300%26doi%3D10.1038%2Fnrm2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Multivalency of non-peptide integrin alphaVbeta3 antagonist slows tumor growth</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3603</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/mp400096z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400096z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12hu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=3603-3611&author=Y.-S.+Kimauthor=F.+Liauthor=R.+Kongauthor=Y.+Baiauthor=K.+C.+P.+Liauthor=Y.+Fanauthor=B.+E.+O%E2%80%99Neillauthor=Z.+Li&title=Multivalency+of+non-peptide+integrin+alphaVbeta3+antagonist+slows+tumor+growth&doi=10.1021%2Fmp400096z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalency of Non-Peptide Integrin αVβ3 Antagonist Slows Tumor Growth</span></div><div class="casAuthors">Kim, Yoo-Shin; Li, Feng; Kong, Ren; Bai, Yang; Li, King C. P.; Fan, Yubo; O'Neill, Brian E.; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3603-3611</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multivalency is a powerful strategy for achieving high-affinity mol. binding of compds. to increase their therapeutic potency or imaging potential.  In our study, multivalent non-peptide integrin αvβ3 antagonists (IA) were designed for antitumor therapy.  Docking and mol. dynamics were employed to explore the binding modes of IA monomer, dimer, and trimer.  In silico, one IA unit binds tightly in the active site with similar pose to native ligand RGD and other parts of dimer and trimer contribute extra binding affinities by interacting with residues in vicinity of the original site.  In vitro studies demonstrated that increasing valency results in increasing antiproliferative and antiorganizational effects against endothelial cells (HUVECs), and a much weaker effect on melanoma B16F10 cells.  The antitumor efficacies of the IA multivalent compds. were evaluated in s.c. B16F10 melanoma tumor-bearing mice.  At 30 mg/kg dose, the mean masses of tumors harvested 18 days after inoculation were significantly reduced (p < 10-7) by 36 ± 9%, 49 ± 8%, and 71 ± 7% for the IA monomer, dimer, and trimer groups, relative to control.  The importance of multivalency was demonstrated to be highly significant beyond the additive effect of the extra pharmacol. sites (p = 0.00011).  These results suggest that the major target of these anti-αvβ3 compds. is the neovasculature rather than the cancer cells, and the success of a multivalent strategy depends on the details of the components and linker.  This is the first integrin αvβ3 multivalent ligand showing clear enhancement in antitumor effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6jjRZfbvM-LVg90H21EOLACvtfcHk0lglZmZxvQjlPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12hu73F&md5=45f25fc183a59bd628ffafd75ace60dd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fmp400096z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400096z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.-S.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DK.%2BC.%2BP.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BE.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DMultivalency%2520of%2520non-peptide%2520integrin%2520alphaVbeta3%2520antagonist%2520slows%2520tumor%2520growth%26jtitle%3DMol.%2520Pharm.%26date%3D2013%26volume%3D10%26spage%3D3603%26epage%3D3611%26doi%3D10.1021%2Fmp400096z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, N.</span></span> <span> </span><span class="NLM_article-title">Integrins as therapeutic targets: lessons and opportunities</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1038/nrd3266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrd3266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20885411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=804-820&author=D.+Coxauthor=M.+Brennanauthor=N.+Moran&title=Integrins+as+therapeutic+targets%3A+lessons+and+opportunities&doi=10.1038%2Fnrd3266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins as therapeutic targets: lessons and opportunities</span></div><div class="casAuthors">Cox, Dermot; Brennan, Marian; Moran, Niamh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">804-820</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The integrins are a large family of cell adhesion mols. that are essential for the regulation of cell growth and function.  The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and autoimmune disorders, has revealed their substantial potential as therapeutic targets.  However, so far, pharmacol. inhibitors for only three integrins have received marketing approval.  This article discusses the structure and function of integrins, their roles in disease and the chequered history of the approved integrin antagonists.  Recent advances in the understanding of integrin function, ligand interaction and signalling pathways suggest novel strategies for inhibiting integrin function that could help harness their full potential as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovx8-nQd0Z5bVg90H21EOLACvtfcHk0lhN8NgvWydY-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur7O&md5=9ecab45ea4bd2b654bb623b7b5c55869</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd3266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3266%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DD.%26aulast%3DBrennan%26aufirst%3DM.%26aulast%3DMoran%26aufirst%3DN.%26atitle%3DIntegrins%2520as%2520therapeutic%2520targets%253A%2520lessons%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2010%26volume%3D9%26spage%3D804%26epage%3D820%26doi%3D10.1038%2Fnrd3266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizejewski, G. J.</span></span> <span> </span><span class="NLM_article-title">Role of integrins in cancer: survey of expression patterns</span>. <i>Proc. Soc. Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1046/j.1525-1373.1999.d01-122.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1046%2Fj.1525-1373.1999.d01-122.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10564536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADyaK1MXntFCgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=1999&pages=124-138&author=G.+J.+Mizejewski&title=Role+of+integrins+in+cancer%3A+survey+of+expression+patterns&doi=10.1046%2Fj.1525-1373.1999.d01-122.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Role of integrins in cancer: survey of expression patterns (44435)</span></div><div class="casAuthors">Mizejewski, Gerald J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">PSEBAA</span>;
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">A review, with 142 refs.  Tumor cells are characterized by uncontrolled growth, invasion to surrounding tissues, and metastatic spread to distant sites.  Mortality from cancer is often due to metastasis since surgical removal of tumors can enhance and prolong survival.  The integrins constitute a family of transmembrane receptor proteins composed of heterodimeric complexes of noncovalently linked α and β chains.  Integrins function in cell-to-cell and cell-to-extracellular matrix (ECM) adhesive interactions and transduce signals from the ECM to the cell interior and vice versa.  Hence, the integrins mediate the ECM influence on cell growth and differentiation.  Since these properties implicate integrin involvement in cell migration, invasion, intra- and extra-vasation, and platelet interaction, a role for integrins in tumor growth and metastasis is obvious.  These findings are underpinned by observations that the integrins are linked to the actin cytoskeleton involving talin, vinculin, and α-actinin as intermediaries.  Such cytoskeletal changes can be manifested by rounded cell morphol., which is often coincident with tumor transformation via decreased or increased integrin expression patterns.  For the various types of cancers, different changes in integrin expression are further assocd. with tumor growth and metastasis.  Tumor progression leading to metastasis appears to involve equipping cancer cells with the appropriate adhesive (integrin) phenotype for interaction with the ECM.  Therapies directed at influencing integrin cell expression and function are presently being explored for inhibition of tumor growth, metastasis, and angiogenesis.  Such therapeutic strategies include antiintegrin monoclonal antibodies, peptidic inhibitors (cyclic and linear), calcium-binding protein antagonists, proline analogs, apoptosis promoters, and antisense oligonucleotides.  Moreover, platelet aggregation induced by tumor cells, which facilitates metastatic spread, can be inhibited by the disintegrins, a family of viper venomlike peptides.  Therefore, adhesion mols. from the integrin family and components of angiogenesis might be useful as tumor progression markers for prognostic and for diagnostic purposes.  Development of integrin cell expression profiles for individual tumors may have further potential in identifying a cell surface signature for a specific tumor type and/or stage.  Thus, recent advances in elucidating the structure, function, ECM binding, and signaling pathways of the integrins have led to new and exciting modalities for cancer therapeutics and diagnoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2NeN0TMPfG7Vg90H21EOLACvtfcHk0lhN8NgvWydY-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFCgtr4%253D&md5=b588fc47db330db893a7d09e043397d7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1046%2Fj.1525-1373.1999.d01-122.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1525-1373.1999.d01-122.x%26sid%3Dliteratum%253Aachs%26aulast%3DMizejewski%26aufirst%3DG.%2BJ.%26atitle%3DRole%2520of%2520integrins%2520in%2520cancer%253A%2520survey%2520of%2520expression%2520patterns%26jtitle%3DProc.%2520Soc.%2520Exp.%2520Biol.%2520Med.%26date%3D1999%26volume%3D222%26spage%3D124%26epage%3D138%26doi%3D10.1046%2Fj.1525-1373.1999.d01-122.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Requirement of vascular integrin alpha v beta 3 for angiogenesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1126/science.7512751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1126%2Fscience.7512751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=7512751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1Sis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=569-571&author=P.+C.+Brooksauthor=R.+A.+Clarkauthor=D.+A.+Cheresh&title=Requirement+of+vascular+integrin+alpha+v+beta+3+for+angiogenesis&doi=10.1126%2Fscience.7512751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of vascular integrin αvβ3 for angiogenesis</span></div><div class="casAuthors">Brooks, Peter C.; Clark, Richard A. F.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5158</span>),
    <span class="NLM_cas:pages">569-71</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Angiogenesis depends on the adhesive interaction of vascular cells.  The adhesion receptor integrin αvβ3 was identified as a marker of angiogenic vascular tissue.  Integrin αvβ3 was expressed on blood vessels in human wound granulation tissue but not in normal skin, and it showed a fourfold increase in expression during angiogenesis on the chick chorioallantoic membrane.  In the latter assay, a monoclonal antibody to αvβ3 blocked angiogenesis induced by basic fibroblast growth factor, tumor necrosis factor-α, and human melanoma fragments but had no effect on preexisting vessels.  These findings suggest that αvβ3 may be a useful therapeutic target for diseases characterized by neovascularization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV5qQMsunLZrVg90H21EOLACvtfcHk0lhN8NgvWydY-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1Sis7w%253D&md5=759c5081d980c4e81058a1594fcd60f1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.7512751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7512751%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DP.%2BC.%26aulast%3DClark%26aufirst%3DR.%2BA.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DRequirement%2520of%2520vascular%2520integrin%2520alpha%2520v%2520beta%25203%2520for%2520angiogenesis%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D569%26epage%3D571%26doi%3D10.1126%2Fscience.7512751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desgrosellier, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Integrins in cancer: biological implications and therapeutic opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc2748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrc2748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20029421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=9-22&author=J.+S.+Desgrosellierauthor=D.+A.+Cheresh&title=Integrins+in+cancer%3A+biological+implications+and+therapeutic+opportunities&doi=10.1038%2Fnrc2748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins in cancer: biological implications and therapeutic opportunities</span></div><div class="casAuthors">Desgrosellier, Jay S.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumors.  The importance of integrins in several cell types that affect tumor progression has made them an appealing target for cancer therapy.  Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clin. trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma.  These exciting clin. developments emphasize the need to identify how integrin antagonists influence the tumor and its microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL2sajdsDI07Vg90H21EOLACvtfcHk0ljOtR710dsE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI&md5=43d0b526ca38021e780aba991a58451b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2748%26sid%3Dliteratum%253Aachs%26aulast%3DDesgrosellier%26aufirst%3DJ.%2BS.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DIntegrins%2520in%2520cancer%253A%2520biological%2520implications%2520and%2520therapeutic%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D9%26epage%3D22%26doi%3D10.1038%2Fnrc2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lafrenie, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewick, M. A.</span></span> <span> </span><span class="NLM_article-title">Cell adhesion and cancer: is there a potential for therapeutic intervention?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1517/14728222.11.6.727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1517%2F14728222.11.6.727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=17504010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=727-731&author=R.+M.+Lafrenieauthor=C.+A.+Bucknerauthor=M.+A.+Bewick&title=Cell+adhesion+and+cancer%3A+is+there+a+potential+for+therapeutic+intervention%3F&doi=10.1517%2F14728222.11.6.727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cell adhesion and cancer: Is there a potential for therapeutic intervention?</span></div><div class="casAuthors">Lafrenie, Robert M.; Buckner, Carly A.; Bewick, Mary A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-731</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Carcinogenesis involves a disruption in adhesion mol. expression and tissue architecture, and tumor invasion requires adhesion-dependent migration into surrounding tissues.  Therefore, a variety of peptide and antibody-based reagents that block integrins, cadherins, Ig superfamily and selectin adhesion mols. have been developed to treat cancers.  Therapeutics directed at adhesion mols. can block interactions between tumor cells, endothelial cells and immune cells to prevent tumor cell invasiveness and metastasis.  Blocking the adhesion mols. that facilitate the invasion of tumors by endothelial cells and immune cells can prevent tumor-assocd. angiogenesis and the recruitment of immune-mediated growth factors which are required for tumor growth and spread.  In addn., targeted therapies using anticancer agents attached to antibodies or peptides directed as tumor-specific adhesion mols. are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohjm-IpASbs7Vg90H21EOLACvtfcHk0ljOtR710dsE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOis7o%253D&md5=067d56ac6d0e21712c17846dce965a90</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F14728222.11.6.727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.11.6.727%26sid%3Dliteratum%253Aachs%26aulast%3DLafrenie%26aufirst%3DR.%2BM.%26aulast%3DBuckner%26aufirst%3DC.%2BA.%26aulast%3DBewick%26aufirst%3DM.%2BA.%26atitle%3DCell%2520adhesion%2520and%2520cancer%253A%2520is%2520there%2520a%2520potential%2520for%2520therapeutic%2520intervention%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2007%26volume%3D11%26spage%3D727%26epage%3D731%26doi%3D10.1517%2F14728222.11.6.727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mas-Moruno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechenmacher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span> <span> </span><span class="NLM_article-title">Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation</span>. <i>Adv. Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.2174/187152010794728639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.2174%2F187152010794728639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=21269250" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=753-768&author=C.+Mas-Morunoauthor=F.+Rechenmacherauthor=H.+Kessler&title=Cilengitide%3A+the+first+anti-angiogenic+small+molecule+drug+candidate+design%2C+synthesis+and+clinical+evaluation&doi=10.2174%2F187152010794728639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F187152010794728639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728639%26sid%3Dliteratum%253Aachs%26aulast%3DMas-Moruno%26aufirst%3DC.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DCilengitide%253A%2520the%2520first%2520anti-angiogenic%2520small%2520molecule%2520drug%2520candidate%2520design%252C%2520synthesis%2520and%2520clinical%2520evaluation%26jtitle%3DAdv.%2520Anticancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D753%26epage%3D768%26doi%3D10.2174%2F187152010794728639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegi, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erridge, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldape, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lhermitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grujicic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarnawski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyerbrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taphoorn, M. J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurzo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrlinger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortmann, R.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabors, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bent, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicking, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markivskyy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group">European Organisation for Research and Treatment of Cancer (EORTC)</span>; <span class="NLM_contrib-group">Canadian Brain Tumor Consortium; CENTRIC study team</span> <span> </span><span class="NLM_article-title">Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(14)70379-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2FS1470-2045%2814%2970379-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=25163906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1100-1108&author=R.+Stuppauthor=M.+E.+Hegiauthor=T.+Gorliaauthor=S.+C.+Erridgeauthor=J.+Perryauthor=Y.-K.+Hongauthor=K.+D.+Aldapeauthor=B.+Lhermitteauthor=T.+Pietschauthor=D.+Grujicicauthor=J.+P.+Steinbachauthor=W.+Wickauthor=R.+Tarnawskiauthor=D.-H.+Namauthor=P.+Hauauthor=A.+Weyerbrockauthor=M.+J.+B.+Taphoornauthor=C.-C.+Shenauthor=N.+Raoauthor=L.+Thurzoauthor=U.+Herrlingerauthor=T.+Guptaauthor=R.-D.+Kortmannauthor=K.+Adamskaauthor=C.+McBainauthor=A.+A.+Brandesauthor=J.+C.+Tonnauthor=O.+Schnellauthor=T.+Wiegelauthor=C.-Y.+Kimauthor=L.+B.+Naborsauthor=D.+A.+Reardonauthor=M.+J.+van+den+Bentauthor=C.+Hickingauthor=A.+Markivskyyauthor=M.+Picardauthor=M.+Wellerauthor=European+Organisation+for+Research+and+Treatment+of+Cancer+%28EORTC%29author=Canadian+Brain+Tumor+Consortium%3B+CENTRIC+study+team&title=Cilengitide+combined+with+standard+treatment+for+patients+with+newly+diagnosed+glioblastoma+with+methylated+MGMT+promoter+%28CENTRIC+EORTC+26071-22072+study%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2Fs1470-2045%2814%2970379-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide Combined With Standard Treatment For Patients With Newly Diagnosed Glioblastoma With Methylated Mgmt Promoter (centric Eortc 26071-22072 Study): A Multicentre, Randomised, Open-label, Phase 3 Trial</span></div><div class="casAuthors">Stupp, Roger; Hegi, Monika E.; Gorlia, Thierry; Erridge, Sara C.; Perry, James; Hong, Yong-Kil; Aldape, Kenneth D.; Lhermitte, Benoit; Pietsch, Torsten; Grujicic, Danica; Steinbach, Joachim Peter; Wick, Wolfgang; Tarnawski, Rafal; Nam, Do-Hyun; Hau, Peter; Weyerbrock, Astrid; Taphoorn, Martin J. B.; Shen, Chiung-Chyi; Rao, Nalini; Thurzo, Laszlo; Herrlinger, Ulrich; Gupta, Tejpal; Kortmann, Rolf-Dieter; Adamska, Krystyna; McBain, Catherine; Brandes, Alba A.; Tonn, Joerg Christian; Schnell, Oliver; Wiegel, Thomas; Kim, Chae-Yong; Nabors, Louis Burt; Reardon, David A.; van den Bent, Martin J.; Hicking, Christine; Markivskyy, Andriy; Picard, Martin; Weller, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1100-1108</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor.  Data from phase 2 trials suggest that it has antitumor activity as a single agent in recurrent glioblastoma and in combination with std. temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumors with methylated MGMT promoter).  We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.  In this multicentre, open-label, phase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries.  Eligible patients (newly diagnosed, histol. proven supratentorial glioblastoma, methylated MGMT promoter, and age ≥18 years) were stratified for prognostic Radiation Therapy Oncol. Group recursive partitioning anal. class and geog. region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg i.v. twice weekly (cilengitide group) or temozolomide chemoradiotherapy alone (control group).  Patients and investigators were unmasked to treatment allocation.  Maintenance temozolomide was given for up to six cycles, and cilengitide was given for up to 18 mo or until disease progression or unacceptable toxic effects.  The primary endpoint was overall survival.  We analyzed survival outcomes by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT00689221.  Overall, 3471 patients were screened.  Of these patients, 3060 had tumor MGMT status tested; 926 patients had a methylated MGMT promoter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oct 31, 2008, and May 12, 2011.  Median overall survival was 26·3 mo (95% CI 23·8-28·8) in the cilengitide group and 26·3 mo (23·9-34·7) in the control group (hazard ratio 1·02, 95% CI 0·81-1·29, p=0·86).  None of the predefined clin. subgroups showed a benefit from cilengitide.  We noted no overall addnl. toxic effects with cilengitide treatment.  The most commonly reported adverse events of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]).  The addn. of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticancer drug.  Nevertheless, integrins remain a potential treatment target for glioblastoma.Merck KGaA, Darmstadt, Germany.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWaDt0u-c9qbVg90H21EOLACvtfcHk0ljOtR710dsE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E&md5=7abd568898db9f543c4db31c74faafbe</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970379-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970379-1%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DHegi%26aufirst%3DM.%2BE.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DErridge%26aufirst%3DS.%2BC.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DY.-K.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DLhermitte%26aufirst%3DB.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DGrujicic%26aufirst%3DD.%26aulast%3DSteinbach%26aufirst%3DJ.%2BP.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DTarnawski%26aufirst%3DR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHau%26aufirst%3DP.%26aulast%3DWeyerbrock%26aufirst%3DA.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%2BB.%26aulast%3DShen%26aufirst%3DC.-C.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DThurzo%26aufirst%3DL.%26aulast%3DHerrlinger%26aufirst%3DU.%26aulast%3DGupta%26aufirst%3DT.%26aulast%3DKortmann%26aufirst%3DR.-D.%26aulast%3DAdamska%26aufirst%3DK.%26aulast%3DMcBain%26aufirst%3DC.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DTonn%26aufirst%3DJ.%2BC.%26aulast%3DSchnell%26aufirst%3DO.%26aulast%3DWiegel%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DC.-Y.%26aulast%3DNabors%26aufirst%3DL.%2BB.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3Dvan%2Bden%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DHicking%26aufirst%3DC.%26aulast%3DMarkivskyy%26aufirst%3DA.%26aulast%3DPicard%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3D%26aulast%3D%26atitle%3DCilengitide%2520combined%2520with%2520standard%2520treatment%2520for%2520patients%2520with%2520newly%2520diagnosed%2520glioblastoma%2520with%2520methylated%2520MGMT%2520promoter%2520%2528CENTRIC%2520EORTC%252026071-22072%2520study%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1100%26epage%3D1108%26doi%3D10.1016%2Fs1470-2045%2814%2970379-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdreich-Epstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metelitsa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stins, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span> <span> </span><span class="NLM_article-title">Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">721</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10676658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1GmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=712-721&author=A.+Erdreich-Epsteinauthor=H.+Shimadaauthor=S.+Groshenauthor=M.+Liuauthor=L.+S.+Metelitsaauthor=K.+S.+Kimauthor=M.+F.+Stinsauthor=R.+C.+Seegerauthor=D.+L.+Durden&title=Integrins+alpha%28v%29beta3+and+alpha%28v%29beta5+are+expressed+by+endothelium+of+high-risk+neuroblastoma+and+their+inhibition+is+associated+with+increased+endogenous+ceramide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins αvβ3 and αvβ5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide</span></div><div class="casAuthors">Erdreich-Epstein, Anat; Shimada, Hiroyuki; Groshen, Susan; Liu, Ming; Metelitsa, Leonid S.; Kim, Kwang Sik; Stins, Monique F.; Seeger, Robert C.; Durden, Donald L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-721</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inhibition of the RGD-binding integrins, αvβ3 and αvβ5, prevents endothelial cell anchorage and induces endothelial apoptosis, which results in disruption of tumor angiogenesis and inhibition of tumor growth in animal models.  In this study, we demonstrate by immunohistochem. anal. that integrin αvβ3 was expressed by 61% (mean) of microvessels in high-risk neuroblastomas (stage IV and MYCN-amplified stage III) but only by 18% (mean) of microvessels in low-risk tumors (stages I and II and non-MYCN-amplified stage III).  Integrin αvβ5 was found on 60% (mean) of microvessels in 21 Stage IV tumors.  These data suggest that neuroblastomas may be targeted for antiangiogenic treatment directed against endothelial integrins αvβ3 and αvβ5.  In cell culture, inhibition of integrin-dependent endothelial cell anchorage to vitronectin by RGDfV, an RGD function-blocking cyclic peptide, induced apoptosis in bovine brain endothelial cells compared with the control peptide, RADfV (37.5% vs. 8.7%, resp.), as detected by chromatin condensation and nuclear fragmentation.  Treatment with RGDfV but not with RADfV, which prevented attachment of endothelial cells to vitronectin or fibronectin, was assocd. with up to a 50% increase in endogenous ceramide, a lipid second messenger that can mediate cell death.  Furthermore, exogenous C2-ceramide was cytotoxic to bovine brain endothelial cells and induced activation of C-jun N-terminal kinase (JNK), a MAP kinase that can be activated in stress-induced apoptosis pathways.  This suggests that ceramide may function in detachment-induced endothelial cell apoptosis, originating from inhibition of vitronectin binding to integrins such as αvβ3 and αvβ5.  This is the first report to demonstrate expression of integrins αvβ3 and αvβ5 by microvascular endothelium of a childhood tumor and assocn. of their expression with neuroblastoma aggressiveness.  Furthermore, our data provide the first suggestion that inhibition of endothelial cell anchorage, resulting from specific blockade of RGD-binding integrins, increases endogenous ceramide, which may contribute to endothelial cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUWfmdoAXZbVg90H21EOLACvtfcHk0lhXmY_Ep2jvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1GmtbY%253D&md5=1400f7cd11196505f84eed0a682e4831</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErdreich-Epstein%26aufirst%3DA.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DGroshen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMetelitsa%26aufirst%3DL.%2BS.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DStins%26aufirst%3DM.%2BF.%26aulast%3DSeeger%26aufirst%3DR.%2BC.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DIntegrins%2520alpha%2528v%2529beta3%2520and%2520alpha%2528v%2529beta5%2520are%2520expressed%2520by%2520endothelium%2520of%2520high-risk%2520neuroblastoma%2520and%2520their%2520inhibition%2520is%2520associated%2520with%2520increased%2520endogenous%2520ceramide%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D712%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisele, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochsenbein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krex, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikkhah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span> <span> </span><span class="NLM_article-title">Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression</span>. <i>J Neurooncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1007/s11060-014-1365-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1007%2Fs11060-014-1365-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=24442484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BC2czmslOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2014&pages=141-145&author=G.+Eiseleauthor=A.+Wickauthor=A.-C.+Eiseleauthor=P.+M.+Cl%C3%A9mentauthor=J.+Tonnauthor=G.+Tabatabaiauthor=A.+Ochsenbeinauthor=U.+Schlegelauthor=B.+Neynsauthor=D.+Krexauthor=M.+Simonauthor=G.+Nikkhahauthor=M.+Picardauthor=R.+Stuppauthor=W.+Wickauthor=M.+Weller&title=Cilengitide+treatment+of+newly+diagnosed+glioblastoma+patients+does+not+alter+patterns+of+progression&doi=10.1007%2Fs11060-014-1365-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression</span></div><div class="casAuthors">Eisele Gunter; Wick Antje; Eisele Anna-Carina; Clement Paul M; Tonn Jorg; Tabatabai Ghazaleh; Ochsenbein Adrian; Schlegel Uwe; Neyns Bart; Krex Dietmar; Simon Matthias; Nikkhah Guido; Picard Martin; Stupp Roger; Wick Wolfgang; Weller Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma.  Preclinical data as well as anecdotal clinical observations indicate that anti-angiogenic treatment may result in altered patterns of tumor progression.  Using a standardized approach, we analyzed patterns of progression on MRI in 21 patients enrolled onto a phase 2 trial of cilengitide added to TMZ/RT → TMZ in newly diagnosed glioblastoma.  Thirty patients from the experimental treatment arm of the EORTC/NCIC pivotal TMZ trial served as a reference.  MRIcro software was used to map location and extent of initial preoperative and recurrent tumors on MRI of both groups into the same stereotaxic space which were then analyzed using an automated tool of image analysis.  Clinical and outcome data of the cilengitide-treated patients were similar to those of the EORTC/NCIC trial except for a higher proportion of patients with a methylated O(6)-methylguanyl-DNA-methyltransferase gene promoter.  Analysis of recurrence pattern revealed neither a difference in the size of the recurrent tumor nor in the distance of the recurrences from the preoperative tumor location between groups.  Overall frequencies of distant recurrences were 20 % in the reference group and 19 % (4/21 patients) in the cilengitide group.  Compared with TMZ/RT → TMZ alone, the addition of cilengitide does not alter patterns of progression.  This analysis does not support concerns that integrin antagonism by cilengitide may induce a more aggressive phenotype at progression, but also provides no evidence for an anti-invasive activity of cilengitide in patients with newly diagnosed glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHwJuTidk9C5Pq5LRczm8ffW6udTcc2eZo6LGzlS19dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czmslOitw%253D%253D&md5=935f11f2cd195b4243c212dc972b2e03</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11060-014-1365-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-014-1365-x%26sid%3Dliteratum%253Aachs%26aulast%3DEisele%26aufirst%3DG.%26aulast%3DWick%26aufirst%3DA.%26aulast%3DEisele%26aufirst%3DA.-C.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DP.%2BM.%26aulast%3DTonn%26aufirst%3DJ.%26aulast%3DTabatabai%26aufirst%3DG.%26aulast%3DOchsenbein%26aufirst%3DA.%26aulast%3DSchlegel%26aufirst%3DU.%26aulast%3DNeyns%26aufirst%3DB.%26aulast%3DKrex%26aufirst%3DD.%26aulast%3DSimon%26aufirst%3DM.%26aulast%3DNikkhah%26aufirst%3DG.%26aulast%3DPicard%26aufirst%3DM.%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DCilengitide%2520treatment%2520of%2520newly%2520diagnosed%2520glioblastoma%2520patients%2520does%2520not%2520alter%2520patterns%2520of%2520progression%26jtitle%3DJ%2520Neurooncol.%26date%3D2014%26volume%3D117%26spage%3D141%26epage%3D145%26doi%3D10.1007%2Fs11060-014-1365-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadiyala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alghamri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fabiani, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asad, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicola Candia, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candolfi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwendeman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M. G.</span></span> <span> </span><span class="NLM_article-title">Prospects of biological and synthetic pharmacotherapies for glioblastoma</span>. <i>Expet Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1080/14712598.2020.1713085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1080%2F14712598.2020.1713085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=31959027" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=305-317&author=D.+B.+Altshulerauthor=P.+Kadiyalaauthor=F.+J.+Nu%C3%B1ezauthor=F.+M.+Nu%C3%B1ezauthor=S.+Carneyauthor=M.+S.+Alghamriauthor=M.+B.+Garcia-Fabianiauthor=A.+S.+Asadauthor=A.+J.+Nicola+Candiaauthor=M.+Candolfiauthor=J.+Lahannauthor=J.+J.+Moonauthor=A.+Schwendemanauthor=P.+R.+Lowensteinauthor=M.+G.+Castro&title=Prospects+of+biological+and+synthetic+pharmacotherapies+for+glioblastoma&doi=10.1080%2F14712598.2020.1713085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F14712598.2020.1713085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2020.1713085%26sid%3Dliteratum%253Aachs%26aulast%3DAltshuler%26aufirst%3DD.%2BB.%26aulast%3DKadiyala%26aufirst%3DP.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DF.%2BJ.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DF.%2BM.%26aulast%3DCarney%26aufirst%3DS.%26aulast%3DAlghamri%26aufirst%3DM.%2BS.%26aulast%3DGarcia-Fabiani%26aufirst%3DM.%2BB.%26aulast%3DAsad%26aufirst%3DA.%2BS.%26aulast%3DNicola%2BCandia%26aufirst%3DA.%2BJ.%26aulast%3DCandolfi%26aufirst%3DM.%26aulast%3DLahann%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DJ.%2BJ.%26aulast%3DSchwendeman%26aufirst%3DA.%26aulast%3DLowenstein%26aufirst%3DP.%2BR.%26aulast%3DCastro%26aufirst%3DM.%2BG.%26atitle%3DProspects%2520of%2520biological%2520and%2520synthetic%2520pharmacotherapies%2520for%2520glioblastoma%26jtitle%3DExpet%2520Opin.%2520Biol.%2520Ther.%26date%3D2020%26volume%3D20%26spage%3D305%26epage%3D317%26doi%3D10.1080%2F14712598.2020.1713085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godugu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharali, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin alphavbeta3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3087</span>– <span class="NLM_lpage">3097</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00742</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00742" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCns73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=3087-3097&author=M.+Rajabiauthor=K.+Goduguauthor=T.+Sudhaauthor=D.+J.+Bharaliauthor=S.+A.+Mousa&title=Triazole+Modified+Tetraiodothyroacetic+Acid+Conjugated+to+Polyethylene+Glycol%3A+High+Affinity+Thyrointegrin+alphavbeta3+Antagonist+with+Potent+Anticancer+Activities+in+Glioblastoma+Multiforme&doi=10.1021%2Facs.bioconjchem.9b00742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin αvβ3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme</span></div><div class="casAuthors">Rajabi, Mehdi; Godugu, Kavitha; Sudha, Thangirala; Bharali, Dhruba J.; Mousa, Shaker A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3087-3097</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of bioactive mols. that target integrins has implicated their role in tumor angiogenesis, tumor growth, metastasis, and other pathol. angiogenesis processes.  Integrins are members of a family of cell surface receptors that play a crit. role in the angiogenesis process.  Tetraiodothyroacetic acid (tetrac), a deaminated deriv. of L-thyroxine (T4), is a "thyrointegrin" antagonist that blocks the actions of L-triiodothyronine (T3) and T4 with an interaction site that is located at or near the RGD recognition site identified on integrin αvβ3's binding pocket (thyrointegrin αvβ3 receptors).  We have enhanced the biol. activity of a tetrac-based inhibitor via significantly improving its αvβ3 receptor binding affinity by introducing a triazole ring on the outer ring of tetrac and covalently conjugating to polymer to increase the product's hydrophilicity via PEGylation.  The product, P-bi-TAT, was restricted from nuclear translocation and demonstrated high blood brain barrier permeability and retention in contrast to the non-PEG conjugated deriv.  Results of biol. activity indicated that this macromol. new chem. entity P-bi-TAT has greater than 400-fold potent integrin αvβ3 affinity vs. the parent compd. tetrac and has potent anticancer/anti-angiogenesis efficacy against glioblastoma multiforme (GBM).  P-bi-TAT administered s.c. once daily for 21 days at 1-10 mg/kg mouse body wt. resulted in a dose-dependent suppression of GBM tumor growth and viability as monitored with IVIS imaging (P < 0.001).  GBM tumors had >95% vol. loss and maximal loss of GBM cell viability during the 21 days ON-treatment expt. as well as in the 21 days ON followed by 21 days OFF-treatment expt. (P < 0.001).  In conclusion, P-bi-TAT is a promising lead clin. candidate effective in the treatment of human GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6VHEbhjNBLbVg90H21EOLACvtfcHk0lgkhxB3amHAGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCns73I&md5=769734f22a93bf5ff2a9766cc4e76a53</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00742%26sid%3Dliteratum%253Aachs%26aulast%3DRajabi%26aufirst%3DM.%26aulast%3DGodugu%26aufirst%3DK.%26aulast%3DSudha%26aufirst%3DT.%26aulast%3DBharali%26aufirst%3DD.%2BJ.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DTriazole%2520Modified%2520Tetraiodothyroacetic%2520Acid%2520Conjugated%2520to%2520Polyethylene%2520Glycol%253A%2520High%2520Affinity%2520Thyrointegrin%2520alphavbeta3%2520Antagonist%2520with%2520Potent%2520Anticancer%2520Activities%2520in%2520Glioblastoma%2520Multiforme%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26spage%3D3087%26epage%3D3097%26doi%3D10.1021%2Facs.bioconjchem.9b00742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrle, J.</span></span> <span> </span><span class="NLM_article-title">Transport of thyroid hormone in brain</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">98</span>, <span class="refDoi"> DOI: 10.3389/fendo.2014.00098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.3389%2Ffendo.2014.00098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=25009532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgvFCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=98&author=E.+K.+Wirthauthor=U.+Schweizerauthor=J.+Kohrle&title=Transport+of+thyroid+hormone+in+brain&doi=10.3389%2Ffendo.2014.00098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of thyroid hormone in brain</span></div><div class="casAuthors">Wirth Eva K; Kohrle Josef; Schweizer Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Thyroid hormone (TH) transport into the brain is not only pivotal for development and differentiation, but also for maintenance and regulation of adult central nervous system (CNS) function.  In this review, we highlight some key factors and structures regulating TH uptake and distribution.  Serum TH binding proteins play a major role for the availability of TH since only free hormone concentrations may dictate cellular uptake.  One of these proteins, transthyretin is also present in the cerebrospinal fluid (CSF) after being secreted by the choroid plexus.  Entry routes into the brain like the blood-brain-barrier (BBB) and the blood-CSF-barrier will be explicated regarding fetal and adult status.  Recently identified TH transmembrane transporters (THTT) like monocarboxylate transporter 8 (Mct8) play a major role in uptake of TH across the BBB but as well in transport between cells like astrocytes and neurons within the brain.  Species differences in transporter expression will be presented and interference of TH transport by endogenous and exogenous compounds including endocrine disruptors and drugs will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiRBDaczwbdYHWj6b1v8uTfW6udTcc2eZubZs3eIrso7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgvFCjug%253D%253D&md5=d0144f25494eb9071e6d97b61e35596f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2014.00098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2014.00098%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DE.%2BK.%26aulast%3DSchweizer%26aufirst%3DU.%26aulast%3DKohrle%26aufirst%3DJ.%26atitle%3DTransport%2520of%2520thyroid%2520hormone%2520in%2520brain%26jtitle%3DFront.%2520Endocrinol.%26date%3D2014%26volume%3D5%26spage%3D98%26doi%3D10.3389%2Ffendo.2014.00098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vehovec, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obreza, A.</span></span> <span> </span><span class="NLM_article-title">Review of operating principle and applications of the charged aerosol detector</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1217</i></span>,  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1556</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2010.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.chroma.2010.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20083252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1217&publication_year=2010&pages=1549-1556&author=T.+Vehovecauthor=A.+Obreza&title=Review+of+operating+principle+and+applications+of+the+charged+aerosol+detector&doi=10.1016%2Fj.chroma.2010.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Review of operating principle and applications of the charged aerosol detector</span></div><div class="casAuthors">Vehovec, Tanja; Obreza, Ales</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography A</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1217</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1549-1556</span>CODEN:
                <span class="NLM_cas:coden">JCRAEY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9673</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recently a new detection method, based upon aerosol charging (the charged aerosol detector (CAD)) was introduced as an alternative to evaporative light-scattering detector (ELSD), chemiluminescent nitrogen detector and refractive index detector for detection of non-UV and weakly UV active compds. and for UV-absorbing compds. in the absence of stds.  The content of this review article includes description of operation principle, advantages and disadvantages of CAD system, and short reports of selected applications of this detector.  The main advantages of CAD detector are unique performance characteristics: better sensitivity than ELSD system, a dynamic range of up to 4 orders of magnitude, ease of use and constancy of response factors.  Both detectors are mass dependent and the response generated does not depend on the spectral or physicochem. properties of the analyte.  This attractive feature of a detection technique generating universal response factors is the potential use of a single, universal std. for calibration against which all other compds. or impurities can be qualified.  CAD also has the same limitation as ELSD, namely, the response is affected by mobile-phase compn.  This problem was resolved by using inverse gradient compensation as is done for HPLC and supercrit. fluid chromatog.  CAD was applied for the anal. of structurally diverse compds. used in the pharmaceutical, chem., food, and consumer products industries and in life science research.  They include nonvolatile and semivolatile neutral, acidic, basic, and zwitterionic compds., both polar and nonpolar (e.g. lipids, proteins, steroids, polymers, carbohydrates, peptides).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAdn4vuFyr8bVg90H21EOLACvtfcHk0lgkhxB3amHAGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVKhu7s%253D&md5=a48d077cdd6a0251ac7a4137e4318062</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2010.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2010.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DVehovec%26aufirst%3DT.%26aulast%3DObreza%26aufirst%3DA.%26atitle%3DReview%2520of%2520operating%2520principle%2520and%2520applications%2520of%2520the%2520charged%2520aerosol%2520detector%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2010%26volume%3D1217%26spage%3D1549%26epage%3D1556%26doi%3D10.1016%2Fj.chroma.2010.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wawro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinbara, K.</span></span> <span> </span><span class="NLM_article-title">Chromatography-free synthesis of monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates and quantitative analysis of oligomer purity</span>. <i>Polym. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2389</span>– <span class="NLM_lpage">2394</span>, <span class="refDoi"> DOI: 10.1039/c6py00127k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1039%2FC6PY00127K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12msr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2389-2394&author=A.+M.+Wawroauthor=T.+Muraokaauthor=K.+Kinbara&title=Chromatography-free+synthesis+of+monodisperse+oligo%28ethylene+glycol%29+mono-p-toluenesulfonates+and+quantitative+analysis+of+oligomer+purity&doi=10.1039%2Fc6py00127k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chromatography-free synthesis of monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates and quantitative analysis of oligomer purity</span></div><div class="casAuthors">Wawro, Adam M.; Muraoka, Takahiro; Kinbara, Kazushi</div><div class="citationInfo"><span class="NLM_cas:title">Polymer Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2389-2394</span>CODEN:
                <span class="NLM_cas:coden">PCOHC2</span>;
        ISSN:<span class="NLM_cas:issn">1759-9962</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Poly(ethylene glycol) (PEG) is a common building block for complex functional mols.  Because of its chain flexibility and hydrophilicity, it is widely used in bioconjugation chem.  Modern applications require PEGs of high purity, hence well-defined, monodisperse PEG oligomers are gaining more attention.  Here we report a large-scale synthetic procedure for monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates, convenient intermediates of various heterobifunctional PEG derivs.  This method features no chromatog. purifn., low total material cost and high purity of the products.  In addn., oligomer dispersity of the products is detd. quant. using reverse-phase HPLC and a no. of bioconjugation-related functionalized PEG derivs. are prepd. from the synthesized toluenesulfonates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgqjyuBxYg6rVg90H21EOLACvtfcHk0ljhPShTRVec9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12msr4%253D&md5=a7201eb12f974505364c4d45d8067466</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC6PY00127K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6PY00127K%26sid%3Dliteratum%253Aachs%26aulast%3DWawro%26aufirst%3DA.%2BM.%26aulast%3DMuraoka%26aufirst%3DT.%26aulast%3DKinbara%26aufirst%3DK.%26atitle%3DChromatography-free%2520synthesis%2520of%2520monodisperse%2520oligo%2528ethylene%2520glycol%2529%2520mono-p-toluenesulfonates%2520and%2520quantitative%2520analysis%2520of%2520oligomer%2520purity%26jtitle%3DPolym.%2520Chem.%26date%3D2016%26volume%3D7%26spage%3D2389%26epage%3D2394%26doi%3D10.1039%2Fc6py00127k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astruc, D.</span></span> <span> </span><span class="NLM_article-title">The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) “click” reaction and its applications. An overview</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">2933</span>– <span class="NLM_lpage">2945</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.ccr.2011.06.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlygsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2011&pages=2933-2945&author=L.+Liangauthor=D.+Astruc&title=The+copper%28I%29-catalyzed+alkyne-azide+cycloaddition+%28CuAAC%29+%E2%80%9Cclick%E2%80%9D+reaction+and+its+applications.+An+overview&doi=10.1016%2Fj.ccr.2011.06.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) "click" reaction and its applications. An overview</span></div><div class="casAuthors">Liang, Liyuan; Astruc, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">2933-2945</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A short overview of the copper(I)-catalyzed azide alkyne cycloaddn. (CuAAC), the most used "click" reaction, is presented, including the introduction of the "click" concept, the conditions of copper(I) catalysis, the regioselectivity, the nature of the catalysts and ligands, mechanistic features, exptl. conditions and applications to org. synthesis and org. materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKJcGwQvlT_LVg90H21EOLACvtfcHk0ljhPShTRVec9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlygsbzI&md5=eb23b7d506593f5b7a9469ddfb20fd52</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DAstruc%26aufirst%3DD.%26atitle%3DThe%2520copper%2528I%2529-catalyzed%2520alkyne-azide%2520cycloaddition%2520%2528CuAAC%2529%2520%25E2%2580%259Cclick%25E2%2580%259D%2520reaction%2520and%2520its%2520applications.%2520An%2520overview%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2011%26volume%3D255%26spage%3D2933%26epage%3D2945%26doi%3D10.1016%2Fj.ccr.2011.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, W. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1021/bm034069l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bm034069l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsl2hsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=1055-1067&author=J.+Liauthor=W.+J.+Kao&title=Synthesis+of+polyethylene+glycol+%28PEG%29+derivatives+and+PEGylated-peptide+biopolymer+conjugates&doi=10.1021%2Fbm034069l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Polyethylene Glycol (PEG) Derivatives and PEGylated-Peptide Biopolymer Conjugates</span></div><div class="casAuthors">Li, Jing; Kao, W. John</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1055-1067</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We synthesized a library of 50 poly(ethylene glycol) (PEG) derivs. to expand the extent of conjugation with biol. active mols. (biopolymers, peptides, drugs, etc.) and biomaterial substrates.  The formation of PEG derivs. was confirmed with HPLC, 1H and 13C NMR.  PEG derivs. were polymd. into networks in order to study the role of PEG and terminal functional groups in modulating the hydrophilicity of biomaterials and cell-biomaterial interaction.  The resulting surface hydrophilicity and the no. of adhered fibroblasts were primarily dependent on the PEG concn. with the mol. wt. and the terminal functional group of PEG derivs. being less important.  One of PEG derivs., PEG-bis-glutarate, was utilized to link peptide sequences to gelatin backbone in the formation of novel biomedical hydrogels.  PEG-peptide conjugates were characterized by mass spectroscopy.  PEG-peptide modified gelatins were characterized by gel permeation chromatog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWCGHHjjfkvLVg90H21EOLACvtfcHk0ljhPShTRVec9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsl2hsrg%253D&md5=10edcce62dfff6302aff763987aee812</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fbm034069l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbm034069l%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKao%26aufirst%3DW.%2BJ.%26atitle%3DSynthesis%2520of%2520polyethylene%2520glycol%2520%2528PEG%2529%2520derivatives%2520and%2520PEGylated-peptide%2520biopolymer%2520conjugates%26jtitle%3DBiomacromolecules%26date%3D2003%26volume%3D4%26spage%3D1055%26epage%3D1067%26doi%3D10.1021%2Fbm034069l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parney, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pafundi, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laack, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizilbash, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laramy, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agar, N. Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span> <span> </span><span class="NLM_article-title">Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nox175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1093%2Fneuonc%2Fnox175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=29016900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1Ogsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=184-191&author=J.+N.+Sarkariaauthor=L.+S.+Huauthor=I.+F.+Parneyauthor=D.+H.+Pafundiauthor=D.+H.+Brinkmannauthor=N.+N.+Laackauthor=C.+Gianniniauthor=T.+C.+Burnsauthor=S.+H.+Kizilbashauthor=J.+K.+Laramyauthor=K.+R.+Swansonauthor=T.+J.+Kaufmannauthor=P.+D.+Brownauthor=N.+Y.+R.+Agarauthor=E.+Galanisauthor=J.+C.+Bucknerauthor=W.+F.+Elmquist&title=Is+the+blood%E2%80%93brain+barrier+really+disrupted+in+all+glioblastomas%3F+A+critical+assessment+of+existing+clinical+data&doi=10.1093%2Fneuonc%2Fnox175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data</span></div><div class="casAuthors">Sarkaria, Jann N.; Hu, Leland S.; Parney, Ian F.; Pafundi, Deanna H.; Brinkmann, Debra H.; Laack, Nadia N.; Giannini, Caterina; Burns, Terence C.; Kizilbash, Sani H.; Laramy, Janice K.; Swanson, Kristin R.; Kaufmann, Timothy J.; Brown, Paul D.; Agar, Nathalie Y. R.; Galanis, Evanthia; Buckner, Jan C.; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain.  However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM).  The accumulation of normally brain impenetrant radiog. contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM.  However, contrary to this view, overwhelming clin. evidence demonstrates that there is also a clin. significant tumor burden with an intact BBB in all GBM, and there is little doubt that drugs with poor BBB permeability do not provide therapeutically effective drug exposures to this fraction of tumor cells.  This review provides an overview of the clin. literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfa57RTmFi7Vg90H21EOLACvtfcHk0ljhPShTRVec9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1Ogsbs%253D&md5=16f3f39fa253e4b5814ca3040c4d661c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnox175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnox175%26sid%3Dliteratum%253Aachs%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26aulast%3DHu%26aufirst%3DL.%2BS.%26aulast%3DParney%26aufirst%3DI.%2BF.%26aulast%3DPafundi%26aufirst%3DD.%2BH.%26aulast%3DBrinkmann%26aufirst%3DD.%2BH.%26aulast%3DLaack%26aufirst%3DN.%2BN.%26aulast%3DGiannini%26aufirst%3DC.%26aulast%3DBurns%26aufirst%3DT.%2BC.%26aulast%3DKizilbash%26aufirst%3DS.%2BH.%26aulast%3DLaramy%26aufirst%3DJ.%2BK.%26aulast%3DSwanson%26aufirst%3DK.%2BR.%26aulast%3DKaufmann%26aufirst%3DT.%2BJ.%26aulast%3DBrown%26aufirst%3DP.%2BD.%26aulast%3DAgar%26aufirst%3DN.%2BY.%2BR.%26aulast%3DGalanis%26aufirst%3DE.%26aulast%3DBuckner%26aufirst%3DJ.%2BC.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26atitle%3DIs%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520really%2520disrupted%2520in%2520all%2520glioblastomas%253F%2520A%2520critical%2520assessment%2520of%2520existing%2520clinical%2520data%26jtitle%3DNeuro%2520Oncol.%26date%3D2018%26volume%3D20%26spage%3D184%26epage%3D191%26doi%3D10.1093%2Fneuonc%2Fnox175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span> <span> </span><span class="NLM_article-title">Thyroid hormone transporters in the brain</span>. <i>Cerebellum</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1007/s12311-008-0029-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1007%2Fs12311-008-0029-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=18418673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2htLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=75-83&author=T.+Suzukiauthor=T.+Abe&title=Thyroid+hormone+transporters+in+the+brain&doi=10.1007%2Fs12311-008-0029-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Thyroid hormone transporters in the brain</span></div><div class="casAuthors">Suzuki, Takehiro; Abe, Takaaki</div><div class="citationInfo"><span class="NLM_cas:title">Cerebellum</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-83</span>CODEN:
                <span class="NLM_cas:coden">CERECF</span>;
        ISSN:<span class="NLM_cas:issn">1473-4222</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Thyroid hormone plays an essential role in proper mammalian development of the central nervous system and peripheral tissues.  Lack of sufficient thyroid hormone results in abnormal development of virtually all organ systems, a syndrome termed cretinism.  In particular, hypothyroidism in the neonatal period causes serious damage to neural cells and leads to mental retardation.  Although thyroxine is the major product secreted by the thyroid follicular cells, the action of thyroid hormone is mediated mainly through the deiodination of T4 to the biol. active form 3,3', 5-triiodo-L-thyronine, followed by the binding of T3 to a specific nuclear receptor.  Before reaching the intracellular targets, thyroid hormone must cross the plasma membrane.  Because of the lipophilic nature of thyroid hormone, it was thought that they traversed the plasma membrane by simple diffusion.  However, in the past decade, a membrane transport system for thyroid hormone has been postulated to exist in various tissues.  Several classes of transporters, org. anion transporter polypeptide (oatp) family, Na+/Taurocholate cotransporting polypeptide (ntcp) and amino acid transporters have been reported to transport thyroid hormones.  Monocarboxylate transporter 8 (MCT8) has recently been identified as an active and specific thyroid hormone transporter.  Mutations in MCT8 are assocd. with severe X-linked psychomotor retardation and strongly elevated serum T3 levels in young male patients.  Several other mols. should be contributed to exert the role of thyroid hormone in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPkIXM35E2FbVg90H21EOLACvtfcHk0lhZgbAR-9okYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2htLrP&md5=a1605658a09eed6bc1811cdbe8afa7e8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs12311-008-0029-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12311-008-0029-9%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DT.%26atitle%3DThyroid%2520hormone%2520transporters%2520in%2520the%2520brain%26jtitle%3DCerebellum%26date%3D2008%26volume%3D7%26spage%3D75%26epage%3D83%26doi%3D10.1007%2Fs12311-008-0029-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Current drug research on PEGylation with small molecular agents</span>. <i>Prog. Polym. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1016/j.progpolymsci.2012.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.progpolymsci.2012.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlymurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=421-444&author=W.+Liauthor=P.+Zhanauthor=E.+De+Clercqauthor=H.+Louauthor=X.+Liu&title=Current+drug+research+on+PEGylation+with+small+molecular+agents&doi=10.1016%2Fj.progpolymsci.2012.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug research on PEGylation with small molecular agents</span></div><div class="casAuthors">Li, Wenjun; Zhan, Peng; De Clercq, Erik; Lou, Hongxiang; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Polymer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">421-444</span>CODEN:
                <span class="NLM_cas:coden">PRPSB8</span>;
        ISSN:<span class="NLM_cas:issn">0079-6700</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  PEGylation, covalent attaching polyethylene glycol (PEG) polymers to therapeutic agents, is one of the most promising techniques to improve the therapeutic effect of drugs.  Initially, this technol. is mainly applied with macromol. drugs, such as proteins, enzymes, with ten PEGylated biomacromols. approved by the FDA for the treatment of related diseases.  The clin. successful use of PEGylated macromol. drug has promoted the application of this technol. with small mols. drugs to overcome shortcomings assocd. with therapy, such as possible low soly., high toxicity, undesirable pharmaceutical characteristics and nonspecific biodistribution profiles.  So far, 4 PEGylated small drugs were taken into clin. trials.  This review mainly focuses on the recent advances of PEGylated small mols., including their general configuration, and the current merits and limits of PEG modification.  Herein PEG delivery systems are distinguished by therapeutic application (anti-tumor, anti-inflammatory, etc.) and their corresponding PEGylated small mols. are described in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1c3uJ8cWgm7Vg90H21EOLACvtfcHk0lhZgbAR-9okYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlymurrE&md5=eb609a4d59ce7e8cc5cf443ce8def9b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.progpolymsci.2012.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.progpolymsci.2012.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DCurrent%2520drug%2520research%2520on%2520PEGylation%2520with%2520small%2520molecular%2520agents%26jtitle%3DProg.%2520Polym.%2520Sci.%26date%3D2013%26volume%3D38%26spage%3D421%26epage%3D444%26doi%3D10.1016%2Fj.progpolymsci.2012.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaghmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Villuendas, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greschner, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haan, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, M. A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation</span>. <i>Mater. Today Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.mtchem.2018.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.mtchem.2018.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWjur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=121-131&author=A.+Zaghmiauthor=A.+A.+Mendez-Villuendasauthor=A.+A.+Greschnerauthor=J.+Y.+Liuauthor=H.+W.+de+Haanauthor=M.+A.+Gauthier&title=Mechanisms+of+activity+loss+for+a+multi-PEGylated+protein+by+experiment+and+simulation&doi=10.1016%2Fj.mtchem.2018.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation</span></div><div class="casAuthors">Zaghmi, A.; Mendez-Villuendas, E.; Greschner, A. A.; Liu, J. Y.; de Haan, H. W.; Gauthier, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Materials Today Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">MTCAD8</span>;
        ISSN:<span class="NLM_cas:issn">2468-5194</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past five decades, one of the most investigated strategies to increase the circulatory half-life and to reduce the immunogenicity of non-human therapeutic proteins has been to cover their surface with multiple copies of methoxy poly(ethylene glycol) (mPEG).  This multi-'PEGylation' strategy, however, is often assocd. with loss of protein activity, which is most often rationalized as direct modification of the protein's active site or to steric hindrance near its surface.  While these mechanisms are generally accepted and likely valid, very few studies investigate other possible mechanisms of activity loss.  To answer this question, this study investigates the mechanisms of activity loss for glutamate dehydrogenase (GDH) bearing up to 25 chains of mPEG per protein.  Through a combination of exptl. design and simulation, the most common proposed causes of protein inactivation (i.e. active-site PEGylation and steric hindrance near the surface of the protein) are circumvented to shed light on less characterized mechanisms such as altered protein structure, altered microenvironment at the surface of the protein, and altered protein dynamics.  Expts. suggest that the secondary and tertiary structure of GDH was (sometimes significantly) affected by PEGylation, though these changes do not necessarily result in a loss of activity.  Structure-activity correlations could not reconcile all trends within the library of bioconjugates tested.  Moreover, by measuring catalytic activity in the presence of five different allosteric modulators, loss of activity could not be ascribed to an altered local microenvironment at the protein's surface.  As such, coarse-grained simulations were exploited to reveal the effect of PEGylation on protein dynamics, which are long-ranged, cooperative, and essential for GDH catalytic activity.  Normal mode anal. of native bovine GDH (i.e. not PEGylated) revealed that the lowest ranking mode displayed several features that bore similarity to movements known for the native protein.  These included rotation/distortion of the 'antenna' regions, closure of the 'catalytic cleft', and constriction of the internal cavity.  A reduced magnitude of this mode was obsd. as a function of degree of PEGylation and mPEG mol. wt. and correlated well with trends obsd. for the library of bioconjugates tested exptl.  Overall, this study provides new insight into fundamental considerations assocd. with loss of activity, which will contribute to the design of future bioconjugates by providing a better understanding of possible mechanisms of loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxmmlyK5ReYbVg90H21EOLACvtfcHk0lhZgbAR-9okYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWjur7F&md5=14b272d375cdbdedce6f083a0842b965</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.mtchem.2018.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mtchem.2018.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DZaghmi%26aufirst%3DA.%26aulast%3DMendez-Villuendas%26aufirst%3DA.%2BA.%26aulast%3DGreschner%26aufirst%3DA.%2BA.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3Dde%2BHaan%26aufirst%3DH.%2BW.%26aulast%3DGauthier%26aufirst%3DM.%2BA.%26atitle%3DMechanisms%2520of%2520activity%2520loss%2520for%2520a%2520multi-PEGylated%2520protein%2520by%2520experiment%2520and%2520simulation%26jtitle%3DMater.%2520Today%2520Chem.%26date%3D2019%26volume%3D12%26spage%3D121%26epage%3D131%26doi%3D10.1016%2Fj.mtchem.2018.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuerck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?</span>. <i>Drug Discov. Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1623</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.drudis.2014.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=24929223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWisrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1623-1631&author=A.+Baumannauthor=D.+Tuerckauthor=S.+Prabhuauthor=L.+Dickmannauthor=J.+Sims&title=Pharmacokinetics%2C+metabolism+and+distribution+of+PEGs+and+PEGylated+proteins%3A+quo+vadis%3F&doi=10.1016%2Fj.drudis.2014.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?</span></div><div class="casAuthors">Baumann, Andreas; Tuerck, Dietrich; Prabhu, Saileta; Dickmann, Leslie; Sims, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1623-1631</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The pharmacokinetics (PK), metab. and biodistribution of polyethylene glycol (PEG) in PEGylated proteins are important to understand the increased cellular vacuolation reported in various tissues in animals.  The tissue distribution profile of PEGylated proteins and 'metabolic' PEG is guided largely by abs. PEG load, PEG mol. wt. and, where applicable, receptor-mediated uptake via the protein moiety.  High mol. wt. PEGs show slow renal clearance, and consequently have a greater potential to accumulate within cells.  The intracellular nonbiodegradable PEG can accumulate within the lysosome ultimately causing distension and vacuolation obsd. by std. histol. examns.  Improved bioanal. methodologies will contribute to the identification of specific PK parameters including distribution behavior to support development of PEGylated proteins as therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbtre-36np7Vg90H21EOLACvtfcHk0lgG3flnvAah1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWisrjL&md5=28d597ff3dfc5fac1b0d9c5893d30446</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DA.%26aulast%3DTuerck%26aufirst%3DD.%26aulast%3DPrabhu%26aufirst%3DS.%26aulast%3DDickmann%26aufirst%3DL.%26aulast%3DSims%26aufirst%3DJ.%26atitle%3DPharmacokinetics%252C%2520metabolism%2520and%2520distribution%2520of%2520PEGs%2520and%2520PEGylated%2520proteins%253A%2520quo%2520vadis%253F%26jtitle%3DDrug%2520Discov.%2520Today%26date%3D2014%26volume%3D19%26spage%3D1623%26epage%3D1631%26doi%3D10.1016%2Fj.drudis.2014.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">8561</span>– <span class="NLM_lpage">8566</span>, <span class="refDoi"> DOI: 10.1039/c8sc01777h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1039%2FC8SC01777H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=30568780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCjsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=8561-8566&author=Y.+Hanauthor=Z.+Yuanauthor=P.+Zhangauthor=S.+Jiang&title=Zwitterlation+mitigates+protein+bioactivity+loss+in+vitro+over+PEGylation&doi=10.1039%2Fc8sc01777h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation</span></div><div class="casAuthors">Han, Yanjiao; Yuan, Zhefan; Zhang, Peng; Jiang, Shaoyi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">8561-8566</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conjugation with poly(ethylene glycol) (PEG) or PEGylation is a widely used tool to overcome the shortcomings of native proteins, such as poor stability, inadequate pharmacokinetic (PK) profiles, and immunogenicity.  However, PEGylation is often accompanied by an unwanted detrimental effect on bioactivity, particularly, resulting from the amphiphilic nature of PEG.  This is esp. true for PEGylated proteins with large binding targets.  Pegasys, a PEGylated interferon alpha-2a (IFN-α2a) bearing a 40 kDa branched PEG, is a typical example that displays only 7% in vitro activity of the unmodified IFN-α2a.  In this work, by employing IFN-α2a as a model protein, we demonstrated that a protein conjugated with zwitterionic polymers (or zwitterlation) could significantly mitigate the antiproliferative bioactivity loss in vitro after polymer conjugation.  The retained antiproliferative activity of zwitterlated IFN-α2a is 4.4-fold higher than that of the PEGylated IFN-α2a with the same polymer mol. wt., or 3-fold higher than that of the PEGylated IFN-α2a with a similar hydrodynamic size.  It is hypothesized that nonspecific interactions between zwitterionic polymers and IFN-α2a/IFN-α2a receptors can be mitigated due to the super-hydrophilic nature of zwitterionic polymers.  This, in turn, reduces the 'nonspecific blocking' between IFN-α2a and IFN-α2a receptors.  In addn., we demonstrated that zwitterlated IFN-α2a showed a prolonged circulation time and a mitigated accelerated blood clearance after repeated injections in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq86LYYLAkrsLVg90H21EOLACvtfcHk0lgG3flnvAah1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCjsLnI&md5=9cb7dbafcca4634530e460e5b3738033</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2FC8SC01777H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC01777H%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DZwitterlation%2520mitigates%2520protein%2520bioactivity%2520loss%2520in%2520vitro%2520over%2520PEGylation%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D8561%26epage%3D8566%26doi%3D10.1039%2Fc8sc01777h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalcin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharali, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godugu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, biodistribution, and anti-angiogenesis efficacy of diamino propane tetraiodothyroacetic acid-conjugated biodegradablepPolymeric nanoparticle</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">9006</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-44979-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fs41598-019-44979-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=31227723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BB3M3psF2gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=9006&author=W.+Liauthor=M.+Yalcinauthor=D.+J.+Bharaliauthor=Q.+Linauthor=K.+Goduguauthor=K.+Fujiokaauthor=K.+A.+Keatingauthor=S.+A.+Mousa&title=Pharmacokinetics%2C+biodistribution%2C+and+anti-angiogenesis+efficacy+of+diamino+propane+tetraiodothyroacetic+acid-conjugated+biodegradablepPolymeric+nanoparticle&doi=10.1038%2Fs41598-019-44979-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle</span></div><div class="casAuthors">Li Weikun; Yalcin Murat; Bharali Dhruba J; Godugu Kavitha; Fujioka Kazutoshi; Keating Kelly A; Mousa Shaker A; Yalcin Murat; Lin Qishan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9006</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The anti-angiogenic agent, diamino propane tetraiodothyroacetic acid (DAT), is a thyro-integrin (integrin αvβ3) antagonist anticancer agent that works via genetic and nongenetic actions.  Tetraiodothyroacetic acid (tetrac) and DAT as thyroid hormone derivatives influence gene expression after they transport across cellular membranes.  To restrict the action of DAT to the integrin αvβ3 receptors on the cell surface, we used DAT-conjugated PLGA nanoparticles (NDAT) in an active targeting mode to bind to these receptors.  Preparation and characterization of NDAT is described, and both in vitro and in vivo experiments were done to compare DAT to NDAT.  Intracellular uptake and distribution of DAT and NDAT in U87 glioblastoma cells were evaluated using confocal microscopy and showed that DAT reached the nucleus, but NDAT was restricted from the nucleus.  Pharmacokinetic studies using LC-MS/MS analysis in male C57BL/6 mice showed that administration of NDAT improved the area under the drug concentration curve AUC(0-48 h) by 4-fold at a dose of 3 mg/kg when compared with DAT, and Cmax of NDAT (4363 ng/mL) was 8-fold greater than that of DAT (548 ng/mL).  Biodistribution studies in the mice showed that the concentrations of NDAT were higher than DAT/Cremophor EL micelles in heart, lung, liver, spleen, and kidney.  In another mouse model using female NCr nude homozygous mice with U87 xenografts, tumor growth was significantly decreased at doses of 1 and 3 mg/kg of NDAT.  In the chick chorioallantoic membrane (CAM) assay used to measure angiogenesis, DAT (500 ng/CAM) resulted in 48% inhibition of angiogenesis levels.  In comparison, NDAT at low dose (50 ng/CAM) showed 45% inhibition of angiogenesis levels.  Our investigation of NDAT bridges the study of polymeric nanoparticles and anti-angiogenic agents and offers new insight for the rational design of anti-angiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPg83-cJoMYq91pGlMMoT5fW6udTcc2eby8WZKdVRo1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3psF2gsQ%253D%253D&md5=16487909e88802d664a21239eb6364b1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44979-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44979-6%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYalcin%26aufirst%3DM.%26aulast%3DBharali%26aufirst%3DD.%2BJ.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DGodugu%26aufirst%3DK.%26aulast%3DFujioka%26aufirst%3DK.%26aulast%3DKeating%26aufirst%3DK.%2BA.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DPharmacokinetics%252C%2520biodistribution%252C%2520and%2520anti-angiogenesis%2520efficacy%2520of%2520diamino%2520propane%2520tetraiodothyroacetic%2520acid-conjugated%2520biodegradablepPolymeric%2520nanoparticle%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D9006%26doi%3D10.1038%2Fs41598-019-44979-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kouns, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadvary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haering, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span> <span> </span><span class="NLM_article-title">Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">18844</span>– <span class="NLM_lpage">18851</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(19)37038-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2FS0021-9258%2819%2937038-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1527012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADyaK38XltVyrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=18844-18851&author=W.+C.+Kounsauthor=P.+Hadvaryauthor=P.+Haeringauthor=B.+Steiner&title=Conformational+modulation+of+purified+glycoprotein+%28GP%29+IIb-IIIa+allows+proteolytic+generation+of+active+fragments+from+either+active+or+inactive+GPIIb-IIIa&doi=10.1016%2Fs0021-9258%2819%2937038-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa</span></div><div class="casAuthors">Kouns, William C.; Hadvary, Paul; Haering, P.; Steiner, Beat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">18844-51</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">This study characterized conformational states of platelet glycoprotein IIb-IIIa (GPIIb-IIIa) and regions of the mol. required for fibrinogen binding.  The data obtained suggest that: (1) purified active and inactive GPIIb-IIIa exist in different conformations and have different affinities for RGDV; (2) certain peptidomimetic inhibitors (Ro 42-1499 and Ro 43-5054) alter the conformation of inactive GPIIb-IIIa; (3) GPIIIa and a 58-kDa N-terminal fragment of GPIIbα form a high-affinity fibrinogen-binding complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvLHawVJ1VNbVg90H21EOLACvtfcHk0liOdN-5yTTBKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVyrs7s%253D&md5=6b84605812c74857b7f4fccfab888f9c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2937038-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252937038-3%26sid%3Dliteratum%253Aachs%26aulast%3DKouns%26aufirst%3DW.%2BC.%26aulast%3DHadvary%26aufirst%3DP.%26aulast%3DHaering%26aufirst%3DP.%26aulast%3DSteiner%26aufirst%3DB.%26atitle%3DConformational%2520modulation%2520of%2520purified%2520glycoprotein%2520%2528GP%2529%2520IIb-IIIa%2520allows%2520proteolytic%2520generation%2520of%2520active%2520fragments%2520from%2520either%2520active%2520or%2520inactive%2520GPIIb-IIIa%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D18844%26epage%3D18851%26doi%3D10.1016%2Fs0021-9258%2819%2937038-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Thyroid hormone derivatives with integrin α<sub>v</sub>β<sub>3</sub> activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding affinity of compounds <b>1</b>, <b>2</b>, <b>10</b>, and <b>13</b> to purified integrin α<sub>v</sub>β<sub>3</sub>. Ninety-six-well plates were coated with purified α<sub>v</sub>β<sub>3</sub> receptors and incubated with different concentrations of compounds in the presence and absence of fibrinogen. The dose–response curve (mean IC<sub>50</sub> ± SD) represents three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of P-bi-TAT <b>1</b> and <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsCl, Et<sub>3</sub>N, and DCM; (b) NaN<sub>3</sub>, DMF, 60 °C; and (c) Cu<sup>+</sup>, TBTA, and <i>t</i>BuOH/H<sub>2</sub>O.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>7</b>, Cu<sup>+</sup>, TBTA, and THF/H<sub>2</sub>O.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Aryl region 600 MHz <sup>1</sup>H NMR spectra (298 K, 50 mM tetrac equivalents) of compounds <b>2</b>, <b>10</b>, and <b>13</b> in D<sub>2</sub>O, showing the resonances for the inner (a) and outer (b) ring protons in the thyromimetic portion of the molecule. The outer ring protons in compound <b>13</b> overlap with some of the protons in the fluorobenzyl group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, and 4-fluorobenzylbromide. (b) <b>7</b>, Cu<sup>+</sup>, TBTA, and THF/H<sub>2</sub>O.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor effect of compound <b>13</b> on glioblastoma xenografts implanted in mice using U87-luc cells for 21 days (ON daily treatment SC) and 21 days on treatment daily SC with compound <b>13</b>, followed by discontinuation of treatment for 21 days (ON + OFF treatment). Mice were treated with compound <b>13</b> at four different doses (1, 3, 6, and 10 mg/kg, SC) daily for 21 days (ON treatment). In another group, the mice were treated for 21 days as above, and then, treatment was discontinued for 21 days (ON + OFF treatment). The subcutaneous xenograft tumors were harvested at the conclusion of both experiments. (A) Tumor weights. (B) Bioluminescence signal intensity. (C) Cell viability measured with in vivo imaging system (IVIS) imaging (bioluminescent signal). The vertical luminescent color bar represents viability ranging from nonviable (blue) to fully viable (red). Values are expressed as mean ± SD. ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Histopathological changes in U87 tumor xenografts in nude mice treated with compound <b>13</b> daily for 21 days (ON treatment) and 21 days on daily treatment with compound <b>13</b>, followed by discontinuation of treatment for 21 days (ON + OFF treatment). Black arrows indicate the viable tumor cells. Scale bar 40×. There was ∼100% infiltration of malignant cells in controls and almost complete conversion to adipose tissue in treated mice, with <2% viable malignant cells in treated <i>vs</i> control groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Uptake of bodipy dye-labeled compound <b>13</b> in brain with and without GBM. (A) Brain, no GBM, no dye-labeled compound. (B) Brain, no GBM, 24 h after dosing with the dye-labeled compound. (C) Brain, with GBM (U87-luc orthotopic tumor) 24 h after dosing with dye-labeled compound <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/medium/jm1c00350_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Plasma and brain pharmacokinetics of compound <b>13</b> in nude mice with orthotopic GBM tumors, 0–24 h. (A) Plasma levels for <b>13</b>. (B) Plasma AUCs for different doses of <b>13</b>. (C) Brain levels for <b>13</b>. (D) Brain AUCs for different doses of <b>13</b>. NS = not significant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00350/20210506/images/large/jm1c00350_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00350&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">The role of angiogenesis in cancer treatment</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.3390/biomedicines5020034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.3390%2Fbiomedicines5020034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVGgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=34&author=M.+Rajabiauthor=S.+A.+Mousa&title=The+role+of+angiogenesis+in+cancer+treatment&doi=10.3390%2Fbiomedicines5020034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The role of angiogenesis in cancer treatment</span></div><div class="casAuthors">Rajabi, Mehdi; Mousa, Shaker A.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">34/1-34/12</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A no. of anti-angiogenesis drugs have been FDA-approved and are being used in cancer treatment, and a no. of other agents are in different stages of clin. development or in preclin. evaluation.  However, pharmacol. anti-angiogenesis strategies that arrest tumor progression might not be enough to eradicate tumors.  Decreased anti-angiogenesis activity in single mechanism-based anti-angiogenic strategies is due to the redundancy, multiplicity, and development of compensatory mechanism by which blood vessels are remodeled.  Improving anti-angiogenesis drug efficacy will require identification of broad-spectrum anti-angiogenesis targets.  These strategies may have novel features, such as increased porosity, and are the result of complex interactions among endothelial cells, extracellular matrix proteins, growth factors, pericyte, and smooth muscle cells.  Thus, combinations of anti-angiogenic drugs and other anticancer strategies such as chemotherapy appear essential for optimal outcome in cancer patients.  This review will focus on the role of anti-angiogenesis strategies in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVZbMB7TcqbVg90H21EOLACvtfcHk0lgdjQjkO6AWhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVGgsLY%253D&md5=1b746595b46851c065d21a9ef49a8b4e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines5020034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines5020034%26sid%3Dliteratum%253Aachs%26aulast%3DRajabi%26aufirst%3DM.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DThe%2520role%2520of%2520angiogenesis%2520in%2520cancer%2520treatment%26jtitle%3DBiomedicines%26date%3D2017%26volume%3D5%26spage%3D34%26doi%3D10.3390%2Fbiomedicines5020034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sökeland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, U.</span></span> <span> </span><span class="NLM_article-title">The functional role of integrins during intra- and extravasation within the metastatic cascade</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0937-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1186%2Fs12943-018-0937-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=30657059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BB3cjivVSjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=12&author=G.+S%C3%B6kelandauthor=U.+Schumacher&title=The+functional+role+of+integrins+during+intra-+and+extravasation+within+the+metastatic+cascade&doi=10.1186%2Fs12943-018-0937-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The functional role of integrins during intra- and extravasation within the metastatic cascade</span></div><div class="casAuthors">Sokeland Greta; Schumacher Udo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Formation of distant metastases is by far the most common cause of cancer-related deaths.  The process of metastasis formation is complex, and within this complex process the formation of migratory cells, the so called epithelial mesenchymal transition (EMT), which enables cancer cells to break loose from the primary tumor mass and to enter the bloodstream, is of particular importance.  To break loose from the primary cancer, cancer cells have to down-regulate the cell-to-cell adhesion molecuIes (CAMs) which keep them attached to neighboring cancer cells.  In contrast to this downregulation of CAMS in the primary tumor, cancer cells up-regulate other types of CAMs, that enable them to attach to the endothelium in the organ of the future metastasis.  During EMT, the expression of cell-to-cell and cell-to-matrix adhesion molecules and their down- and upregulation is therefore critical for metastasis formation.  Tumor cells mimic leukocytes to enable transmigration of the endothelial barrier at the metastatic site.  The attachment of leukocytes/cancer cells to the endothelium are mediated by several CAMs different from those at the site of the primary tumor.  These CAMs and their ligands are organized in a sequential row, the leukocyte adhesion cascade.  In this adhesion process, integrins and their ligands are centrally involved in the molecular interactions governing the transmigration.  This review discusses the integrin expression patterns found on primary tumor cells and studies whether their expression correlates with tumor progression, metastatic capacity and prognosis.  Simultaneously, further possible, but so far unclearly characterized, alternative adhesion molecules and/or ligands, will be considered and emerging therapeutic possibilities reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-MrG1fXAfThBrI9DTGjC0fW6udTcc2ea2Ei4hZUVbJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjivVSjsg%253D%253D&md5=8790bdf6a90ce4fcb41776e3ddfb2c7a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0937-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0937-3%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B6keland%26aufirst%3DG.%26aulast%3DSchumacher%26aufirst%3DU.%26atitle%3DThe%2520functional%2520role%2520of%2520integrins%2520during%2520intra-%2520and%2520extravasation%2520within%2520the%2520metastatic%2520cascade%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D12%26doi%3D10.1186%2Fs12943-018-0937-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gogiraju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochenek, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, K.</span></span> <span> </span><span class="NLM_article-title">Angiogenic endothelial cell signaling in cardiac hypertrophy and heart Ffailure</span>. <i>Front. Cardiovasc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.3389/fcvm.2019.00020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.3389%2Ffcvm.2019.00020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=30895179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWmtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=20&author=R.+Gogirajuauthor=M.+L.+Bochenekauthor=K.+Sch%C3%A4fer&title=Angiogenic+endothelial+cell+signaling+in+cardiac+hypertrophy+and+heart+Ffailure&doi=10.3389%2Ffcvm.2019.00020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure</span></div><div class="casAuthors">Gogiraju, Rajinikanth; Bochenek, Magdalena L.; Schaefer, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cardiovascular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20</span>CODEN:
                <span class="NLM_cas:coden">FCMRCE</span>;
        ISSN:<span class="NLM_cas:issn">2297-055X</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Endothelial cells are, by no., one of the most abundant cell types in the heart and active players in cardiac physiol. and pathol.  Coronary angiogenesis plays a vital role in maintaining cardiac vascularization and perfusion during physiol. and pathol. hypertrophy.  On the other hand, a redn. in cardiac capillary d. with subsequent tissue hypoxia, cell death and interstitial fibrosis contributes to the development of contractile dysfunction and heart failure, as suggested by clin. as well as exptl. evidence.  Although the mol. causes underlying the inadequate (with respect to the increased oxygen and energy demands of the hypertrophied cardiomyocyte) cardiac vascularization developing during pathol. hypertrophy are incompletely understood.  Research efforts over the past years have discovered interesting mediators and potential candidates involved in this process.  In this review article, we will focus on the vascular changes occurring during cardiac hypertrophy and the transition toward heart failure both in human disease and preclin. models.  We will summarize recent findings in transgenic mice and exptl. models of cardiac hypertrophy on factors expressed and released from cardiomyocytes, pericytes and inflammatory cells involved in the paracrine (dys)regulation of cardiac angiogenesis.  Moreover, we will discuss major signaling events of crit. angiogenic ligands in endothelial cells and their possible disturbance by hypoxia or oxidative stress.  In this regard, we will particularly highlight findings on neg. regulators of angiogenesis, including protein tyrosine phosphatase-1B and tumor suppressor p53, and how they link signaling involved in cell growth and metabolic control to cardiac angiogenesis.  Besides endothelial cell death, phenotypic conversion and acquisition of myofibroblast-like characteristics may also contribute to the development of cardiac fibrosis, the structural correlate of cardiac dysfunction.  Factors secreted by (dysfunctional) endothelial cells and their effects on cardiomyocytes including hypertrophy, contractility and fibrosis, close the vicious circle of reciprocal cell-cell interactions within the heart during pathol. hypertrophy remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6MdE4j6JAybVg90H21EOLACvtfcHk0ljwXNrxEwclrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWmtLfO&md5=16225d5568579d9f374c64c25330274e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffcvm.2019.00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcvm.2019.00020%26sid%3Dliteratum%253Aachs%26aulast%3DGogiraju%26aufirst%3DR.%26aulast%3DBochenek%26aufirst%3DM.%2BL.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DK.%26atitle%3DAngiogenic%2520endothelial%2520cell%2520signaling%2520in%2520cardiac%2520hypertrophy%2520and%2520heart%2520Ffailure%26jtitle%3DFront.%2520Cardiovasc.%2520Med.%26date%3D2019%26volume%3D6%26spage%3D20%26doi%3D10.3389%2Ffcvm.2019.00020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caswell, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadrevu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J. C.</span></span> <span> </span><span class="NLM_article-title">Integrins: masters and slaves of endocytic transport</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">853</span>, <span class="refDoi"> DOI: 10.1038/nrm2799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrm2799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=19904298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2hs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=843-853&author=P.+T.+Caswellauthor=S.+Vadrevuauthor=J.+C.+Norman&title=Integrins%3A+masters+and+slaves+of+endocytic+transport&doi=10.1038%2Fnrm2799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins: masters and slaves of endocytic transport</span></div><div class="casAuthors">Caswell, Patrick T.; Vadrevu, Suryakiran; Norman, Jim C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-853</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since it has become clear that adhesion receptors are trafficked through the endosomal pathway and that this can influence their function, much effort has been invested in obtaining detailed descriptions of the mol. machinery responsible for internalizing and recycling integrins.  New findings indicate that integrin trafficking dictates the nature of Rho GTPase signaling during cytokinesis and cell migration.  Furthermore, integrins can exert control over the trafficking of other receptors in a way that drives cancer cell invasion and tumor angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoonj62hSypLLVg90H21EOLACvtfcHk0ljwXNrxEwclrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2hs7fI&md5=e48a279467d140d584dfc222172bc458</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2799%26sid%3Dliteratum%253Aachs%26aulast%3DCaswell%26aufirst%3DP.%2BT.%26aulast%3DVadrevu%26aufirst%3DS.%26aulast%3DNorman%26aufirst%3DJ.%2BC.%26atitle%3DIntegrins%253A%2520masters%2520and%2520slaves%2520of%2520endocytic%2520transport%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D843%26epage%3D853%26doi%3D10.1038%2Fnrm2799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shattil, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, M. H.</span></span> <span> </span><span class="NLM_article-title">The final steps of integrin activation: the end game</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/nrm2871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrm2871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20308986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1Kju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=288-300&author=S.+J.+Shattilauthor=C.+Kimauthor=M.+H.+Ginsberg&title=The+final+steps+of+integrin+activation%3A+the+end+game&doi=10.1038%2Fnrm2871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The final steps of integrin activation: the end game</span></div><div class="casAuthors">Shattil, Sanford J.; Kim, Chungho; Ginsberg, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">288-300</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cell-directed changes in the ligand-binding affinity ('activation') of integrins regulate cell adhesion and migration, extracellular matrix assembly and mechanotransduction, thereby contributing to embryonic development and diseases such as atherothrombosis and cancer.  Integrin activation comprises triggering events, intermediate signaling events and, finally, the interaction of integrins with cytoplasmic regulators, which changes an integrin's affinity for its ligands.  The 1st 2 events involve diverse interacting signaling pathways, whereas the final steps are immediately proximal to integrins, thus enabling integrin-focused therapeutic strategies.  Recent progress provides insight into the structure of integrin transmembrane domains, and reveals how the final steps of integrin activation are mediated by integrin-binding proteins such as talins and kindlins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJodIAdYgfn7Vg90H21EOLACvtfcHk0ljwXNrxEwclrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1Kju7g%253D&md5=3fd9cbf3b676edbdff66724f40a17a22</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2871%26sid%3Dliteratum%253Aachs%26aulast%3DShattil%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DGinsberg%26aufirst%3DM.%2BH.%26atitle%3DThe%2520final%2520steps%2520of%2520integrin%2520activation%253A%2520the%2520end%2520game%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D288%26epage%3D300%26doi%3D10.1038%2Fnrm2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Multivalency of non-peptide integrin alphaVbeta3 antagonist slows tumor growth</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3603</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/mp400096z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400096z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12hu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=3603-3611&author=Y.-S.+Kimauthor=F.+Liauthor=R.+Kongauthor=Y.+Baiauthor=K.+C.+P.+Liauthor=Y.+Fanauthor=B.+E.+O%E2%80%99Neillauthor=Z.+Li&title=Multivalency+of+non-peptide+integrin+alphaVbeta3+antagonist+slows+tumor+growth&doi=10.1021%2Fmp400096z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalency of Non-Peptide Integrin αVβ3 Antagonist Slows Tumor Growth</span></div><div class="casAuthors">Kim, Yoo-Shin; Li, Feng; Kong, Ren; Bai, Yang; Li, King C. P.; Fan, Yubo; O'Neill, Brian E.; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3603-3611</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multivalency is a powerful strategy for achieving high-affinity mol. binding of compds. to increase their therapeutic potency or imaging potential.  In our study, multivalent non-peptide integrin αvβ3 antagonists (IA) were designed for antitumor therapy.  Docking and mol. dynamics were employed to explore the binding modes of IA monomer, dimer, and trimer.  In silico, one IA unit binds tightly in the active site with similar pose to native ligand RGD and other parts of dimer and trimer contribute extra binding affinities by interacting with residues in vicinity of the original site.  In vitro studies demonstrated that increasing valency results in increasing antiproliferative and antiorganizational effects against endothelial cells (HUVECs), and a much weaker effect on melanoma B16F10 cells.  The antitumor efficacies of the IA multivalent compds. were evaluated in s.c. B16F10 melanoma tumor-bearing mice.  At 30 mg/kg dose, the mean masses of tumors harvested 18 days after inoculation were significantly reduced (p < 10-7) by 36 ± 9%, 49 ± 8%, and 71 ± 7% for the IA monomer, dimer, and trimer groups, relative to control.  The importance of multivalency was demonstrated to be highly significant beyond the additive effect of the extra pharmacol. sites (p = 0.00011).  These results suggest that the major target of these anti-αvβ3 compds. is the neovasculature rather than the cancer cells, and the success of a multivalent strategy depends on the details of the components and linker.  This is the first integrin αvβ3 multivalent ligand showing clear enhancement in antitumor effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6jjRZfbvM-LVg90H21EOLACvtfcHk0lhIdhZ9Kndd_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12hu73F&md5=45f25fc183a59bd628ffafd75ace60dd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fmp400096z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400096z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.-S.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DK.%2BC.%2BP.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BE.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DMultivalency%2520of%2520non-peptide%2520integrin%2520alphaVbeta3%2520antagonist%2520slows%2520tumor%2520growth%26jtitle%3DMol.%2520Pharm.%26date%3D2013%26volume%3D10%26spage%3D3603%26epage%3D3611%26doi%3D10.1021%2Fmp400096z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, N.</span></span> <span> </span><span class="NLM_article-title">Integrins as therapeutic targets: lessons and opportunities</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1038/nrd3266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrd3266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20885411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=804-820&author=D.+Coxauthor=M.+Brennanauthor=N.+Moran&title=Integrins+as+therapeutic+targets%3A+lessons+and+opportunities&doi=10.1038%2Fnrd3266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins as therapeutic targets: lessons and opportunities</span></div><div class="casAuthors">Cox, Dermot; Brennan, Marian; Moran, Niamh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">804-820</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The integrins are a large family of cell adhesion mols. that are essential for the regulation of cell growth and function.  The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and autoimmune disorders, has revealed their substantial potential as therapeutic targets.  However, so far, pharmacol. inhibitors for only three integrins have received marketing approval.  This article discusses the structure and function of integrins, their roles in disease and the chequered history of the approved integrin antagonists.  Recent advances in the understanding of integrin function, ligand interaction and signalling pathways suggest novel strategies for inhibiting integrin function that could help harness their full potential as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovx8-nQd0Z5bVg90H21EOLACvtfcHk0lhIdhZ9Kndd_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur7O&md5=9ecab45ea4bd2b654bb623b7b5c55869</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd3266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3266%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DD.%26aulast%3DBrennan%26aufirst%3DM.%26aulast%3DMoran%26aufirst%3DN.%26atitle%3DIntegrins%2520as%2520therapeutic%2520targets%253A%2520lessons%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2010%26volume%3D9%26spage%3D804%26epage%3D820%26doi%3D10.1038%2Fnrd3266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizejewski, G. J.</span></span> <span> </span><span class="NLM_article-title">Role of integrins in cancer: survey of expression patterns</span>. <i>Proc. Soc. Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1046/j.1525-1373.1999.d01-122.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1046%2Fj.1525-1373.1999.d01-122.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10564536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADyaK1MXntFCgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=1999&pages=124-138&author=G.+J.+Mizejewski&title=Role+of+integrins+in+cancer%3A+survey+of+expression+patterns&doi=10.1046%2Fj.1525-1373.1999.d01-122.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Role of integrins in cancer: survey of expression patterns (44435)</span></div><div class="casAuthors">Mizejewski, Gerald J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">PSEBAA</span>;
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">A review, with 142 refs.  Tumor cells are characterized by uncontrolled growth, invasion to surrounding tissues, and metastatic spread to distant sites.  Mortality from cancer is often due to metastasis since surgical removal of tumors can enhance and prolong survival.  The integrins constitute a family of transmembrane receptor proteins composed of heterodimeric complexes of noncovalently linked α and β chains.  Integrins function in cell-to-cell and cell-to-extracellular matrix (ECM) adhesive interactions and transduce signals from the ECM to the cell interior and vice versa.  Hence, the integrins mediate the ECM influence on cell growth and differentiation.  Since these properties implicate integrin involvement in cell migration, invasion, intra- and extra-vasation, and platelet interaction, a role for integrins in tumor growth and metastasis is obvious.  These findings are underpinned by observations that the integrins are linked to the actin cytoskeleton involving talin, vinculin, and α-actinin as intermediaries.  Such cytoskeletal changes can be manifested by rounded cell morphol., which is often coincident with tumor transformation via decreased or increased integrin expression patterns.  For the various types of cancers, different changes in integrin expression are further assocd. with tumor growth and metastasis.  Tumor progression leading to metastasis appears to involve equipping cancer cells with the appropriate adhesive (integrin) phenotype for interaction with the ECM.  Therapies directed at influencing integrin cell expression and function are presently being explored for inhibition of tumor growth, metastasis, and angiogenesis.  Such therapeutic strategies include antiintegrin monoclonal antibodies, peptidic inhibitors (cyclic and linear), calcium-binding protein antagonists, proline analogs, apoptosis promoters, and antisense oligonucleotides.  Moreover, platelet aggregation induced by tumor cells, which facilitates metastatic spread, can be inhibited by the disintegrins, a family of viper venomlike peptides.  Therefore, adhesion mols. from the integrin family and components of angiogenesis might be useful as tumor progression markers for prognostic and for diagnostic purposes.  Development of integrin cell expression profiles for individual tumors may have further potential in identifying a cell surface signature for a specific tumor type and/or stage.  Thus, recent advances in elucidating the structure, function, ECM binding, and signaling pathways of the integrins have led to new and exciting modalities for cancer therapeutics and diagnoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2NeN0TMPfG7Vg90H21EOLACvtfcHk0lhIdhZ9Kndd_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFCgtr4%253D&md5=b588fc47db330db893a7d09e043397d7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1046%2Fj.1525-1373.1999.d01-122.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1525-1373.1999.d01-122.x%26sid%3Dliteratum%253Aachs%26aulast%3DMizejewski%26aufirst%3DG.%2BJ.%26atitle%3DRole%2520of%2520integrins%2520in%2520cancer%253A%2520survey%2520of%2520expression%2520patterns%26jtitle%3DProc.%2520Soc.%2520Exp.%2520Biol.%2520Med.%26date%3D1999%26volume%3D222%26spage%3D124%26epage%3D138%26doi%3D10.1046%2Fj.1525-1373.1999.d01-122.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Requirement of vascular integrin alpha v beta 3 for angiogenesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1126/science.7512751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1126%2Fscience.7512751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=7512751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1Sis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=569-571&author=P.+C.+Brooksauthor=R.+A.+Clarkauthor=D.+A.+Cheresh&title=Requirement+of+vascular+integrin+alpha+v+beta+3+for+angiogenesis&doi=10.1126%2Fscience.7512751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of vascular integrin αvβ3 for angiogenesis</span></div><div class="casAuthors">Brooks, Peter C.; Clark, Richard A. F.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5158</span>),
    <span class="NLM_cas:pages">569-71</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Angiogenesis depends on the adhesive interaction of vascular cells.  The adhesion receptor integrin αvβ3 was identified as a marker of angiogenic vascular tissue.  Integrin αvβ3 was expressed on blood vessels in human wound granulation tissue but not in normal skin, and it showed a fourfold increase in expression during angiogenesis on the chick chorioallantoic membrane.  In the latter assay, a monoclonal antibody to αvβ3 blocked angiogenesis induced by basic fibroblast growth factor, tumor necrosis factor-α, and human melanoma fragments but had no effect on preexisting vessels.  These findings suggest that αvβ3 may be a useful therapeutic target for diseases characterized by neovascularization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV5qQMsunLZrVg90H21EOLACvtfcHk0lgCc476pIfAmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1Sis7w%253D&md5=759c5081d980c4e81058a1594fcd60f1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.7512751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7512751%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DP.%2BC.%26aulast%3DClark%26aufirst%3DR.%2BA.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DRequirement%2520of%2520vascular%2520integrin%2520alpha%2520v%2520beta%25203%2520for%2520angiogenesis%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D569%26epage%3D571%26doi%3D10.1126%2Fscience.7512751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desgrosellier, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Integrins in cancer: biological implications and therapeutic opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc2748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fnrc2748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20029421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=9-22&author=J.+S.+Desgrosellierauthor=D.+A.+Cheresh&title=Integrins+in+cancer%3A+biological+implications+and+therapeutic+opportunities&doi=10.1038%2Fnrc2748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins in cancer: biological implications and therapeutic opportunities</span></div><div class="casAuthors">Desgrosellier, Jay S.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumors.  The importance of integrins in several cell types that affect tumor progression has made them an appealing target for cancer therapy.  Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clin. trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma.  These exciting clin. developments emphasize the need to identify how integrin antagonists influence the tumor and its microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL2sajdsDI07Vg90H21EOLACvtfcHk0lgCc476pIfAmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI&md5=43d0b526ca38021e780aba991a58451b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2748%26sid%3Dliteratum%253Aachs%26aulast%3DDesgrosellier%26aufirst%3DJ.%2BS.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DIntegrins%2520in%2520cancer%253A%2520biological%2520implications%2520and%2520therapeutic%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D9%26epage%3D22%26doi%3D10.1038%2Fnrc2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lafrenie, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewick, M. A.</span></span> <span> </span><span class="NLM_article-title">Cell adhesion and cancer: is there a potential for therapeutic intervention?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1517/14728222.11.6.727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1517%2F14728222.11.6.727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=17504010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=727-731&author=R.+M.+Lafrenieauthor=C.+A.+Bucknerauthor=M.+A.+Bewick&title=Cell+adhesion+and+cancer%3A+is+there+a+potential+for+therapeutic+intervention%3F&doi=10.1517%2F14728222.11.6.727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cell adhesion and cancer: Is there a potential for therapeutic intervention?</span></div><div class="casAuthors">Lafrenie, Robert M.; Buckner, Carly A.; Bewick, Mary A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-731</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Carcinogenesis involves a disruption in adhesion mol. expression and tissue architecture, and tumor invasion requires adhesion-dependent migration into surrounding tissues.  Therefore, a variety of peptide and antibody-based reagents that block integrins, cadherins, Ig superfamily and selectin adhesion mols. have been developed to treat cancers.  Therapeutics directed at adhesion mols. can block interactions between tumor cells, endothelial cells and immune cells to prevent tumor cell invasiveness and metastasis.  Blocking the adhesion mols. that facilitate the invasion of tumors by endothelial cells and immune cells can prevent tumor-assocd. angiogenesis and the recruitment of immune-mediated growth factors which are required for tumor growth and spread.  In addn., targeted therapies using anticancer agents attached to antibodies or peptides directed as tumor-specific adhesion mols. are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohjm-IpASbs7Vg90H21EOLACvtfcHk0lgCc476pIfAmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOis7o%253D&md5=067d56ac6d0e21712c17846dce965a90</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F14728222.11.6.727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.11.6.727%26sid%3Dliteratum%253Aachs%26aulast%3DLafrenie%26aufirst%3DR.%2BM.%26aulast%3DBuckner%26aufirst%3DC.%2BA.%26aulast%3DBewick%26aufirst%3DM.%2BA.%26atitle%3DCell%2520adhesion%2520and%2520cancer%253A%2520is%2520there%2520a%2520potential%2520for%2520therapeutic%2520intervention%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2007%26volume%3D11%26spage%3D727%26epage%3D731%26doi%3D10.1517%2F14728222.11.6.727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mas-Moruno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechenmacher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span> <span> </span><span class="NLM_article-title">Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation</span>. <i>Adv. Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.2174/187152010794728639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.2174%2F187152010794728639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=21269250" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=753-768&author=C.+Mas-Morunoauthor=F.+Rechenmacherauthor=H.+Kessler&title=Cilengitide%3A+the+first+anti-angiogenic+small+molecule+drug+candidate+design%2C+synthesis+and+clinical+evaluation&doi=10.2174%2F187152010794728639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F187152010794728639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728639%26sid%3Dliteratum%253Aachs%26aulast%3DMas-Moruno%26aufirst%3DC.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DCilengitide%253A%2520the%2520first%2520anti-angiogenic%2520small%2520molecule%2520drug%2520candidate%2520design%252C%2520synthesis%2520and%2520clinical%2520evaluation%26jtitle%3DAdv.%2520Anticancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D753%26epage%3D768%26doi%3D10.2174%2F187152010794728639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegi, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erridge, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldape, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lhermitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grujicic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarnawski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyerbrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taphoorn, M. J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurzo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrlinger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortmann, R.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabors, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bent, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicking, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markivskyy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group">European Organisation for Research and Treatment of Cancer (EORTC)</span>; <span class="NLM_contrib-group">Canadian Brain Tumor Consortium; CENTRIC study team</span> <span> </span><span class="NLM_article-title">Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(14)70379-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2FS1470-2045%2814%2970379-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=25163906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1100-1108&author=R.+Stuppauthor=M.+E.+Hegiauthor=T.+Gorliaauthor=S.+C.+Erridgeauthor=J.+Perryauthor=Y.-K.+Hongauthor=K.+D.+Aldapeauthor=B.+Lhermitteauthor=T.+Pietschauthor=D.+Grujicicauthor=J.+P.+Steinbachauthor=W.+Wickauthor=R.+Tarnawskiauthor=D.-H.+Namauthor=P.+Hauauthor=A.+Weyerbrockauthor=M.+J.+B.+Taphoornauthor=C.-C.+Shenauthor=N.+Raoauthor=L.+Thurzoauthor=U.+Herrlingerauthor=T.+Guptaauthor=R.-D.+Kortmannauthor=K.+Adamskaauthor=C.+McBainauthor=A.+A.+Brandesauthor=J.+C.+Tonnauthor=O.+Schnellauthor=T.+Wiegelauthor=C.-Y.+Kimauthor=L.+B.+Naborsauthor=D.+A.+Reardonauthor=M.+J.+van+den+Bentauthor=C.+Hickingauthor=A.+Markivskyyauthor=M.+Picardauthor=M.+Wellerauthor=European+Organisation+for+Research+and+Treatment+of+Cancer+%28EORTC%29author=Canadian+Brain+Tumor+Consortium%3B+CENTRIC+study+team&title=Cilengitide+combined+with+standard+treatment+for+patients+with+newly+diagnosed+glioblastoma+with+methylated+MGMT+promoter+%28CENTRIC+EORTC+26071-22072+study%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2Fs1470-2045%2814%2970379-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide Combined With Standard Treatment For Patients With Newly Diagnosed Glioblastoma With Methylated Mgmt Promoter (centric Eortc 26071-22072 Study): A Multicentre, Randomised, Open-label, Phase 3 Trial</span></div><div class="casAuthors">Stupp, Roger; Hegi, Monika E.; Gorlia, Thierry; Erridge, Sara C.; Perry, James; Hong, Yong-Kil; Aldape, Kenneth D.; Lhermitte, Benoit; Pietsch, Torsten; Grujicic, Danica; Steinbach, Joachim Peter; Wick, Wolfgang; Tarnawski, Rafal; Nam, Do-Hyun; Hau, Peter; Weyerbrock, Astrid; Taphoorn, Martin J. B.; Shen, Chiung-Chyi; Rao, Nalini; Thurzo, Laszlo; Herrlinger, Ulrich; Gupta, Tejpal; Kortmann, Rolf-Dieter; Adamska, Krystyna; McBain, Catherine; Brandes, Alba A.; Tonn, Joerg Christian; Schnell, Oliver; Wiegel, Thomas; Kim, Chae-Yong; Nabors, Louis Burt; Reardon, David A.; van den Bent, Martin J.; Hicking, Christine; Markivskyy, Andriy; Picard, Martin; Weller, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1100-1108</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor.  Data from phase 2 trials suggest that it has antitumor activity as a single agent in recurrent glioblastoma and in combination with std. temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumors with methylated MGMT promoter).  We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.  In this multicentre, open-label, phase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries.  Eligible patients (newly diagnosed, histol. proven supratentorial glioblastoma, methylated MGMT promoter, and age ≥18 years) were stratified for prognostic Radiation Therapy Oncol. Group recursive partitioning anal. class and geog. region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg i.v. twice weekly (cilengitide group) or temozolomide chemoradiotherapy alone (control group).  Patients and investigators were unmasked to treatment allocation.  Maintenance temozolomide was given for up to six cycles, and cilengitide was given for up to 18 mo or until disease progression or unacceptable toxic effects.  The primary endpoint was overall survival.  We analyzed survival outcomes by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT00689221.  Overall, 3471 patients were screened.  Of these patients, 3060 had tumor MGMT status tested; 926 patients had a methylated MGMT promoter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oct 31, 2008, and May 12, 2011.  Median overall survival was 26·3 mo (95% CI 23·8-28·8) in the cilengitide group and 26·3 mo (23·9-34·7) in the control group (hazard ratio 1·02, 95% CI 0·81-1·29, p=0·86).  None of the predefined clin. subgroups showed a benefit from cilengitide.  We noted no overall addnl. toxic effects with cilengitide treatment.  The most commonly reported adverse events of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]).  The addn. of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticancer drug.  Nevertheless, integrins remain a potential treatment target for glioblastoma.Merck KGaA, Darmstadt, Germany.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWaDt0u-c9qbVg90H21EOLACvtfcHk0li2ukSdMBHBUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E&md5=7abd568898db9f543c4db31c74faafbe</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970379-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970379-1%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DHegi%26aufirst%3DM.%2BE.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DErridge%26aufirst%3DS.%2BC.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DY.-K.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DLhermitte%26aufirst%3DB.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DGrujicic%26aufirst%3DD.%26aulast%3DSteinbach%26aufirst%3DJ.%2BP.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DTarnawski%26aufirst%3DR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHau%26aufirst%3DP.%26aulast%3DWeyerbrock%26aufirst%3DA.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%2BB.%26aulast%3DShen%26aufirst%3DC.-C.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DThurzo%26aufirst%3DL.%26aulast%3DHerrlinger%26aufirst%3DU.%26aulast%3DGupta%26aufirst%3DT.%26aulast%3DKortmann%26aufirst%3DR.-D.%26aulast%3DAdamska%26aufirst%3DK.%26aulast%3DMcBain%26aufirst%3DC.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DTonn%26aufirst%3DJ.%2BC.%26aulast%3DSchnell%26aufirst%3DO.%26aulast%3DWiegel%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DC.-Y.%26aulast%3DNabors%26aufirst%3DL.%2BB.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3Dvan%2Bden%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DHicking%26aufirst%3DC.%26aulast%3DMarkivskyy%26aufirst%3DA.%26aulast%3DPicard%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3D%26aulast%3D%26atitle%3DCilengitide%2520combined%2520with%2520standard%2520treatment%2520for%2520patients%2520with%2520newly%2520diagnosed%2520glioblastoma%2520with%2520methylated%2520MGMT%2520promoter%2520%2528CENTRIC%2520EORTC%252026071-22072%2520study%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1100%26epage%3D1108%26doi%3D10.1016%2Fs1470-2045%2814%2970379-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdreich-Epstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metelitsa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stins, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span> <span> </span><span class="NLM_article-title">Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">721</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10676658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1GmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=712-721&author=A.+Erdreich-Epsteinauthor=H.+Shimadaauthor=S.+Groshenauthor=M.+Liuauthor=L.+S.+Metelitsaauthor=K.+S.+Kimauthor=M.+F.+Stinsauthor=R.+C.+Seegerauthor=D.+L.+Durden&title=Integrins+alpha%28v%29beta3+and+alpha%28v%29beta5+are+expressed+by+endothelium+of+high-risk+neuroblastoma+and+their+inhibition+is+associated+with+increased+endogenous+ceramide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins αvβ3 and αvβ5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide</span></div><div class="casAuthors">Erdreich-Epstein, Anat; Shimada, Hiroyuki; Groshen, Susan; Liu, Ming; Metelitsa, Leonid S.; Kim, Kwang Sik; Stins, Monique F.; Seeger, Robert C.; Durden, Donald L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-721</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inhibition of the RGD-binding integrins, αvβ3 and αvβ5, prevents endothelial cell anchorage and induces endothelial apoptosis, which results in disruption of tumor angiogenesis and inhibition of tumor growth in animal models.  In this study, we demonstrate by immunohistochem. anal. that integrin αvβ3 was expressed by 61% (mean) of microvessels in high-risk neuroblastomas (stage IV and MYCN-amplified stage III) but only by 18% (mean) of microvessels in low-risk tumors (stages I and II and non-MYCN-amplified stage III).  Integrin αvβ5 was found on 60% (mean) of microvessels in 21 Stage IV tumors.  These data suggest that neuroblastomas may be targeted for antiangiogenic treatment directed against endothelial integrins αvβ3 and αvβ5.  In cell culture, inhibition of integrin-dependent endothelial cell anchorage to vitronectin by RGDfV, an RGD function-blocking cyclic peptide, induced apoptosis in bovine brain endothelial cells compared with the control peptide, RADfV (37.5% vs. 8.7%, resp.), as detected by chromatin condensation and nuclear fragmentation.  Treatment with RGDfV but not with RADfV, which prevented attachment of endothelial cells to vitronectin or fibronectin, was assocd. with up to a 50% increase in endogenous ceramide, a lipid second messenger that can mediate cell death.  Furthermore, exogenous C2-ceramide was cytotoxic to bovine brain endothelial cells and induced activation of C-jun N-terminal kinase (JNK), a MAP kinase that can be activated in stress-induced apoptosis pathways.  This suggests that ceramide may function in detachment-induced endothelial cell apoptosis, originating from inhibition of vitronectin binding to integrins such as αvβ3 and αvβ5.  This is the first report to demonstrate expression of integrins αvβ3 and αvβ5 by microvascular endothelium of a childhood tumor and assocn. of their expression with neuroblastoma aggressiveness.  Furthermore, our data provide the first suggestion that inhibition of endothelial cell anchorage, resulting from specific blockade of RGD-binding integrins, increases endogenous ceramide, which may contribute to endothelial cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUWfmdoAXZbVg90H21EOLACvtfcHk0li2ukSdMBHBUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1GmtbY%253D&md5=1400f7cd11196505f84eed0a682e4831</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErdreich-Epstein%26aufirst%3DA.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DGroshen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMetelitsa%26aufirst%3DL.%2BS.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DStins%26aufirst%3DM.%2BF.%26aulast%3DSeeger%26aufirst%3DR.%2BC.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DIntegrins%2520alpha%2528v%2529beta3%2520and%2520alpha%2528v%2529beta5%2520are%2520expressed%2520by%2520endothelium%2520of%2520high-risk%2520neuroblastoma%2520and%2520their%2520inhibition%2520is%2520associated%2520with%2520increased%2520endogenous%2520ceramide%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D712%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisele, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochsenbein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krex, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikkhah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span> <span> </span><span class="NLM_article-title">Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression</span>. <i>J Neurooncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1007/s11060-014-1365-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1007%2Fs11060-014-1365-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=24442484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BC2czmslOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2014&pages=141-145&author=G.+Eiseleauthor=A.+Wickauthor=A.-C.+Eiseleauthor=P.+M.+Cl%C3%A9mentauthor=J.+Tonnauthor=G.+Tabatabaiauthor=A.+Ochsenbeinauthor=U.+Schlegelauthor=B.+Neynsauthor=D.+Krexauthor=M.+Simonauthor=G.+Nikkhahauthor=M.+Picardauthor=R.+Stuppauthor=W.+Wickauthor=M.+Weller&title=Cilengitide+treatment+of+newly+diagnosed+glioblastoma+patients+does+not+alter+patterns+of+progression&doi=10.1007%2Fs11060-014-1365-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression</span></div><div class="casAuthors">Eisele Gunter; Wick Antje; Eisele Anna-Carina; Clement Paul M; Tonn Jorg; Tabatabai Ghazaleh; Ochsenbein Adrian; Schlegel Uwe; Neyns Bart; Krex Dietmar; Simon Matthias; Nikkhah Guido; Picard Martin; Stupp Roger; Wick Wolfgang; Weller Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma.  Preclinical data as well as anecdotal clinical observations indicate that anti-angiogenic treatment may result in altered patterns of tumor progression.  Using a standardized approach, we analyzed patterns of progression on MRI in 21 patients enrolled onto a phase 2 trial of cilengitide added to TMZ/RT → TMZ in newly diagnosed glioblastoma.  Thirty patients from the experimental treatment arm of the EORTC/NCIC pivotal TMZ trial served as a reference.  MRIcro software was used to map location and extent of initial preoperative and recurrent tumors on MRI of both groups into the same stereotaxic space which were then analyzed using an automated tool of image analysis.  Clinical and outcome data of the cilengitide-treated patients were similar to those of the EORTC/NCIC trial except for a higher proportion of patients with a methylated O(6)-methylguanyl-DNA-methyltransferase gene promoter.  Analysis of recurrence pattern revealed neither a difference in the size of the recurrent tumor nor in the distance of the recurrences from the preoperative tumor location between groups.  Overall frequencies of distant recurrences were 20 % in the reference group and 19 % (4/21 patients) in the cilengitide group.  Compared with TMZ/RT → TMZ alone, the addition of cilengitide does not alter patterns of progression.  This analysis does not support concerns that integrin antagonism by cilengitide may induce a more aggressive phenotype at progression, but also provides no evidence for an anti-invasive activity of cilengitide in patients with newly diagnosed glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHwJuTidk9C5Pq5LRczm8ffW6udTcc2eYRljXvkcXQgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czmslOitw%253D%253D&md5=935f11f2cd195b4243c212dc972b2e03</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11060-014-1365-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-014-1365-x%26sid%3Dliteratum%253Aachs%26aulast%3DEisele%26aufirst%3DG.%26aulast%3DWick%26aufirst%3DA.%26aulast%3DEisele%26aufirst%3DA.-C.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DP.%2BM.%26aulast%3DTonn%26aufirst%3DJ.%26aulast%3DTabatabai%26aufirst%3DG.%26aulast%3DOchsenbein%26aufirst%3DA.%26aulast%3DSchlegel%26aufirst%3DU.%26aulast%3DNeyns%26aufirst%3DB.%26aulast%3DKrex%26aufirst%3DD.%26aulast%3DSimon%26aufirst%3DM.%26aulast%3DNikkhah%26aufirst%3DG.%26aulast%3DPicard%26aufirst%3DM.%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DCilengitide%2520treatment%2520of%2520newly%2520diagnosed%2520glioblastoma%2520patients%2520does%2520not%2520alter%2520patterns%2520of%2520progression%26jtitle%3DJ%2520Neurooncol.%26date%3D2014%26volume%3D117%26spage%3D141%26epage%3D145%26doi%3D10.1007%2Fs11060-014-1365-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadiyala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alghamri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fabiani, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asad, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicola Candia, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candolfi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwendeman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M. G.</span></span> <span> </span><span class="NLM_article-title">Prospects of biological and synthetic pharmacotherapies for glioblastoma</span>. <i>Expet Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1080/14712598.2020.1713085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1080%2F14712598.2020.1713085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=31959027" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=305-317&author=D.+B.+Altshulerauthor=P.+Kadiyalaauthor=F.+J.+Nu%C3%B1ezauthor=F.+M.+Nu%C3%B1ezauthor=S.+Carneyauthor=M.+S.+Alghamriauthor=M.+B.+Garcia-Fabianiauthor=A.+S.+Asadauthor=A.+J.+Nicola+Candiaauthor=M.+Candolfiauthor=J.+Lahannauthor=J.+J.+Moonauthor=A.+Schwendemanauthor=P.+R.+Lowensteinauthor=M.+G.+Castro&title=Prospects+of+biological+and+synthetic+pharmacotherapies+for+glioblastoma&doi=10.1080%2F14712598.2020.1713085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F14712598.2020.1713085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2020.1713085%26sid%3Dliteratum%253Aachs%26aulast%3DAltshuler%26aufirst%3DD.%2BB.%26aulast%3DKadiyala%26aufirst%3DP.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DF.%2BJ.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DF.%2BM.%26aulast%3DCarney%26aufirst%3DS.%26aulast%3DAlghamri%26aufirst%3DM.%2BS.%26aulast%3DGarcia-Fabiani%26aufirst%3DM.%2BB.%26aulast%3DAsad%26aufirst%3DA.%2BS.%26aulast%3DNicola%2BCandia%26aufirst%3DA.%2BJ.%26aulast%3DCandolfi%26aufirst%3DM.%26aulast%3DLahann%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DJ.%2BJ.%26aulast%3DSchwendeman%26aufirst%3DA.%26aulast%3DLowenstein%26aufirst%3DP.%2BR.%26aulast%3DCastro%26aufirst%3DM.%2BG.%26atitle%3DProspects%2520of%2520biological%2520and%2520synthetic%2520pharmacotherapies%2520for%2520glioblastoma%26jtitle%3DExpet%2520Opin.%2520Biol.%2520Ther.%26date%3D2020%26volume%3D20%26spage%3D305%26epage%3D317%26doi%3D10.1080%2F14712598.2020.1713085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godugu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharali, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin alphavbeta3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3087</span>– <span class="NLM_lpage">3097</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00742</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00742" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCns73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=3087-3097&author=M.+Rajabiauthor=K.+Goduguauthor=T.+Sudhaauthor=D.+J.+Bharaliauthor=S.+A.+Mousa&title=Triazole+Modified+Tetraiodothyroacetic+Acid+Conjugated+to+Polyethylene+Glycol%3A+High+Affinity+Thyrointegrin+alphavbeta3+Antagonist+with+Potent+Anticancer+Activities+in+Glioblastoma+Multiforme&doi=10.1021%2Facs.bioconjchem.9b00742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin αvβ3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme</span></div><div class="casAuthors">Rajabi, Mehdi; Godugu, Kavitha; Sudha, Thangirala; Bharali, Dhruba J.; Mousa, Shaker A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3087-3097</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of bioactive mols. that target integrins has implicated their role in tumor angiogenesis, tumor growth, metastasis, and other pathol. angiogenesis processes.  Integrins are members of a family of cell surface receptors that play a crit. role in the angiogenesis process.  Tetraiodothyroacetic acid (tetrac), a deaminated deriv. of L-thyroxine (T4), is a "thyrointegrin" antagonist that blocks the actions of L-triiodothyronine (T3) and T4 with an interaction site that is located at or near the RGD recognition site identified on integrin αvβ3's binding pocket (thyrointegrin αvβ3 receptors).  We have enhanced the biol. activity of a tetrac-based inhibitor via significantly improving its αvβ3 receptor binding affinity by introducing a triazole ring on the outer ring of tetrac and covalently conjugating to polymer to increase the product's hydrophilicity via PEGylation.  The product, P-bi-TAT, was restricted from nuclear translocation and demonstrated high blood brain barrier permeability and retention in contrast to the non-PEG conjugated deriv.  Results of biol. activity indicated that this macromol. new chem. entity P-bi-TAT has greater than 400-fold potent integrin αvβ3 affinity vs. the parent compd. tetrac and has potent anticancer/anti-angiogenesis efficacy against glioblastoma multiforme (GBM).  P-bi-TAT administered s.c. once daily for 21 days at 1-10 mg/kg mouse body wt. resulted in a dose-dependent suppression of GBM tumor growth and viability as monitored with IVIS imaging (P < 0.001).  GBM tumors had >95% vol. loss and maximal loss of GBM cell viability during the 21 days ON-treatment expt. as well as in the 21 days ON followed by 21 days OFF-treatment expt. (P < 0.001).  In conclusion, P-bi-TAT is a promising lead clin. candidate effective in the treatment of human GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6VHEbhjNBLbVg90H21EOLACvtfcHk0lhHWuNnCBZyPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCns73I&md5=769734f22a93bf5ff2a9766cc4e76a53</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00742%26sid%3Dliteratum%253Aachs%26aulast%3DRajabi%26aufirst%3DM.%26aulast%3DGodugu%26aufirst%3DK.%26aulast%3DSudha%26aufirst%3DT.%26aulast%3DBharali%26aufirst%3DD.%2BJ.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DTriazole%2520Modified%2520Tetraiodothyroacetic%2520Acid%2520Conjugated%2520to%2520Polyethylene%2520Glycol%253A%2520High%2520Affinity%2520Thyrointegrin%2520alphavbeta3%2520Antagonist%2520with%2520Potent%2520Anticancer%2520Activities%2520in%2520Glioblastoma%2520Multiforme%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26spage%3D3087%26epage%3D3097%26doi%3D10.1021%2Facs.bioconjchem.9b00742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrle, J.</span></span> <span> </span><span class="NLM_article-title">Transport of thyroid hormone in brain</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">98</span>, <span class="refDoi"> DOI: 10.3389/fendo.2014.00098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.3389%2Ffendo.2014.00098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=25009532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgvFCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=98&author=E.+K.+Wirthauthor=U.+Schweizerauthor=J.+Kohrle&title=Transport+of+thyroid+hormone+in+brain&doi=10.3389%2Ffendo.2014.00098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of thyroid hormone in brain</span></div><div class="casAuthors">Wirth Eva K; Kohrle Josef; Schweizer Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Thyroid hormone (TH) transport into the brain is not only pivotal for development and differentiation, but also for maintenance and regulation of adult central nervous system (CNS) function.  In this review, we highlight some key factors and structures regulating TH uptake and distribution.  Serum TH binding proteins play a major role for the availability of TH since only free hormone concentrations may dictate cellular uptake.  One of these proteins, transthyretin is also present in the cerebrospinal fluid (CSF) after being secreted by the choroid plexus.  Entry routes into the brain like the blood-brain-barrier (BBB) and the blood-CSF-barrier will be explicated regarding fetal and adult status.  Recently identified TH transmembrane transporters (THTT) like monocarboxylate transporter 8 (Mct8) play a major role in uptake of TH across the BBB but as well in transport between cells like astrocytes and neurons within the brain.  Species differences in transporter expression will be presented and interference of TH transport by endogenous and exogenous compounds including endocrine disruptors and drugs will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiRBDaczwbdYHWj6b1v8uTfW6udTcc2ebSw0vhFp2xGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgvFCjug%253D%253D&md5=d0144f25494eb9071e6d97b61e35596f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2014.00098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2014.00098%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DE.%2BK.%26aulast%3DSchweizer%26aufirst%3DU.%26aulast%3DKohrle%26aufirst%3DJ.%26atitle%3DTransport%2520of%2520thyroid%2520hormone%2520in%2520brain%26jtitle%3DFront.%2520Endocrinol.%26date%3D2014%26volume%3D5%26spage%3D98%26doi%3D10.3389%2Ffendo.2014.00098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vehovec, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obreza, A.</span></span> <span> </span><span class="NLM_article-title">Review of operating principle and applications of the charged aerosol detector</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1217</i></span>,  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1556</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2010.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.chroma.2010.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=20083252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1217&publication_year=2010&pages=1549-1556&author=T.+Vehovecauthor=A.+Obreza&title=Review+of+operating+principle+and+applications+of+the+charged+aerosol+detector&doi=10.1016%2Fj.chroma.2010.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Review of operating principle and applications of the charged aerosol detector</span></div><div class="casAuthors">Vehovec, Tanja; Obreza, Ales</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography A</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1217</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1549-1556</span>CODEN:
                <span class="NLM_cas:coden">JCRAEY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9673</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recently a new detection method, based upon aerosol charging (the charged aerosol detector (CAD)) was introduced as an alternative to evaporative light-scattering detector (ELSD), chemiluminescent nitrogen detector and refractive index detector for detection of non-UV and weakly UV active compds. and for UV-absorbing compds. in the absence of stds.  The content of this review article includes description of operation principle, advantages and disadvantages of CAD system, and short reports of selected applications of this detector.  The main advantages of CAD detector are unique performance characteristics: better sensitivity than ELSD system, a dynamic range of up to 4 orders of magnitude, ease of use and constancy of response factors.  Both detectors are mass dependent and the response generated does not depend on the spectral or physicochem. properties of the analyte.  This attractive feature of a detection technique generating universal response factors is the potential use of a single, universal std. for calibration against which all other compds. or impurities can be qualified.  CAD also has the same limitation as ELSD, namely, the response is affected by mobile-phase compn.  This problem was resolved by using inverse gradient compensation as is done for HPLC and supercrit. fluid chromatog.  CAD was applied for the anal. of structurally diverse compds. used in the pharmaceutical, chem., food, and consumer products industries and in life science research.  They include nonvolatile and semivolatile neutral, acidic, basic, and zwitterionic compds., both polar and nonpolar (e.g. lipids, proteins, steroids, polymers, carbohydrates, peptides).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAdn4vuFyr8bVg90H21EOLACvtfcHk0lgYmt-P-J52xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVKhu7s%253D&md5=a48d077cdd6a0251ac7a4137e4318062</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2010.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2010.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DVehovec%26aufirst%3DT.%26aulast%3DObreza%26aufirst%3DA.%26atitle%3DReview%2520of%2520operating%2520principle%2520and%2520applications%2520of%2520the%2520charged%2520aerosol%2520detector%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2010%26volume%3D1217%26spage%3D1549%26epage%3D1556%26doi%3D10.1016%2Fj.chroma.2010.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wawro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinbara, K.</span></span> <span> </span><span class="NLM_article-title">Chromatography-free synthesis of monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates and quantitative analysis of oligomer purity</span>. <i>Polym. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2389</span>– <span class="NLM_lpage">2394</span>, <span class="refDoi"> DOI: 10.1039/c6py00127k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1039%2FC6PY00127K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12msr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2389-2394&author=A.+M.+Wawroauthor=T.+Muraokaauthor=K.+Kinbara&title=Chromatography-free+synthesis+of+monodisperse+oligo%28ethylene+glycol%29+mono-p-toluenesulfonates+and+quantitative+analysis+of+oligomer+purity&doi=10.1039%2Fc6py00127k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chromatography-free synthesis of monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates and quantitative analysis of oligomer purity</span></div><div class="casAuthors">Wawro, Adam M.; Muraoka, Takahiro; Kinbara, Kazushi</div><div class="citationInfo"><span class="NLM_cas:title">Polymer Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2389-2394</span>CODEN:
                <span class="NLM_cas:coden">PCOHC2</span>;
        ISSN:<span class="NLM_cas:issn">1759-9962</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Poly(ethylene glycol) (PEG) is a common building block for complex functional mols.  Because of its chain flexibility and hydrophilicity, it is widely used in bioconjugation chem.  Modern applications require PEGs of high purity, hence well-defined, monodisperse PEG oligomers are gaining more attention.  Here we report a large-scale synthetic procedure for monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates, convenient intermediates of various heterobifunctional PEG derivs.  This method features no chromatog. purifn., low total material cost and high purity of the products.  In addn., oligomer dispersity of the products is detd. quant. using reverse-phase HPLC and a no. of bioconjugation-related functionalized PEG derivs. are prepd. from the synthesized toluenesulfonates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgqjyuBxYg6rVg90H21EOLACvtfcHk0lgYmt-P-J52xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12msr4%253D&md5=a7201eb12f974505364c4d45d8067466</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC6PY00127K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6PY00127K%26sid%3Dliteratum%253Aachs%26aulast%3DWawro%26aufirst%3DA.%2BM.%26aulast%3DMuraoka%26aufirst%3DT.%26aulast%3DKinbara%26aufirst%3DK.%26atitle%3DChromatography-free%2520synthesis%2520of%2520monodisperse%2520oligo%2528ethylene%2520glycol%2529%2520mono-p-toluenesulfonates%2520and%2520quantitative%2520analysis%2520of%2520oligomer%2520purity%26jtitle%3DPolym.%2520Chem.%26date%3D2016%26volume%3D7%26spage%3D2389%26epage%3D2394%26doi%3D10.1039%2Fc6py00127k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astruc, D.</span></span> <span> </span><span class="NLM_article-title">The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) “click” reaction and its applications. An overview</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">2933</span>– <span class="NLM_lpage">2945</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.ccr.2011.06.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlygsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2011&pages=2933-2945&author=L.+Liangauthor=D.+Astruc&title=The+copper%28I%29-catalyzed+alkyne-azide+cycloaddition+%28CuAAC%29+%E2%80%9Cclick%E2%80%9D+reaction+and+its+applications.+An+overview&doi=10.1016%2Fj.ccr.2011.06.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) "click" reaction and its applications. An overview</span></div><div class="casAuthors">Liang, Liyuan; Astruc, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">2933-2945</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A short overview of the copper(I)-catalyzed azide alkyne cycloaddn. (CuAAC), the most used "click" reaction, is presented, including the introduction of the "click" concept, the conditions of copper(I) catalysis, the regioselectivity, the nature of the catalysts and ligands, mechanistic features, exptl. conditions and applications to org. synthesis and org. materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKJcGwQvlT_LVg90H21EOLACvtfcHk0lgYmt-P-J52xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlygsbzI&md5=eb23b7d506593f5b7a9469ddfb20fd52</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DAstruc%26aufirst%3DD.%26atitle%3DThe%2520copper%2528I%2529-catalyzed%2520alkyne-azide%2520cycloaddition%2520%2528CuAAC%2529%2520%25E2%2580%259Cclick%25E2%2580%259D%2520reaction%2520and%2520its%2520applications.%2520An%2520overview%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2011%26volume%3D255%26spage%3D2933%26epage%3D2945%26doi%3D10.1016%2Fj.ccr.2011.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, W. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1021/bm034069l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bm034069l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsl2hsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=1055-1067&author=J.+Liauthor=W.+J.+Kao&title=Synthesis+of+polyethylene+glycol+%28PEG%29+derivatives+and+PEGylated-peptide+biopolymer+conjugates&doi=10.1021%2Fbm034069l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Polyethylene Glycol (PEG) Derivatives and PEGylated-Peptide Biopolymer Conjugates</span></div><div class="casAuthors">Li, Jing; Kao, W. John</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1055-1067</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We synthesized a library of 50 poly(ethylene glycol) (PEG) derivs. to expand the extent of conjugation with biol. active mols. (biopolymers, peptides, drugs, etc.) and biomaterial substrates.  The formation of PEG derivs. was confirmed with HPLC, 1H and 13C NMR.  PEG derivs. were polymd. into networks in order to study the role of PEG and terminal functional groups in modulating the hydrophilicity of biomaterials and cell-biomaterial interaction.  The resulting surface hydrophilicity and the no. of adhered fibroblasts were primarily dependent on the PEG concn. with the mol. wt. and the terminal functional group of PEG derivs. being less important.  One of PEG derivs., PEG-bis-glutarate, was utilized to link peptide sequences to gelatin backbone in the formation of novel biomedical hydrogels.  PEG-peptide conjugates were characterized by mass spectroscopy.  PEG-peptide modified gelatins were characterized by gel permeation chromatog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWCGHHjjfkvLVg90H21EOLACvtfcHk0lgYmt-P-J52xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsl2hsrg%253D&md5=10edcce62dfff6302aff763987aee812</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fbm034069l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbm034069l%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKao%26aufirst%3DW.%2BJ.%26atitle%3DSynthesis%2520of%2520polyethylene%2520glycol%2520%2528PEG%2529%2520derivatives%2520and%2520PEGylated-peptide%2520biopolymer%2520conjugates%26jtitle%3DBiomacromolecules%26date%3D2003%26volume%3D4%26spage%3D1055%26epage%3D1067%26doi%3D10.1021%2Fbm034069l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parney, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pafundi, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laack, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizilbash, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laramy, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agar, N. Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span> <span> </span><span class="NLM_article-title">Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nox175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1093%2Fneuonc%2Fnox175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=29016900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1Ogsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=184-191&author=J.+N.+Sarkariaauthor=L.+S.+Huauthor=I.+F.+Parneyauthor=D.+H.+Pafundiauthor=D.+H.+Brinkmannauthor=N.+N.+Laackauthor=C.+Gianniniauthor=T.+C.+Burnsauthor=S.+H.+Kizilbashauthor=J.+K.+Laramyauthor=K.+R.+Swansonauthor=T.+J.+Kaufmannauthor=P.+D.+Brownauthor=N.+Y.+R.+Agarauthor=E.+Galanisauthor=J.+C.+Bucknerauthor=W.+F.+Elmquist&title=Is+the+blood%E2%80%93brain+barrier+really+disrupted+in+all+glioblastomas%3F+A+critical+assessment+of+existing+clinical+data&doi=10.1093%2Fneuonc%2Fnox175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data</span></div><div class="casAuthors">Sarkaria, Jann N.; Hu, Leland S.; Parney, Ian F.; Pafundi, Deanna H.; Brinkmann, Debra H.; Laack, Nadia N.; Giannini, Caterina; Burns, Terence C.; Kizilbash, Sani H.; Laramy, Janice K.; Swanson, Kristin R.; Kaufmann, Timothy J.; Brown, Paul D.; Agar, Nathalie Y. R.; Galanis, Evanthia; Buckner, Jan C.; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain.  However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM).  The accumulation of normally brain impenetrant radiog. contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM.  However, contrary to this view, overwhelming clin. evidence demonstrates that there is also a clin. significant tumor burden with an intact BBB in all GBM, and there is little doubt that drugs with poor BBB permeability do not provide therapeutically effective drug exposures to this fraction of tumor cells.  This review provides an overview of the clin. literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfa57RTmFi7Vg90H21EOLACvtfcHk0liACQ-S49Ergg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1Ogsbs%253D&md5=16f3f39fa253e4b5814ca3040c4d661c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnox175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnox175%26sid%3Dliteratum%253Aachs%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26aulast%3DHu%26aufirst%3DL.%2BS.%26aulast%3DParney%26aufirst%3DI.%2BF.%26aulast%3DPafundi%26aufirst%3DD.%2BH.%26aulast%3DBrinkmann%26aufirst%3DD.%2BH.%26aulast%3DLaack%26aufirst%3DN.%2BN.%26aulast%3DGiannini%26aufirst%3DC.%26aulast%3DBurns%26aufirst%3DT.%2BC.%26aulast%3DKizilbash%26aufirst%3DS.%2BH.%26aulast%3DLaramy%26aufirst%3DJ.%2BK.%26aulast%3DSwanson%26aufirst%3DK.%2BR.%26aulast%3DKaufmann%26aufirst%3DT.%2BJ.%26aulast%3DBrown%26aufirst%3DP.%2BD.%26aulast%3DAgar%26aufirst%3DN.%2BY.%2BR.%26aulast%3DGalanis%26aufirst%3DE.%26aulast%3DBuckner%26aufirst%3DJ.%2BC.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26atitle%3DIs%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520really%2520disrupted%2520in%2520all%2520glioblastomas%253F%2520A%2520critical%2520assessment%2520of%2520existing%2520clinical%2520data%26jtitle%3DNeuro%2520Oncol.%26date%3D2018%26volume%3D20%26spage%3D184%26epage%3D191%26doi%3D10.1093%2Fneuonc%2Fnox175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span> <span> </span><span class="NLM_article-title">Thyroid hormone transporters in the brain</span>. <i>Cerebellum</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1007/s12311-008-0029-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1007%2Fs12311-008-0029-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=18418673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2htLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=75-83&author=T.+Suzukiauthor=T.+Abe&title=Thyroid+hormone+transporters+in+the+brain&doi=10.1007%2Fs12311-008-0029-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Thyroid hormone transporters in the brain</span></div><div class="casAuthors">Suzuki, Takehiro; Abe, Takaaki</div><div class="citationInfo"><span class="NLM_cas:title">Cerebellum</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-83</span>CODEN:
                <span class="NLM_cas:coden">CERECF</span>;
        ISSN:<span class="NLM_cas:issn">1473-4222</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Thyroid hormone plays an essential role in proper mammalian development of the central nervous system and peripheral tissues.  Lack of sufficient thyroid hormone results in abnormal development of virtually all organ systems, a syndrome termed cretinism.  In particular, hypothyroidism in the neonatal period causes serious damage to neural cells and leads to mental retardation.  Although thyroxine is the major product secreted by the thyroid follicular cells, the action of thyroid hormone is mediated mainly through the deiodination of T4 to the biol. active form 3,3', 5-triiodo-L-thyronine, followed by the binding of T3 to a specific nuclear receptor.  Before reaching the intracellular targets, thyroid hormone must cross the plasma membrane.  Because of the lipophilic nature of thyroid hormone, it was thought that they traversed the plasma membrane by simple diffusion.  However, in the past decade, a membrane transport system for thyroid hormone has been postulated to exist in various tissues.  Several classes of transporters, org. anion transporter polypeptide (oatp) family, Na+/Taurocholate cotransporting polypeptide (ntcp) and amino acid transporters have been reported to transport thyroid hormones.  Monocarboxylate transporter 8 (MCT8) has recently been identified as an active and specific thyroid hormone transporter.  Mutations in MCT8 are assocd. with severe X-linked psychomotor retardation and strongly elevated serum T3 levels in young male patients.  Several other mols. should be contributed to exert the role of thyroid hormone in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPkIXM35E2FbVg90H21EOLACvtfcHk0liACQ-S49Ergg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2htLrP&md5=a1605658a09eed6bc1811cdbe8afa7e8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs12311-008-0029-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12311-008-0029-9%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DT.%26atitle%3DThyroid%2520hormone%2520transporters%2520in%2520the%2520brain%26jtitle%3DCerebellum%26date%3D2008%26volume%3D7%26spage%3D75%26epage%3D83%26doi%3D10.1007%2Fs12311-008-0029-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Current drug research on PEGylation with small molecular agents</span>. <i>Prog. Polym. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1016/j.progpolymsci.2012.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.progpolymsci.2012.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlymurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=421-444&author=W.+Liauthor=P.+Zhanauthor=E.+De+Clercqauthor=H.+Louauthor=X.+Liu&title=Current+drug+research+on+PEGylation+with+small+molecular+agents&doi=10.1016%2Fj.progpolymsci.2012.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug research on PEGylation with small molecular agents</span></div><div class="casAuthors">Li, Wenjun; Zhan, Peng; De Clercq, Erik; Lou, Hongxiang; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Polymer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">421-444</span>CODEN:
                <span class="NLM_cas:coden">PRPSB8</span>;
        ISSN:<span class="NLM_cas:issn">0079-6700</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  PEGylation, covalent attaching polyethylene glycol (PEG) polymers to therapeutic agents, is one of the most promising techniques to improve the therapeutic effect of drugs.  Initially, this technol. is mainly applied with macromol. drugs, such as proteins, enzymes, with ten PEGylated biomacromols. approved by the FDA for the treatment of related diseases.  The clin. successful use of PEGylated macromol. drug has promoted the application of this technol. with small mols. drugs to overcome shortcomings assocd. with therapy, such as possible low soly., high toxicity, undesirable pharmaceutical characteristics and nonspecific biodistribution profiles.  So far, 4 PEGylated small drugs were taken into clin. trials.  This review mainly focuses on the recent advances of PEGylated small mols., including their general configuration, and the current merits and limits of PEG modification.  Herein PEG delivery systems are distinguished by therapeutic application (anti-tumor, anti-inflammatory, etc.) and their corresponding PEGylated small mols. are described in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1c3uJ8cWgm7Vg90H21EOLACvtfcHk0liACQ-S49Ergg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlymurrE&md5=eb609a4d59ce7e8cc5cf443ce8def9b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.progpolymsci.2012.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.progpolymsci.2012.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DCurrent%2520drug%2520research%2520on%2520PEGylation%2520with%2520small%2520molecular%2520agents%26jtitle%3DProg.%2520Polym.%2520Sci.%26date%3D2013%26volume%3D38%26spage%3D421%26epage%3D444%26doi%3D10.1016%2Fj.progpolymsci.2012.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaghmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Villuendas, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greschner, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haan, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, M. A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation</span>. <i>Mater. Today Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.mtchem.2018.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.mtchem.2018.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWjur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=121-131&author=A.+Zaghmiauthor=A.+A.+Mendez-Villuendasauthor=A.+A.+Greschnerauthor=J.+Y.+Liuauthor=H.+W.+de+Haanauthor=M.+A.+Gauthier&title=Mechanisms+of+activity+loss+for+a+multi-PEGylated+protein+by+experiment+and+simulation&doi=10.1016%2Fj.mtchem.2018.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation</span></div><div class="casAuthors">Zaghmi, A.; Mendez-Villuendas, E.; Greschner, A. A.; Liu, J. Y.; de Haan, H. W.; Gauthier, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Materials Today Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">MTCAD8</span>;
        ISSN:<span class="NLM_cas:issn">2468-5194</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past five decades, one of the most investigated strategies to increase the circulatory half-life and to reduce the immunogenicity of non-human therapeutic proteins has been to cover their surface with multiple copies of methoxy poly(ethylene glycol) (mPEG).  This multi-'PEGylation' strategy, however, is often assocd. with loss of protein activity, which is most often rationalized as direct modification of the protein's active site or to steric hindrance near its surface.  While these mechanisms are generally accepted and likely valid, very few studies investigate other possible mechanisms of activity loss.  To answer this question, this study investigates the mechanisms of activity loss for glutamate dehydrogenase (GDH) bearing up to 25 chains of mPEG per protein.  Through a combination of exptl. design and simulation, the most common proposed causes of protein inactivation (i.e. active-site PEGylation and steric hindrance near the surface of the protein) are circumvented to shed light on less characterized mechanisms such as altered protein structure, altered microenvironment at the surface of the protein, and altered protein dynamics.  Expts. suggest that the secondary and tertiary structure of GDH was (sometimes significantly) affected by PEGylation, though these changes do not necessarily result in a loss of activity.  Structure-activity correlations could not reconcile all trends within the library of bioconjugates tested.  Moreover, by measuring catalytic activity in the presence of five different allosteric modulators, loss of activity could not be ascribed to an altered local microenvironment at the protein's surface.  As such, coarse-grained simulations were exploited to reveal the effect of PEGylation on protein dynamics, which are long-ranged, cooperative, and essential for GDH catalytic activity.  Normal mode anal. of native bovine GDH (i.e. not PEGylated) revealed that the lowest ranking mode displayed several features that bore similarity to movements known for the native protein.  These included rotation/distortion of the 'antenna' regions, closure of the 'catalytic cleft', and constriction of the internal cavity.  A reduced magnitude of this mode was obsd. as a function of degree of PEGylation and mPEG mol. wt. and correlated well with trends obsd. for the library of bioconjugates tested exptl.  Overall, this study provides new insight into fundamental considerations assocd. with loss of activity, which will contribute to the design of future bioconjugates by providing a better understanding of possible mechanisms of loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxmmlyK5ReYbVg90H21EOLACvtfcHk0ljCN5-E1AJEdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWjur7F&md5=14b272d375cdbdedce6f083a0842b965</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.mtchem.2018.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mtchem.2018.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DZaghmi%26aufirst%3DA.%26aulast%3DMendez-Villuendas%26aufirst%3DA.%2BA.%26aulast%3DGreschner%26aufirst%3DA.%2BA.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3Dde%2BHaan%26aufirst%3DH.%2BW.%26aulast%3DGauthier%26aufirst%3DM.%2BA.%26atitle%3DMechanisms%2520of%2520activity%2520loss%2520for%2520a%2520multi-PEGylated%2520protein%2520by%2520experiment%2520and%2520simulation%26jtitle%3DMater.%2520Today%2520Chem.%26date%3D2019%26volume%3D12%26spage%3D121%26epage%3D131%26doi%3D10.1016%2Fj.mtchem.2018.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuerck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?</span>. <i>Drug Discov. Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1623</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2Fj.drudis.2014.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=24929223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWisrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1623-1631&author=A.+Baumannauthor=D.+Tuerckauthor=S.+Prabhuauthor=L.+Dickmannauthor=J.+Sims&title=Pharmacokinetics%2C+metabolism+and+distribution+of+PEGs+and+PEGylated+proteins%3A+quo+vadis%3F&doi=10.1016%2Fj.drudis.2014.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?</span></div><div class="casAuthors">Baumann, Andreas; Tuerck, Dietrich; Prabhu, Saileta; Dickmann, Leslie; Sims, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1623-1631</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The pharmacokinetics (PK), metab. and biodistribution of polyethylene glycol (PEG) in PEGylated proteins are important to understand the increased cellular vacuolation reported in various tissues in animals.  The tissue distribution profile of PEGylated proteins and 'metabolic' PEG is guided largely by abs. PEG load, PEG mol. wt. and, where applicable, receptor-mediated uptake via the protein moiety.  High mol. wt. PEGs show slow renal clearance, and consequently have a greater potential to accumulate within cells.  The intracellular nonbiodegradable PEG can accumulate within the lysosome ultimately causing distension and vacuolation obsd. by std. histol. examns.  Improved bioanal. methodologies will contribute to the identification of specific PK parameters including distribution behavior to support development of PEGylated proteins as therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbtre-36np7Vg90H21EOLACvtfcHk0ljCN5-E1AJEdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWisrjL&md5=28d597ff3dfc5fac1b0d9c5893d30446</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DA.%26aulast%3DTuerck%26aufirst%3DD.%26aulast%3DPrabhu%26aufirst%3DS.%26aulast%3DDickmann%26aufirst%3DL.%26aulast%3DSims%26aufirst%3DJ.%26atitle%3DPharmacokinetics%252C%2520metabolism%2520and%2520distribution%2520of%2520PEGs%2520and%2520PEGylated%2520proteins%253A%2520quo%2520vadis%253F%26jtitle%3DDrug%2520Discov.%2520Today%26date%3D2014%26volume%3D19%26spage%3D1623%26epage%3D1631%26doi%3D10.1016%2Fj.drudis.2014.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">8561</span>– <span class="NLM_lpage">8566</span>, <span class="refDoi"> DOI: 10.1039/c8sc01777h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1039%2FC8SC01777H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=30568780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCjsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=8561-8566&author=Y.+Hanauthor=Z.+Yuanauthor=P.+Zhangauthor=S.+Jiang&title=Zwitterlation+mitigates+protein+bioactivity+loss+in+vitro+over+PEGylation&doi=10.1039%2Fc8sc01777h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation</span></div><div class="casAuthors">Han, Yanjiao; Yuan, Zhefan; Zhang, Peng; Jiang, Shaoyi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">8561-8566</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conjugation with poly(ethylene glycol) (PEG) or PEGylation is a widely used tool to overcome the shortcomings of native proteins, such as poor stability, inadequate pharmacokinetic (PK) profiles, and immunogenicity.  However, PEGylation is often accompanied by an unwanted detrimental effect on bioactivity, particularly, resulting from the amphiphilic nature of PEG.  This is esp. true for PEGylated proteins with large binding targets.  Pegasys, a PEGylated interferon alpha-2a (IFN-α2a) bearing a 40 kDa branched PEG, is a typical example that displays only 7% in vitro activity of the unmodified IFN-α2a.  In this work, by employing IFN-α2a as a model protein, we demonstrated that a protein conjugated with zwitterionic polymers (or zwitterlation) could significantly mitigate the antiproliferative bioactivity loss in vitro after polymer conjugation.  The retained antiproliferative activity of zwitterlated IFN-α2a is 4.4-fold higher than that of the PEGylated IFN-α2a with the same polymer mol. wt., or 3-fold higher than that of the PEGylated IFN-α2a with a similar hydrodynamic size.  It is hypothesized that nonspecific interactions between zwitterionic polymers and IFN-α2a/IFN-α2a receptors can be mitigated due to the super-hydrophilic nature of zwitterionic polymers.  This, in turn, reduces the 'nonspecific blocking' between IFN-α2a and IFN-α2a receptors.  In addn., we demonstrated that zwitterlated IFN-α2a showed a prolonged circulation time and a mitigated accelerated blood clearance after repeated injections in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq86LYYLAkrsLVg90H21EOLACvtfcHk0ljCN5-E1AJEdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCjsLnI&md5=9cb7dbafcca4634530e460e5b3738033</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2FC8SC01777H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC01777H%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DZwitterlation%2520mitigates%2520protein%2520bioactivity%2520loss%2520in%2520vitro%2520over%2520PEGylation%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D8561%26epage%3D8566%26doi%3D10.1039%2Fc8sc01777h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalcin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharali, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godugu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, biodistribution, and anti-angiogenesis efficacy of diamino propane tetraiodothyroacetic acid-conjugated biodegradablepPolymeric nanoparticle</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">9006</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-44979-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1038%2Fs41598-019-44979-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=31227723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A280%3ADC%252BB3M3psF2gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=9006&author=W.+Liauthor=M.+Yalcinauthor=D.+J.+Bharaliauthor=Q.+Linauthor=K.+Goduguauthor=K.+Fujiokaauthor=K.+A.+Keatingauthor=S.+A.+Mousa&title=Pharmacokinetics%2C+biodistribution%2C+and+anti-angiogenesis+efficacy+of+diamino+propane+tetraiodothyroacetic+acid-conjugated+biodegradablepPolymeric+nanoparticle&doi=10.1038%2Fs41598-019-44979-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle</span></div><div class="casAuthors">Li Weikun; Yalcin Murat; Bharali Dhruba J; Godugu Kavitha; Fujioka Kazutoshi; Keating Kelly A; Mousa Shaker A; Yalcin Murat; Lin Qishan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9006</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The anti-angiogenic agent, diamino propane tetraiodothyroacetic acid (DAT), is a thyro-integrin (integrin αvβ3) antagonist anticancer agent that works via genetic and nongenetic actions.  Tetraiodothyroacetic acid (tetrac) and DAT as thyroid hormone derivatives influence gene expression after they transport across cellular membranes.  To restrict the action of DAT to the integrin αvβ3 receptors on the cell surface, we used DAT-conjugated PLGA nanoparticles (NDAT) in an active targeting mode to bind to these receptors.  Preparation and characterization of NDAT is described, and both in vitro and in vivo experiments were done to compare DAT to NDAT.  Intracellular uptake and distribution of DAT and NDAT in U87 glioblastoma cells were evaluated using confocal microscopy and showed that DAT reached the nucleus, but NDAT was restricted from the nucleus.  Pharmacokinetic studies using LC-MS/MS analysis in male C57BL/6 mice showed that administration of NDAT improved the area under the drug concentration curve AUC(0-48 h) by 4-fold at a dose of 3 mg/kg when compared with DAT, and Cmax of NDAT (4363 ng/mL) was 8-fold greater than that of DAT (548 ng/mL).  Biodistribution studies in the mice showed that the concentrations of NDAT were higher than DAT/Cremophor EL micelles in heart, lung, liver, spleen, and kidney.  In another mouse model using female NCr nude homozygous mice with U87 xenografts, tumor growth was significantly decreased at doses of 1 and 3 mg/kg of NDAT.  In the chick chorioallantoic membrane (CAM) assay used to measure angiogenesis, DAT (500 ng/CAM) resulted in 48% inhibition of angiogenesis levels.  In comparison, NDAT at low dose (50 ng/CAM) showed 45% inhibition of angiogenesis levels.  Our investigation of NDAT bridges the study of polymeric nanoparticles and anti-angiogenic agents and offers new insight for the rational design of anti-angiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPg83-cJoMYq91pGlMMoT5fW6udTcc2eYWjsDdkS7jO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3psF2gsQ%253D%253D&md5=16487909e88802d664a21239eb6364b1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44979-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44979-6%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYalcin%26aufirst%3DM.%26aulast%3DBharali%26aufirst%3DD.%2BJ.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DGodugu%26aufirst%3DK.%26aulast%3DFujioka%26aufirst%3DK.%26aulast%3DKeating%26aufirst%3DK.%2BA.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DPharmacokinetics%252C%2520biodistribution%252C%2520and%2520anti-angiogenesis%2520efficacy%2520of%2520diamino%2520propane%2520tetraiodothyroacetic%2520acid-conjugated%2520biodegradablepPolymeric%2520nanoparticle%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D9006%26doi%3D10.1038%2Fs41598-019-44979-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kouns, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadvary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haering, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span> <span> </span><span class="NLM_article-title">Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">18844</span>– <span class="NLM_lpage">18851</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(19)37038-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=10.1016%2FS0021-9258%2819%2937038-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1527012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;key=1%3ACAS%3A528%3ADyaK38XltVyrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=18844-18851&author=W.+C.+Kounsauthor=P.+Hadvaryauthor=P.+Haeringauthor=B.+Steiner&title=Conformational+modulation+of+purified+glycoprotein+%28GP%29+IIb-IIIa+allows+proteolytic+generation+of+active+fragments+from+either+active+or+inactive+GPIIb-IIIa&doi=10.1016%2Fs0021-9258%2819%2937038-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa</span></div><div class="casAuthors">Kouns, William C.; Hadvary, Paul; Haering, P.; Steiner, Beat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">18844-51</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">This study characterized conformational states of platelet glycoprotein IIb-IIIa (GPIIb-IIIa) and regions of the mol. required for fibrinogen binding.  The data obtained suggest that: (1) purified active and inactive GPIIb-IIIa exist in different conformations and have different affinities for RGDV; (2) certain peptidomimetic inhibitors (Ro 42-1499 and Ro 43-5054) alter the conformation of inactive GPIIb-IIIa; (3) GPIIIa and a 58-kDa N-terminal fragment of GPIIbα form a high-affinity fibrinogen-binding complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvLHawVJ1VNbVg90H21EOLACvtfcHk0lhw8auhhUF7IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVyrs7s%253D&md5=6b84605812c74857b7f4fccfab888f9c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2937038-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252937038-3%26sid%3Dliteratum%253Aachs%26aulast%3DKouns%26aufirst%3DW.%2BC.%26aulast%3DHadvary%26aufirst%3DP.%26aulast%3DHaering%26aufirst%3DP.%26aulast%3DSteiner%26aufirst%3DB.%26atitle%3DConformational%2520modulation%2520of%2520purified%2520glycoprotein%2520%2528GP%2529%2520IIb-IIIa%2520allows%2520proteolytic%2520generation%2520of%2520active%2520fragments%2520from%2520either%2520active%2520or%2520inactive%2520GPIIb-IIIa%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D18844%26epage%3D18851%26doi%3D10.1016%2Fs0021-9258%2819%2937038-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i33"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00350">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_54823"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00350?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00350</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR spectra, HPLC traces, and molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Smiles strings of compounds <b>2</b>, <b>10</b>, and <b>13</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_001.pdf">jm1c00350_si_001.pdf (942.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00350/suppl_file/jm1c00350_si_002.csv">jm1c00350_si_002.csv (0.65 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00350&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00350" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00350" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994e39afaa3dd7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
